Specific sites used to modify antibodies to prepare immunoconjugates
By selecting specific sites in the constant region of the antibody for cysteine substitution and utilizing the thiol-maleimide conjugation reaction, the heterogeneity and instability of antibody-drug conjugates were solved, achieving efficient and stable preparation of drug conjugates.
Patent Information
- Application Number
- CN202210867143.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-02-08
- Filing Date
- 2014-02-07
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2034-02-07
AI Technical Summary
Existing technologies make it difficult to selectively introduce improved properties or functions into antibodies, leading to heterogeneity and instability in drug conjugates and affecting treatment efficacy.
Cysteine substitution is performed at specific sites in the constant region of the antibody, and a stable immunoconjugate is formed by a thiol-maleimide conjugation reaction, avoiding unwanted disulfide bond formation and drug loss.
This achieves efficient and stable conjugation of antibodies and drug payloads, reduces heterogeneous products, and improves the therapeutic index and the stability of the conjugate.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure BDA0003759041590000031
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201480017839.4, the original application being filed on February 7, 2014, with the invention title "Specific sites for modifying antibodies to prepare immune conjugates". Invention Field
[0002] Due to the importance of antibodies in various therapeutic applications, robust methods are needed to selectively modify antibodies to introduce improved properties or additional functions. This invention provides specific sites for attaching to antibody attachment sites for the preparation of modified antibodies, such as for the preparation of antibody-drug conjugates (ADCs). The selective conjugation sites are located in constant regions of the antibody and are therefore applicable to a variety of antibodies. Background of the Invention
[0003] The value of methods for modifying antibodies is well-known, and numerous methods have been developed for conjugating antibodies to attach multiple “payload” portions. Many of these methods rely on the natural presence of specific reactive amino acid residues on the antibody, such as lysine and cysteine (which can be used to attach the payload). However, reliance on natural amino acids is not always desirable because the position and amount of the attached payload depend on the number and position of these reactive amino acids: too many or too few of these residues make it difficult to effectively control the loading of the payload onto the antibody. Furthermore, the placement of reactive amino acids can make it difficult to obtain a complete conjugation, resulting in heterogeneous products during the conjugation process. Heterogeneity of the active pharmaceutical ingredient is generally undesirable, for example, because it exacerbates the unpredictability of administering the drug to a heterogeneous population of subjects: it is preferable to administer a homogeneous product, and it is much more difficult to fully characterize and predict the behavior of heterogeneous products. Cytotoxic drugs have produced homogeneous immunoconjugates by, for example, by conjugating antibodies to cysteine residue sites specifically, which have shown improved therapeutic indices (Junutula et al., (2008)). Nat Biotechnol. 26(8):925-932).
[0004] Antibodies have been modified to add certain residues, such as cysteine, at specific positions where these residues can be used for conjugation (Lyons et al., (1990) Protein Eng., 3:703-708). However, the value of a specific substitution can vary depending on the antibody, as the modified cysteine may interfere with antibody folding and the oxidation of appropriate intramolecular disulfide bonds (Voynov et al., (2010) Bioconjug. Chem. 21(2):385-392).
[0005] Because modified cysteine in antibodies expressed in mammalian cells is modified during their biosynthesis via disulfide bonds with glutathione (GSH) and / or cysteine (Chen et al. (2009) mAbs 1:6, 563-571), the modified cysteine in the initially expressed antibody-drug conjugate does not react with thiol-reacting reagents. Activation of the modified cysteine requires reduction of GSH and / or cysteine adducts (which typically result in the reduction of all interchain disulfide bonds in the antibody), followed by reoxidation and re-formation of native interchain disulfide bonds before conjugation (Junutula et al., (2008) Nat. Biotechnol. 26(8):925-32). Some sites where cysteine has been inserted interfere with the reoxidation process, leading to unwanted non-homogeneous conjugate products. Therefore, it is important to identify sites on the antibody where the introduced cysteine does not interfere with the reoxidation process before conjugation with thiol-reacting reagents such as maleimide or brominated, chloroinated, or iodoacetamide groups.
[0006] The conjugation of cysteine residues with bromoacetamide, iodoacetamide, or chloroacetamide results in the formation of a stable thioether linker (Alley et al., (2008) Bioconjug Chem. 19(3):759-65). However, chemical conjugation is less efficient than maleimide conjugation. Since forming this thiol-maleimide linker is a popular and highly efficient method for attaching a payload or linker to a cysteine residue, it is necessary to identify cysteine substitution sites on the antibody where maleimide linkers can be used. More importantly, site-specific conjugated immunoconjugates can exhibit improved therapeutic indices; therefore, it is still necessary to identify specific privileged sites for cysteine substitution in the antibody that enable efficient conjugation of payloads to the antibody and provide conjugates with high stability. This invention provides such privileged cysteine substitution sites (which produce improved antibodies for conjugation purposes) and immunoconjugates containing such improved antibodies. Invention Overview
[0007] This invention provides specific sites in a constant region of an antibody or antibody fragment on which a cysteine (“Cys”) residue of a natural amino acid on the parent antibody or antibody fragment can be substituted to provide Cys residues for attaching chemical moieties (e.g., payload / drug moieties) to form immunoconjugates with good potency and stability. This invention also provides modified antibodies or antibody fragments having one or more Cys residues at one or more of these specific sites, and immunoconjugates prepared from such modified antibodies or antibody fragments.
[0008] Methods for inserting Cys at specific sites on antibodies are known in the art, see, for example, WO 2011 / 005481. However, the present invention discloses specific sites in the constant region of an antibody or antibody fragment, wherein replacing one or more natural amino acids of the parent antibody or antibody fragment with Cys provides one or more of the following advantages: good reactivity to facilitate effective immunoconjugation; reduced tendency to lose payload when using Cys-maleimide conjugation linkers; reduced tendency to form unwanted disulfide bonds between antibodies, such as crosslinks or non-natural intramolecular disulfide bonds; and low hydrophobicity of the resulting ADC.
[0009] Specific privileged sites for Cys substitution of native amino acids in a constant region of a parent antibody or antibody fragment are selected to provide efficient conjugation while minimizing unwanted effects. First, specific sites for modification are selected so that substituting a native amino acid of the parent antibody or antibody fragment at one or more selected sites provides an antibody or antibody fragment readily conjugated to a new cysteine residue. Specific sites are selected to be sufficiently surface accessible to allow the thiol group of the cysteine residue to react with an electrophilic reagent in aqueous solution. Identifying suitable sites for Cys substitution of native amino acids in the parent antibody or antibody fragment involves analyzing the surface exposure of the native amino acid based on crystal structure data. Because the sites described herein are sufficiently accessible and reactive, they can be used to form immunoconjugates through chemical reactions well known in the art for modifying naturally occurring cysteine residues. Conjugation of the Cys residue substitution is therefore performed using conventional methods.
[0010] When the thiol-maleimide moiety is used for conjugation, the selected modification site can show a low tendency for inverse conjugation. Thiol-maleimide conjugation reactions are often highly selective and extremely efficient, and can be used to attach payloads to the thiol groups of cysteine residues in proteins or elsewhere as linkers in the connection between proteins and payloads. For example, maleimides can attach to proteins (e.g., antibodies or antibody fragments), and payloads with attached thiol groups can be added to maleimides to form conjugates.
[0011]
[0012] Therefore, in this conjugation step, the protein (e.g., antibody or antibody fragment) can be monocyclic or bicyclic; the other represents the payload. The immunoconjugation stability information herein specifically relates to the conjugation of substituted cysteine residues via reaction with maleimide groups. In some embodiments, the thiol group originates from a cysteine residue on the protein (e.g., antibody or antibody fragment), so a bicyclic ring represents the protein, and a monocyclic ring represents the payload.
[0013] Although the thiol-maleimide reaction is frequently used to prepare conjugates, reversing the conjugation step as described below can lead to loss of the effective load or confusion of the effective load with other thiol-containing species:
[0014]
[0015] Some sites for cysteine substitution have been reported to provide more stable maleimide conjugates than others, presumably because the local chemical environment at certain points on the antibody surface around the new cysteine can promote the hydrolysis of the succinimide ring and thus prevent the reversal of the thiol-maleimide link in the immunoconjugate (Shen et al. (2012), Nat. Biotechnol. 30(2):184-9). Identifying favorable sites to meet this criterion involves inserting Cys to replace many native amino acids with suitable surface exposure, preparing immunoconjugates containing thiol-maleimide links, and assessing the stability of the immunoconjugates to remove sites where the stability of the conjugate is reduced by the local microenvironment around the destabilizing site. Based on this, chemical methods that can be used to attach linkers and payloads to the substituted Cys residues are not limited by stability issues related to the reversibility of thiol-maleimide conjugates discussed above. Many methods can be used to form conjugates on cysteine, including maleimide conjugates. When using one of the most commonly used conjugation methods, the sites described herein for cysteine substitution promote the stability of the antibody conjugation product, making these sites advantageous for antibody modification because the modified antibodies can be used with well-known and highly efficient maleimide conjugation methods. The site selection based on this criterion is illustrated by the data given in Table 22 and Example 9.
[0016] Selected sites can be targeted to minimize the formation of unwanted disulfides (which may interfere with the formation of homoconjugates). When antibodies or antibody fragments containing modified cysteine are produced in mammalian cells, Cys residues are typically present as disulfides with free Cys amino acids or glutathione (Chen et al., (2009) mAbs 16, 353-571). To release Cys residues for conjugation with thiol reactive groups, the antibody or antibody fragment needs to be reduced, breaking all disulfide bonds. The antibody or antibody fragment is then re-oxidized under conditions that promote the formation of native disulfides (which stabilize the antibody or antibody fragment). After re-oxidation, cysteine residues that are too significantly exposed on the surface of the antibody or antibody fragment can form disulfides by reacting with Cys on another antibody or antibody fragment (“inter-antibody disulfides”) or by forming unwanted intra-antibody disulfides. It has been found that cysteine residues positioned at the specific sites described herein are suitably readily available for efficient conjugation, but are adequately shielded or properly positioned to reduce or eliminate the formation of disulfide bonds between and within antibodies, which otherwise occur during the reduction / reoxidation process typically required when expressing cys-modified antibodies. Similarly, upon reoxidation, some sites have been found to produce heterogeneous conjugated products, which appears to be due to the localization of the modified novel Cys residues into the protein, and the specific sites identified herein are among those where such heterogeneity is minimized.
[0017] It is preferable to attach drug payloads at sites where they are isolated from solvent interactions, and attachment can increase the hydrophobicity of the antibody after drug attachment, as reducing the hydrophobicity of protein drugs is generally considered beneficial because it may reduce aggregation and clearance from circulation. Choosing attachment sites that result in minimal alteration of hydrophobicity may be particularly advantageous when each antibody is attached to 4, 6, or 8 drugs, or when using particularly hydrophobic payloads.
[0018] The evaluation of sites for Cys integration using the methods and additional techniques described in the embodiments herein leads to the selection of preferred sites for Cys integration for modifying antibodies or antibody fragments to introduce Cys as a site for conjugation, particularly for the preparation of ADCs. Additional details regarding the selection of specific sites for Cys replacement of native amino acids in antibodies are provided herein.
[0019] Cysteine substitution sites are located in the constant region of an antibody or antibody fragment, and are identified herein using a standard numbering convention. However, it is well known that portions or fragments of antibodies, rather than the complete full-length antibody, can be used for many purposes, and antibodies can be modified in a variety of ways that affect the numbering of sites in the constant region, even if they do not substantially affect the function of the constant region. For example, it has been shown that inserting an S6 tag (short peptide) into the loop region of an antibody can allow for preservation of antibody activity, even if it may alter the numbering of many sites in the antibody. Therefore, although the preferred cysteine substitution sites described herein are identified by a standard numbering system based on the numbering of the complete antibody, the present invention includes corresponding sites in antibody fragments or antibodies containing other modifications, such as peptide tag insertions. Those corresponding sites in fragments or modified antibodies are therefore preferred sites for cysteine substitution in fragments or modified antibodies, and reference to cysteine substitution sites by numbering includes corresponding sites in modified antibodies or antibody fragments that retain the function of the relevant portion of the full-length antibody.
[0020] The corresponding sites in the antibody fragment or modified antibody can be readily identified by comparing a segment of the antibody fragment or modified antibody with a full-length antibody to identify sites that match one of the preferred cysteine substitution sites of the present invention. The comparison can be based on a segment long enough to ensure that the segment matches the correct portion of the full-length antibody, such as a segment of at least 20 amino acid residues, or at least 50 residues, or at least 100 residues, or at least 150 residues. The comparison can also take into account other modifications that have been incorporated into the antibody fragment or modified antibody, thus allowing for sequence differences due to point mutations, particularly conserved substitutions, in the segment used for comparison. Thus, for example, an Fc domain may be excised from the antibody and will contain amino acid residues corresponding to the cysteine substitution sites described herein, despite numbering differences; it is also desirable that sites in the Fc domain corresponding to the cysteine substitution sites of the present invention are advantageous sites for cysteine substitution in the Fc domain and are included within the scope of the present invention.
[0021] In one embodiment, the present invention provides an immunoconjugate of formula (I):
[0022]
[0023] Where Ab represents an antibody or antibody fragment that contains at least one cysteine residue at one of the preferred cysteine substitution sites described herein.
[0024] LU is the connector unit as described herein;
[0025] X represents the payload or drug component;
[0026] And n is an integer from 1 to 16.
[0027] Typically, in compounds of formula (I), LU is attached to a cysteine residue at one of the cysteine substitution sites described herein, X is a pharmaceutical moiety, such as an anticancer drug, and n is 2-8 when Ab is an antibody, or 1-8 when Ab is an antibody fragment.
[0028] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises, in its constant region, a cysteine substitution for one or more amino acids selected from the heavy chain of the antibody or antibody fragment at positions 121, 124, 152, 171, 174, 258, 292, 333, 360, and 375, and wherein the positions are numbered according to EU system designations.
[0029] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises, in its constant region, a cysteine substitution for one or more amino acids at positions 107, 108, 142, 145, 159, 161, and 165 of a light chain selected from the antibody or antibody fragment, wherein the positions are numbered according to EU system numbers, and wherein the light chain is a human κ light chain.
[0030] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises, in its constant region, a substitution of one or more amino acids for cysteine at positions 143, 147, 159, 163, and 168 selected from the light chain of the antibody or antibody fragment, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0031] In one embodiment, the present invention provides a modified antibody or antibody fragment thereof comprising a cysteine substitution for one or more amino acids at the positions described herein. The sites for cysteine substitution are located in the constant region of the antibody and are therefore applicable to a variety of antibodies, and the sites are selected to provide stable and homogeneous conjugates. The modified antibody or fragment may have two or more cysteine substitutions, and these substitutions may be used in combination with other antibody modification and conjugation methods as described herein.
[0032] In one embodiment, the present invention provides a pharmaceutical composition comprising the immunoconjugates disclosed above, and a method of using the immunoconjugates.
[0033] In one embodiment, the present invention provides a nucleic acid encoding a modified antibody or antibody fragment having at least one cysteine substitution at the site described herein. The present invention also provides a host cell comprising these nucleic acids and a method for expressing and producing the antibody or fragment described herein using said nucleic acid or host cell.
[0034] In one embodiment, the present invention provides a method for selecting amino acids suitable for antibodies replaced by cysteine to provide a favorable conjugation site, comprising:
[0035] (1) Identify amino acids in the constant region of the antibody with suitable surface exposure to provide an initial set of candidate sites;
[0036] (2) For each initial candidate site, express an antibody in which the native amino acid at that site is replaced by a cysteine;
[0037] (3) For each expressed antibody, determine whether the expressed protein is substantially homogeneous after reduction and re-oxidation to provide a functional antibody with free cysteine at the initial candidate site.
[0038] (4) For each expressed protein that is essentially homogeneous and functional, the cysteine residue at the initial candidate site is concatenated with maleimide to determine whether the thiol-maleimide linkage at that site is stable.
[0039] (5) Remove from an initial set of candidate sites those sites to which the expressed antibody is substantially heterogeneous and nonfunctional, and those sites in which the thiol-maleimide linker is unstable, to provide a set of favorable sites for cysteine substitution.
[0040] Optionally, the method further includes determining the melting temperature of conjugates for each favorable cysteine substitution site and excluding any such sites from the group, wherein cysteine substitution and conjugation cause a melting temperature that differs from the melting temperature of the natural antibody by 5°C or more.
[0041] In one embodiment, the present invention provides a method for producing an immunoconjugate comprising attaching a linker unit (LU) or a linker unit-payload combination (-LU-X) to a cysteine residue in an antibody or antibody fragment, wherein the cysteine residue is located at a cysteine substitution site selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 360, and 375 of the heavy chain of the antibody or antibody fragment and positions 107, 108, 142, 145, 159, 161, and 165 of the light chain of the antibody or antibody fragment, wherein the positions are numbered according to the EU system.
[0042] Other aspects and embodiments of the invention are described in more detail herein.
[0043] 1. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids at positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375, and 392 on the heavy chain of the antibody or antibody fragment in its constant region, and wherein said positions are numbered according to EU system designations.
[0044] 2. The immunoconjugate of embodiment 1, wherein the substitution of one or more amino acids for cysteine is selected from positions 121, 124, 152, 258, 334, 360 and 392.
[0045] 3. The immunoconjugate of embodiment 1 or 2, wherein the antibody or antibody fragment comprises a sequence selected from SEQ ID NOs:4, 5, 10, 17, 18, 29, 35, 42, 43, 48, 50, 54, 290, 291, 292, 293, 294 and 295.
[0046] 4. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids at positions 107, 108, 142, 145, 159, 161, and 165 of a light chain selected from the antibody or antibody fragment in its constant region, wherein the positions are numbered according to the EU system, and wherein the light chain is a human κ light chain.
[0047] 5. The immunoconjugate of embodiment 4, wherein the substitution of one or more amino acids with cysteine is selected from position 145 or 165.
[0048] 6. The immunoconjugate of embodiment 4, wherein the antibody or antibody fragment comprises a sequence selected from SEQ ID NOs: 61, 62, 69, 71, 75, 76 and 77.
[0049] 7. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids at positions 143, 147, 159, 163, and 168 of a light chain selected from the antibody or antibody fragment in its constant region, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0050] 8. The immunoconjugate of embodiment 7, wherein the antibody or antibody fragment comprises a sequence selected from SEQ ID NOs: 92, 94, 96, 97 and 98.
[0051] 9. An immunoconjugate according to embodiment 1, 2 or 3, wherein the modified antibody or antibody fragment further comprises, in its constant region, a substitution of one or more amino acids for cysteine at positions selected from the light chain of the antibody or antibody fragment at positions 107, 108, 142, 145, 159, 161, and 165, wherein the positions are numbered according to the EU system, and wherein the light chain is a human κ light chain.
[0052] 10. An immunoconjugate according to embodiment 1, 2 or 3, wherein the modified antibody or antibody fragment further comprises, in its constant region, a substitution of one or more amino acids for cysteine at positions 143, 147, 159, 163 and 168 of a light chain selected from the antibody or antibody fragment, wherein the light chain positions are numbered according to the Kabat system, and wherein the light chain is a human κ light chain.
[0053] 11. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a combination of cysteine substitutions for two or more amino acids at positions 152 and 375, or at positions 327 and 375, in the heavy chain constant region, wherein the positions are numbered according to EU system designations.
[0054] 12. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises, in its constant region, a combination of substitutions of two or more amino acids by cysteine residues at position 107 of the light chain and at position 360 of the heavy chain, wherein the light chain is a κ chain, and wherein the position is numbered according to the EU system.
[0055] 13. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises, in a constant region selected from positions 117, 119, 121, 124, 139, 152, 153, 155, 157, 164, 169, 171, 174, 189, 205, 207, 246, 258, 269, 274, 286, 288, 290, 292, 293, 320, 322, 326, 333, 334, 335, 337, 344, 355, 360, 375, 382, 390, 392, 398, 400, or 422 of its heavy chain, a substitution of one or more amino acids for a cysteine residue, and wherein the positions are numbered according to the EU system.
[0056] 14. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids in a constant region selected from positions 107, 108, 109, 114, 129, 142, 143, 145, 152, 154, 156, 159, 161, 165, 168, 169, 170, 182, 183, 197, 199, and 203 of its light chain, wherein the positions are numbered according to EU system designations, and wherein the light chain is a human κ light chain.
[0057] 15. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids on a light chain constant region selected from positions 143, 145, 147, 156, 159, 163, and 168, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0058] 16. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a combination of substitutions of cysteine for two or more amino acids in its constant region, wherein the combination comprises substitutions at position 375 of the antibody heavy chain and position 165 of the antibody light chain, or at position 334 of the antibody heavy chain and position 165 of the antibody light chain, and wherein the light chain is a κ chain, and wherein the positions are numbered according to EU system designations.
[0059] 17. An immunoconjugate according to any one of embodiments 11, 12 and 16, wherein the drug-antibody ratio is approximately 4.
[0060] 18. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises, in its constant region, a combination of cysteine substitutions for three or more amino acids, wherein the combination comprises a selection from...
[0061] a. Positions of the antibody heavy chain at 375 and 392 and position of the antibody light chain at 165.
[0062] b. Positions of the antibody heavy chain at 334 and 375 and position of the antibody light chain at 165, and
[0063] c. Substitution of antibody heavy chain positions 334 and 392 and antibody light chain position 165.
[0064] And the light chain therein is a κ chain, and the position therein is according to the EU system number.
[0065] 19. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a combination of cysteine substitutions for three or more amino acids in its constant region, wherein the combination comprises a selection from...
[0066] a. Positions of the antibody heavy chain at 152, 375, and 392.
[0067] b. Positions of the antibody heavy chain at 152, 334, and 375, and
[0068] c. Substitution at positions 152, 334, and 392 of the antibody heavy chain.
[0069] And the location mentioned therein is based on the EU system number.
[0070] 20. The immunoconjugate of embodiment 18 or 19, wherein the drug-antibody ratio is approximately 6.
[0071] 21. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment thereof comprises, in its constant region, a combination of substitutions of cysteine for four or more amino acids, wherein the combination comprises substitutions at positions 334, 375, and 392 of the antibody heavy chain and position 165 of the antibody light chain, or at positions 333, 375, and 392 of the antibody heavy chain and position 165 of the antibody light chain, and wherein the light chain is a κ chain, and wherein the positions are numbered according to EU system designations.
[0072] 22. An immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment thereof comprises a combination of substitutions of four or more amino acids for cysteine residues in its constant region, wherein the combination comprises substitutions at positions 152, 334, 375 and 392 of the antibody heavy chain, or at positions 152, 333, 375 and 392 of the antibody heavy chain, and wherein the positions are numbered according to EU system designations.
[0073] 23. The immunoconjugate of embodiment 21 or 22, wherein the drug-antibody ratio is approximately 8.
[0074] 24. An immunoconjugate according to any one of implementation schemes 1-23, further comprising a pharmaceutical portion.
[0075] 25. The immunoconjugate of embodiment 24, wherein the pharmaceutical portion is attached to the modified antibody or antibody fragment via the sulfur of the cysteine and optionally a linker.
[0076] 26. The immunoconjugate of embodiment 25, wherein the pharmaceutical portion is connected to the sulfur of the cysteine via a cleavable or non-cleavable connector.
[0077] 27. The immunoconjugate of embodiment 25, wherein the pharmaceutical portion is connected to the sulfur of the cysteine via an incisional linker.
[0078] 28. The immunoconjugate of embodiment 25, wherein the immunoconjugate comprises a thiol-maleimide linker.
[0079] 29. The immunoconjugate of embodiment 25, wherein the immunoconjugate comprises a -S-CH2-C(=O)-linked or disulfide bond.
[0080] 30. An immunoconjugate according to any one of embodiments 25-29, wherein the pharmaceutical portion is a cytotoxic agent.
[0081] 31. The immunoconjugate of embodiment 30, wherein the pharmaceutical portion is selected from taxanes, DNA alkylating agents (e.g., CC-1065 analogs), anthracyclines, tubulysin analogs, docalmicin analogs, auristatin E, auristatin F, and maytansinoids.
[0082] 32. An immunoconjugate according to any one of embodiments 1-31, wherein the antibody is a monoclonal antibody.
[0083] 33. An immunoconjugate according to any one of embodiments 1-31, wherein the antibody is a chimeric antibody.
[0084] 34. The immunoconjugate of embodiment 31, wherein the antibody is a humanized or fully human antibody.
[0085] 35. The immunoconjugate of embodiment 31, wherein the antibody is a bispecific or multispecific antibody.
[0086] 36. An immunoconjugate according to any one of embodiments 1-32, wherein the antibody or antibody fragment specifically binds to a tumor-characteristic cell surface marker.
[0087] 37. A pharmaceutical composition comprising an immunoconjugate of any one of embodiments 1-36.
[0088] 38. A modified antibody or antibody fragment thereof, wherein the modified antibody or antibody fragment comprises a cysteine substitution for one or more amino acids in a constant region selected from positions 117, 119, 121, 124, 139, 152, 153, 155, 157, 164, 169, 171, 174, 189, 205, 207, 246, 258, 269, 274, 286, 288, 290, 292, 293, 320, 322, 326, 333, 334, 335, 337, 344, 355, 360, 375, 382, 390, 392, 398, 400, or 422 of its heavy chain, wherein said positions are numbered according to the EU system.
[0089] 39. A modified antibody or antibody fragment thereof, wherein positions 107, 108, 109, 114, 129, 142, 143, 145, 152, 154, 156, 159, 161, 165, 168, 169, 170, 182, 183, 197, 199 and 203 in the constant region of the light chain of the antibody or antibody fragment contain a substitution of one or more amino acids for a cysteine residue, wherein the positions are numbered according to the EU system, and wherein the light chain is a human κ light chain.
[0090] 40. A modified antibody or antibody fragment thereof, wherein positions 143, 145, 147, 156, 159, 163, 168 on a constant region selected from the light chain of the antibody or antibody fragment contain a substitution of one or more amino acids for a cysteine residue, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0091] 41. The modified antibody or antibody fragment of embodiment 38, wherein the substitution is at least one cysteine residue selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 360 and 375 of the heavy chain, and wherein the position is numbered according to the EU system number.
[0092] 42. The modified antibody or antibody fragment of embodiment 39, wherein the substitution is two to six cysteine residues, wherein the cysteine residues are located at positions selected from 121, 124, 152, 171, 174, 258, 292, 333, 360 and 375 of the heavy chain, and wherein the positions are according to EU system numbers.
[0093] 43. The modified antibody or antibody fragment of embodiment 39, wherein the substitution is at least one cysteine selected from positions 107, 108, 142, 145, 159, 161 and 165 of the light chain, wherein the positions are numbered according to the EU system, and wherein the light chain is a human κ light chain.
[0094] 44. The modified antibody or antibody fragment of embodiment 40, wherein the substitution is two to six cysteine residues, wherein the cysteine residues are located at positions selected from light chains 107, 108, 142, 145, 159, 161, and 165, wherein the positions are according to EU system numbers, and wherein the light chain is a human κ light chain.
[0095] 45. The modified antibody or antibody fragment of embodiment 40, wherein the substitution is at least one cysteine selected from positions 143, 147, 159, 163 and 168 of the light chain, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0096] 46. The modified antibody or antibody fragment of embodiment 40, wherein the substitution is two to six cysteine residues, wherein the cysteine residues are at positions selected from light chains 143, 147, 159, 163 and 168, wherein the positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0097] 47. A modified antibody or antibody fragment of any one of embodiments 11, 12, 14-22, 38-47, further attached to a pharmaceutical portion, wherein the pharmaceutical portion is attached to the modified antibody or antibody fragment via the sulfur of the cysteine and an optional linker.
[0098] 48. The modified antibody or antibody fragment of embodiment 47, wherein the drug portion is attached to the sulfur of the cysteine via a linker unit.
[0099] 49. A modified antibody or antibody fragment of any one of embodiments 38-48, further comprising at least one Pcl or non-natural amino acid substitution or peptide tag for enzyme-mediated conjugation and / or combinations thereof.
[0100] 50. Nucleic acid, which encodes a modified antibody or antibody fragment of any one of embodiments 38-49.
[0101] 51. A host cell containing the nucleic acid of implementation scheme 50.
[0102] 52. A method for producing a modified antibody or antibody fragment, comprising incubating a host cell of embodiment 49 under suitable conditions for expressing the antibody or antibody fragment, and isolating the antibody or antibody fragment.
[0103] 53. Methods for selecting suitable amino acids for antibodies replaced by cysteine to provide appropriate conjugation sites include:
[0104] (1) Identify amino acids in the constant region of the antibody with suitable surface exposure to provide an initial set of candidate sites;
[0105] (2) For each initial candidate site, express an antibody in which the native amino acid at that site is replaced by a cysteine;
[0106] (3) For each expressed antibody, determine whether the expressed protein is substantially homogeneous after reduction and re-oxidation to provide a functional antibody with free cysteine at the initial candidate site.
[0107] (4) For each expressed protein that is essentially homogeneous and functional, the cysteine residue at the initial candidate site is concatenated with maleimide to determine whether the thiol-maleimide linkage at that site is destabilized.
[0108] (5) Remove from an initial set of candidate sites those sites to which the expressed antibody is substantially heterogeneous and nonfunctional, and those sites in which the thiol-maleimide linker is destabilized, to provide a set of favorable sites for cysteine substitution.
[0109] 54. The method of embodiment 53, further comprising determining a melting temperature for each conjugate of a favorable cysteine substitution site and excluding any such site from the group, wherein cysteine substitution and conjugation cause a melting temperature that differs from the melting temperature of the parent antibody by 5°C or more.
[0110] 55. The method of embodiment 53 or 54, further comprising generating an antibody or antibody fragment containing a cysteine residue at one or more of the identified substitution sites.
[0111] 56. A method for generating an immunoconjugate, comprising attaching a linker unit (LU) or a linker unit-payload combination (-LU-X) to a cysteine residue in an antibody or antibody fragment, wherein the cysteine residue is located at a cysteine substitution site selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 360, and 375 of the heavy chain of the antibody or antibody fragment and positions 107, 108, 142, 145, 159, 161, and 165 of the light chain of the antibody or antibody fragment, wherein the positions are numbered according to the EU system.
[0112] 57. The method of embodiment 56, wherein the immunoconjugate is an immunoconjugate of formula (I):
[0113]
[0114] Where Ab represents an antibody or antibody fragment that contains at least one cysteine residue at one of the preferred cysteine substitution sites described herein.
[0115] LU is the connector unit as described herein;
[0116] X represents the payload or drug component;
[0117] And n is an integer from 1 to 16.
[0118] definition
[0119] The term "amino acid" refers to typical, synthetic, and non-natural amino acids, as well as amino acid analogs and amino acid mimics that function in a manner similar to that of typical amino acids. Typical amino acids are those encoded by the genetic code that form proteins and include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and selenocysteine, pyrrolidone, and their analogues pyrrolino-carboxy-lysine. Amino acid analogs are compounds that share the same basic chemical structure as typical amino acids—namely, an α-carbon bound to hydrogen, a carboxyl group, an amino group, and an R group—e.g., citrulline, homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonium. These analogs may have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure as typical amino acids.
[0120] Amino acid mimics are chemical compounds that have a structure different from the general chemical structure of amino acids, but function in a manner similar to that of typical amino acids. As used herein, the term “non-natural amino acid” is intended to represent an amino acid structure that cannot be produced by biosynthesis in any organism using unmodified or modified genes (whether identical or different). Furthermore, such “non-natural amino acids” typically require incorporation into proteins using modified tRNA and modified tRNA synthetase (RS). The tRNA / RS pair preferentially incorporates non-natural amino acids over typical amino acids. Such orthogonal tRNA / RS pairs are generated by selection methods developed by Schultz et al. (see, for example, Liu et al., (2010) Annu. Rev. Biochem. 79:413-444) or similar methods. The term “non-natural amino acid” does not include the 22 naturally occurring amino acids. ndThe amino acids pyrrolysine (Pyl) and its demethylated analogue pyrrolino-carboxy-lysine (Pcl) are incorporated into the protein via unmodified, naturally occurring pyrrolysyl-tRNA / tRNA synthetase pairs, and because Pyl and Pcl are produced through biosynthesis (see, for example, Ou et al., (2011) Proc. Natl. Acad. Sci. USA, 108:10437-10442; Cellitti et al., (2011) Nat. Chem. Biol. 27; 7(8):528-30). See also U.S. Provisional Application 61 / 76236, incorporated by reference, where site-specific amino acid residues in the antibody light and heavy chains may be substituted with Pcl.
[0121] As used herein, the term "antibody" refers to a polypeptide belonging to the immunoglobulin family that can non-covalently, reversibly, and in a specific manner bind to a corresponding antigen. For example, naturally occurring IgG antibodies are tetramers comprising at least two heavy (H) chains (also called "antibody heavy chains") and two light (L) chains (also called "antibody light chains") linked by disulfide bonds. Each heavy chain contains a heavy chain variable region (abbreviated herein as V). H The heavy chain constant region contains three domains: CH1, CH2, and CH3. Each light chain contains a light chain variable region (abbreviated as V in this paper). L ) and the light chain constant region. The light chain constant region contains a structural domain, C L V H and V L The region can be further subdivided into highly variable regions called complementarity-determining regions (CDRs), which are scattered within more conservative regions called framework regions (FRs). Each V H and V L Composed of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The constant regions of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0122] The term "antibody" includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camel antibodies, chimeric antibodies, and anti-idiotype (anti-Id) antibodies (including, for example, anti-Id antibodies of the antibodies of the present invention). Antibodies can be any isotype / type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or subtype (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).
[0123] Both light and heavy chains are divided into regions of structural and functional homology. Functions are described using the terms "constant" and "variable." In this regard, light (V) chains will be understood... L Chain and heavy (V) H The variable domains of the light chain (C1) determine antigen recognition and specificity. Conversely, the variable domains of the light chain (C2) determine antigen recognition and specificity. L The constant domains of the N-terminus and the heavy chain (CH1, CH2, or CH3) endow important biological properties, such as secretion, transplacental mobility, Fc receptor binding, and complement binding. By convention, the numbering of constant domains increases as they move further from the antigen-binding site or N-terminus of the antibody. The N-terminus is the variable region, and the C-terminus is the constant region; CH3 and C... L The structural domains actually contain carboxyl-terminal structural domains of the heavy chain and the light chain, respectively.
[0124] As used herein, the term "antibody fragment" refers to an antigen-binding fragment of an antibody or a non-antigen-binding fragment of an antibody (e.g., Fc). As used herein, the term "antigen-binding fragment" refers to one or more portions of an antibody that retain the ability to specifically interact with epitopes of an antigen (e.g., through binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of binding fragments include, but are not limited to, single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), Fab fragments, F(ab') fragments, and V... L V H C L The monovalent segment composed of the CH1 domain; the F(ab)2 segment, a divalent segment containing two Fab segments connected by disulfide bonds in the hinge region; and the V... H The Fd fragment consists of the CH1 domain; the V-band of the antibody single arm L and V H The Fv fragment is composed of structural domains; the dAb fragment (Ward et al., Nature 341:544-546, 1989) is composed of V H The domains consist of a separate complementarity-determining region (CDR), or other epitope-binding fragments of the antibody.
[0125] Furthermore, although the two structural domains V of the Fv fragment L and V H Encoded by individual genes, but which can be linked together using recombination methods via synthetic adapters that allow them to be prepared as single protein chains, wherein V L and V HRegions pair to form monovalent molecules (referred to as single-chain Fvs (“scFv”); see, for example, Bird et al., Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. 85:5879-5883, 1988). Such single-chain antibodies are also intended to be included in the term “antigen-binding fragment”. These antigen-binding fragments can be obtained using conventional techniques known to those skilled in the art, and their usefulness can be screened in the same manner as for intact antibodies.
[0126] Antigen-binding fragments can also be incorporated into single-domain antibodies, macrobodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, for example, Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can be grafted onto peptide-based scaffolds, such as fibronectin type III (Fn3) (see U.S. Patent No. 6,703,199, which describes a fibronectin peptide monoclonal antibody).
[0127] Antigen-binding fragments can be incorporated into a compound containing a pair of tandem Fv segments (V... H -CH1-V H In the single-chain molecule of (-CH1), it forms a pair of antigen-binding regions together with the complementary light chain polypeptide (Zapata et al., Protein Eng. 8:1057-1062, 1995; and US Patent No. 5,641,870).
[0128] As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to a polypeptide comprising antibodies and antibody fragments having substantially the same amino acid sequence or originating from the same genetic source. The term also includes formulations of antibody molecules composed of a single molecular combination. Monoclonal antibody compositions exhibit single binding specificity and affinity for a specific epitope.
[0129] As used herein, the term "human antibody" includes antibodies having variable regions in which both the framework and the CDR region are derived from human-origin sequences. Furthermore, if an antibody contains a constant region, then that constant region is also derived from such human sequences, for example, human germline sequences, or mutant forms of human germline sequences, or antibodies containing a common framework sequence derived from human framework sequence analysis, as described, for example, in Knappik et al., J. Mol. Biol. 296:57-86, 2000.
[0130] The human antibodies of the present invention may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutations in vivo, or conserved substitutions to promote stability or manufacture).
[0131] As used herein, the term “humanized” antibody refers to an antibody that retains the reactivity of a non-human antibody while exhibiting low immunogenicity in humans. This is achieved, for example, by retaining the non-human CDR region and replacing the remainder of the antibody with its human counterpart. See, for example, Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984); Morrison and Oi, Adv. Immunol., 44:65-92 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988); Padlan, Molec. Immun., 28:489-498 (1991); Padlan, Molec. Immun., 31(3):169-217 (1994).
[0132] As used herein, the term “recognition” refers to an antibody or its antigen-binding fragment that finds and interacts with (e.g., binds to) an epitope, whether the epitope is linear or conformational. The term “epitope” refers to a site on an antigen to which the antibody or antigen-binding fragment of the present invention specifically binds. Epitopes can be formed from adjacent amino acids or from non-adjacent amino acids juxtaposed due to the ternary folding of a protein. Epitopes formed from adjacent amino acids are generally retained upon exposure to denaturing agents, while epitopes formed by ternary folding are generally lost upon treatment with denaturing agents. Epitopes typically comprise at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids with a unique spatial conformation. Methods for determining the spatial conformation of an epitope include techniques in the art, such as X-ray crystallography and 2D nuclear magnetic resonance (see, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GEMorris, ed. (1996)).
[0133] As used in this article, “affinity” refers to the strength of the interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable region of the antibody “arm” interacts with the antigen at multiple sites through weak non-covalent forces; the stronger the interaction, the stronger the affinity.
[0134] The term "isolated antibody" refers to an antibody that is essentially free of other antibodies with different antigen specificities. However, an isolated antibody that specifically binds to one antigen may exhibit cross-reactivity with other antigens. Furthermore, isolated antibodies may be substantially free of other cellular material and / or chemicals.
[0135] The term "conservatively modified variant" applies to amino acid and nucleic acid sequences. For a given nucleic acid sequence, a conservatively modified variant refers to those nucleic acids that encode the same or substantially the same amino acid sequence, or substantially the same sequence when the nucleic acid does not encode an amino acid sequence. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. At each position (where alanine is determined by a single codon), the codon can be changed to any of the corresponding codons without altering the encoded polypeptide. Such nucleic acid variations are "silent variants," a type of conservatively modified variant. Each nucleic acid sequence encoding a polypeptide described herein also describes every possible silent variant of the nucleic acid. Those skilled in the art will recognize that every codon in the nucleic acid (except AUG, which is typically the only codon for methionine, and TGG, which is typically the only codon for tryptophan) can be modified to produce functionally identical molecules. Therefore, each silent variant of the nucleic acid encoding a polypeptide is implicitly contained in each of the sequences described.
[0136] For polypeptide sequences, “conservatively modified variants” include individual substitutions, deletions, or additions to the polypeptide sequence that result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitutions that provide functionally similar amino acids are well known in the art. Such conservedly modified variants are, in addition to and do not exclude, the polymorphic variants, interspecies homologs, and alleles of the present invention. The following eight groups contain amino acids that are conservedly substituted for each other: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M) (see, for example, Creighton, Proteins (1984)). In some implementations, the term "conservative sequence modification" is used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody containing an amino acid sequence.
[0137] As used herein, the term "optimized" refers to a nucleotide sequence with selected codons that has been modified to encode an amino acid sequence in production cells or organisms, typically eukaryotic cells such as yeast cells, Pichia cells, fungal cells, Trichoderma cells, Chinese hamster ovary cells (CHO), or human cells. The optimized nucleotide sequence is modified to fully or to the greatest extent possible preserve the amino acid sequence originally encoded by the starting nucleotide sequence (also known as the "parental" sequence).
[0138] In the context of two or more nucleic acid or polypeptide sequences, the term "percentage identity" or "percentage similarity" refers to two or more identical sequences or subsequences. When comparing and aligning within a comparison window or designated region for maximum correspondence using the sequence comparison algorithm below or by manual alignment and visual inspection, two sequences are considered "substantially identical" if they have a specific percentage of identical amino acid residues or nucleotides (i.e., 60% identity in a specific region or, when not specified, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity across the entire sequence). Optionally, the identity is present in a region of at least about 30 nucleotides (or 10 amino acids) in length, or more preferably in a region of at least 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
[0139] For sequence comparisons, typically one sequence is used as a reference sequence, and the test sequence is compared to it. When using a sequence comparison algorithm, the test and reference sequences are input into the computer, and if necessary, the coordinates of the subsequences and the sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the percentage sequence identity of the test sequence relative to the reference sequence based on the program parameters.
[0140] As used herein, a “comparison window” includes a range of references selected from any number of adjacent positions, ranging from 20 to 600, typically from about 50 to about 200, and more typically from about 100 to about 150, wherein the sequence can be compared with a reference sequence of the same number of adjacent positions after optimal alignment of the two sequences. The sequence alignment methods used for comparison are well known in the art. For example, sequence alignment can be performed using the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c (1970), the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443 (1970), the similarity search method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), the computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, for example, Brent et al., Current Protocols in Molecular Biology, 2003) for optimal sequence alignment.
[0141] Two examples of algorithms suitable for determining percentage sequence identity and sequence similarity are the BLAST and BLAST2.0 algorithms, described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively. Software used for BLAST analysis is publicly available from the National Center for Biotechnology Information. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which match or satisfy a positive threshold score T when compared with words of the same length in the database sequence. T is called the neighbor word score threshold (Altschul et al., above). These initial neighbor word hits serve as seeds for the initial search to discover longer HSPs containing them. Word hits are extended in both directions along each sequence as long as the cumulative alignment score can be increased. For nucleotide sequences, a cumulative score is calculated using parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a score matrix is used to calculate the cumulative score. Word matching is stopped in each direction when: the cumulative alignment score drops by X from its highest value; the cumulative score reaches zero or below due to the accumulation of one or more negatively scored residues; or the end of any sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a default word length (W) of 11, an expected value (E) of 10, M = 5, N = -4, and a comparison of two strands. For amino acid sequences, the BLASTP program uses the default word length 3, and the expected value (E) 10 and BLOSUM62 score matrix (see Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89:10915) to compare (B) 50, expected value (E) 10, M=5, N=-4 and the two strands.
[0142] The BLAST algorithm also performs statistical analysis of the similarity between two sequences (see, for example, Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993). One similarity measure provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match will occur by chance between two nucleotide or amino acid sequences. For example, if the minimum sum probability in the comparison of the test nucleic acid with the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001, then the nucleic acid is considered similar to the reference sequence.
[0143] Alternatively, the algorithm integrated into the ALIGN algorithm (version 2.0) by E. Meyers and W. Miller (Comput. Appl. Biosci. 4:11-17, 1988) can be used, employing a PAM120 weighted residue table, a vacancy length penalty of 12, and a vacancy penalty of 4, to determine the percentage identity between two amino acid sequences. Furthermore, the algorithm of Needleman and Wunsch (J. Mol. Biol. 48:444-453, 1970), which is integrated into the GCG software package (available at www.gcg.com), can be used, employing a Blossom 62 matrix or a PAM250 matrix, and vacancy weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6, to determine the percentage identity between two amino acid sequences.
[0144] In addition to the percentage of sequence identity mentioned above, another indication that two nucleic acid sequences or peptides are substantially identical is the cross-reactivity of antibodies against the peptide encoded by the first nucleic acid and the peptide encoded by the second nucleic acid, as described below. Therefore, the peptide is often substantially identical to the second peptide; for example, the two peptides differ only due to conserved substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complementary sequences hybridize under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.
[0145] The term "nucleic acid" is used interchangeably with the term "polynucleotide" herein and refers to deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form and their polymers. The term includes nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, or unnaturally occurring, have similar binding properties to a reference nucleic acid, and are metabolized in a similar manner to a reference nucleotide. Examples of such analogs include, but are not limited to, phosphate thioesters, aminophosphate esters, methylphosphonates, chiral methylphosphonates, 2-O-methylribonucleotides, and peptide nucleic acids (PNAs).
[0146] Unless otherwise indicated, specific nucleic acid sequences also implicitly include their silent variants (e.g., degenerate codon substitutions) and complementary sequences, as well as explicitly indicated sequences. In particular, as described in detail below, degenerate codon substitutions can be accomplished by generating sequences in which the third position of one or more selected (or all) codons is replaced with a mixture of bases and / or deoxyinosine residues (Batzer et al., (1991) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) J. Biol. Chem. 260:2605-2608; and Rossolini et al., (1994) Mol. Cell. Probes 8:91-98).
[0147] In the context of nucleic acids, the term "effective link" refers to the functional relationship between two or more segments of a polynucleotide (e.g., DNA). Typically, it refers to the functional relationship between a transcriptional regulatory sequence and a transcriptional sequence. For example, if a promoter or enhancer sequence stimulates or regulates transcription of a coding sequence in a suitable host cell or other expression system, then that promoter or enhancer sequence effectively links the coding sequence. Generally, the promoter and transcriptional regulatory sequences that effectively link transcriptional sequences are physically adjacent to the transcribed sequence; that is, they act in cis. However, some transcriptional regulatory sequences, such as enhancers, do not need to be physically adjacent to or near the coding sequence (an enhancer enhances its transcription).
[0148] The terms “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acid residues. The terms apply to both typical and atypical amino acid polymers. Unless otherwise noted, a particular peptide sequence also implicitly includes variants of its conserved modifications.
[0149] As used herein, the term "immunoconjugate" or "antibody conjugate" refers to the connection of an antibody or an antibody fragment thereof with another reagent, such as a chemotherapeutic agent, toxin, immunotherapeutic agent, imaging probe, spectroscopic probe, etc. This connection can be through one or more covalent bonds, or non-covalent interactions, and may include chelation. A variety of adapters (many of which are known in the art) can be used to form immunoconjugates. Furthermore, immunoconjugates can be provided in the form of fusion proteins, which can be expressed from polynucleotides encoding the immunoconjugate. As used herein, "fusion protein" refers to a protein produced by connecting two or more genes or gene fragments that originally encode individual proteins, including peptides and polypeptides. Fusion proteins are produced by joining at the N or C ends, or by inserting a gene or gene fragment into a licensed region of one of the companion proteins. Translation of the fusion gene produces a single protein having functional properties derived from each of the initial proteins.
[0150] The term "subject" includes both humans and non-human animals. Non-human animals include all vertebrates, such as mammals and non-mammals, including non-human primates, sheep, dogs, cows, chickens, amphibians, and reptiles. Unless otherwise specified, the terms "patient" or "subject" are used interchangeably in this document.
[0151] As used herein, the term "cytotoxin" or "cytotoxic agent" refers to any agent that is harmful to cell growth and proliferation and may act to reduce, inhibit or destroy cells or malignant tumors.
[0152] As used herein, the term "anticancer agent" refers to any agent that can be used to treat cell-proliferating disorders such as cancer, including but not limited to cytotoxic agents, chemotherapy agents, radiotherapy and radiotherapy agents, targeted anticancer agents, and immunotherapy agents.
[0153] The terms "pharmaceutical portion" or "payload" are used interchangeably and refer to the chemical portion of the antibody or antibody fragment incorporated in this invention, and may include any portion used for attaching the antibody or antibody fragment. For example, the pharmaceutical portion or payload may be an anticancer agent, anti-inflammatory agent, antifungal agent, antibacterial agent, antiparasitic agent, antiviral agent, or anesthetic. In some embodiments, the pharmaceutical portion is selected from V-ATPase inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule stabilizers, microtubule destabilizers, aristatin, dolalastatin, metansan-like compounds, MetAP (methionine aminopeptidase), inhibitors of protein CRM1 nuclear export, DPPIV inhibitors, inhibitors of mitochondrial phosphoryl transfer reactions, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, proteasome inhibitors, kinase inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalating agents, DNA minor groove binding agents, and DHFR inhibitors. Suitable examples include arithmeticins such as MMAE and MMAF; cephalosporins such as γ-cephalosporins; and metansan derivatives such as DM1 and DM4. Methods for attaching each of these to connectors compatible with the antibodies and methods of the present invention are known in the art. See, for example, Singh et al., (2009) Therapeutic Antibodies: Methods and Protocols, Vol. 525, 445-457. Furthermore, the payload can be a biophysical probe, fluorophore, spin label, infrared probe, affinity probe, chelating agent, spectroscopic probe, radioactive probe, lipid molecule, polyethylene glycol, polymer, spin label, DNA, RNA, protein, peptide, surface, antibody, antibody fragment, nanoparticle, quantum dot, liposome, PLGA particle, sugar or polysaccharide, reactive functional group, or a conjugate, surface, etc., that can link the conjugate to another part.
[0154] The term "drug-antibody ratio" (also known as "DAR") refers to the effective payload or number of drug moieties of an immunoconjugate bound to it. For example, a drug-antibody ratio of 2 indicates the average number of drug moieties bound to each antibody in the immunoconjugate sample. Some individual immunoconjugates with a drug-antibody ratio of 2 in a sample may have no or only one drug moiety bound to them; other immunoconjugates in the same sample will have two, three, four, or even more moieties on individual antibodies. However, the average in the sample will be 2. Different methods exist in the art for measuring the drug-antibody ratio of immunoconjugates.
[0155] In embodiments of the invention, the DAR in the immunoconjugated sample can be “homogeneous.” A “homogeneous conjugated sample” is a sample having a narrow distribution of DAR. As an exemplary embodiment, in a homogeneous conjugated sample with a DAR of 2, the sample may contain unconjugated antibodies and some antibodies having more than two portions conjugated with about 2 DARs. “Most of the sample” means that at least 70%, at least 80%, or at least 90% of the antibodies in the sample will conjugate to both portions.
[0156] As an exemplary implementation, in a homogeneous conjugated sample with a DAR of 4, the sample may contain antibodies having more or fewer than four portions conjugated with a DAR of about 4. "Most samples" means that at least 70%, at least 80%, or at least 90% of the antibodies in the sample are conjugated to the four portions.
[0157] As an exemplary implementation, in a homogeneous conjugated sample with a DAR of 6, the sample may contain antibodies having more or fewer than six portions conjugated to about 6 DAR. "Most samples" means that at least 70%, at least 80%, or at least 90% of the antibodies in the sample are conjugated to the six portions.
[0158] As an exemplary implementation, in a homogeneous conjugated sample with a DAR of 8, the sample may contain some antibodies having fewer or more than eight portions conjugated with a DAR of about 4. "Most of the sample" means that at least 70%, or at least 80%, or at least 90% of the antibodies in the sample will be conjugated to the eight portions.
[0159] An immunoconjugate with a drug-to-antibody ratio of approximately 2 refers to an immunoconjugate sample in which the drug-to-antibody ratio can vary in the range of approximately 1.6–2.4 part / antibody, 1.8–2.3 part / antibody, or 1.9–2.1 part / antibody.
[0160] An immunoconjugate with a drug-to-antibody ratio of approximately 4 refers to an immunoconjugate sample in which the drug-to-antibody ratio can vary in the range of approximately 3.6–4.4 part / antibody, 3.8–4.3 part / antibody, or 3.9–4.1 part / antibody.
[0161] An immunoconjugate with a drug-to-antibody ratio of approximately 6 refers to an immunoconjugate sample in which the drug-to-antibody ratio can vary in the range of approximately 5.6–6.4 part / antibody, 5.8–6.3 part / antibody, or 5.9–6.1 part / antibody.
[0162] An immunoconjugate with a drug-to-antibody ratio of approximately 8 refers to an immunoconjugate sample in which the drug-to-antibody ratio can vary in the range of approximately 7.6–84 parts / antibody, 7.8–8.3 parts / antibody, or 7.9–8.1 parts / antibody.
[0163] "Tumor" refers to the growth and proliferation of proliferative cells, whether malignant or benign, and all precancerous and cancerous cells and tissues.
[0164] The term "antitumor activity" refers to a reduction in the rate of tumor cell proliferation, viability, or metastatic activity. Possible ways to demonstrate antitumor activity include showing a decrease or reduction in the growth rate of abnormal cells or tumor size stability during treatment. This activity can be assessed using recognized in vitro or in vivo tumor models, including but not limited to xenograft models, allogeneic graft models, MMTV models, and other known models in the art.
[0165] The term "malignant tumor" refers to a non-benign tumor or cancer. As used herein, the term "cancer" includes malignant tumors characterized by disordered or uncontrolled cell growth. Exemplary cancers include carcinoma, sarcoma, leukemia, and lymphoma.
[0166] The term “cancer” includes primary malignant tumors (e.g., those tumors whose cells have not yet migrated to a site in the subject’s body other than the site of the primary tumor) and secondary malignant tumors (e.g., those tumors that originate from metastases, where the metastasis is the migration of tumor cells to a second site different from the primary tumor).
[0167] As used herein, the terms "optical isomer" or "stereoisomer" refer to any plurality of stereoisomeric configurations that may exist for a given compound of the invention and include geometric isomers. It should be understood that substituents may be attached to the chiral center of a carbon atom. The term "chiral" refers to a molecule that has a non-overlapping property on its mirror partner, while the term "chiral" refers to a molecule that is overlapping on its mirror partner. Thus, the invention includes enantiomers, diastereomers, or racemates of compounds. An "enantiomer" is a pair of stereoisomers that are non-overlapping mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Where appropriate, this term is used to specify racemic mixtures. A "diastereomer" is a stereoisomer that has at least two asymmetric atoms but is not a mirror image of each other. Absolute stereochemistry is specified according to the Cahn-Lngold-Prelog RS system. When the compound is a pure enantiomer, the stereochemistry on each chiral carbon can be specified by R or S. Compounds whose absolute configuration is unknown are designated as (+) or (-) based on the direction (right-handed or left-handed) of their rotational plane-polarized light at the wavelength of the sodium D line. Some of the compounds described herein contain one or more asymmetric centers or axes and thus produce enantiomers, diastereomers, and other stereoisomers defined in absolute stereochemistry as (R)- or (S)-.
[0168] Depending on the choice of starting materials and methods, the compound may exist as one of the possible isomers or a mixture thereof, for example as a pure optical isomer, or as a mixture of isomers, such as racemic compounds and diastereomeric mixtures, depending on the number of asymmetric carbon atoms. This invention aims to include all such possible isomers, including racemic mixtures, diastereomeric mixtures, and optically pure forms. Optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent can be of E or Z configuration. If the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituent can have a cis or trans configuration. All tautomeric forms are also intended to be included.
[0169] As used herein, the term "salt" refers to an acid addition salt or a base addition salt of the compounds of the present invention. "Salt" specifically includes "pharmaceutically acceptable salts." The term "pharmaceutically acceptable salt" refers to a salt that retains the biological efficacy and properties of the present invention and is generally not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid salts and / or base salts due to the presence of amino and / or carboxyl groups or similar groups.
[0170] Pharmaceutically acceptable acid addition salts can be formed using inorganic and organic acids, such as acetates, aspartates, benzoates, benzenesulfonates, bromides / hydrobromines, bicarbonates / carbonates, hydrogen sulfates / sulfates, camphor sulfonates, chlorides / hydrochlorides, chlorotheophyllinate, citrates, ethanedisulfonates, fumarates, gluconate, glucuronide, glucuronide, hippurate, hydroiodide / iodide, hydroxyethyl sulfonate, lactate, lacturonide, dodecyl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methyl sulfate, naphthate, naphthalenesulfonate, nicotinate, nitrates, stearate, oleate, oxalate, palmitate, pyrate, phosphates / hydrogen phosphates / dihydrogen phosphates, polygalacturonates, propionates, stearates, succinates, sulfosalicylate, tartrates, toluenesulfonates, and trifluoroacetates.
[0171] Inorganic acids that can derive salts include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid.
[0172] Organic acids that can be used to derive salts include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, toluenesulfonic acid, and sulfosalicylic acid. Pharmaceutically acceptable base addition salts can be formed using inorganic and organic bases.
[0173] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I through XII of the periodic table. In some embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.
[0174] Organic bases that can derive salts include, for example, primary, secondary, and tertiary amines, as well as substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins. Some organic amines include isopropylamine, benzathine penicillin, choline, diethanolamine, diethylamine, lysine, meglumine, piperazine, and aminobutanetriol.
[0175] Pharmaceutically acceptable salts of the present invention can be synthesized from the base or acid fraction using conventional chemical methods. Generally, such salts can be prepared by reacting the free acid form of these compounds with a suitable stoichiometric amount of a base (such as Na, Ca, Mg, or K hydroxides, carbonates, bicarbonates, etc.), or by reacting the free base form of these compounds with a suitable stoichiometric amount of an acid. Such reactions are typically carried out in water or an organic solvent, or a mixture of both. Generally, non-aqueous media such as ethers, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred for application. Additional lists of suitable salts can be found, for example, in Remington's Pharmaceutical Sciences, 20th edition, Mack Publishing Company, Easton, Pa., (1985); and Stahl and Wermuth's Handbook of Pharmaceutical Salts: Properties, Selection, and Use (Wiley-VCH, Weinheim, Germany, 2002).
[0176] Any chemical formulas given herein are intended to represent both the unlabeled and isotopically labeled forms of the compounds. Isotopically labeled compounds have the structures described by the chemical formulas given herein, except that one or more atoms are replaced by atoms of a selected atomic weight or mass number. Examples of isotopes that can be incorporated into the compounds of this invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as... 2 H, 3 H, 11 C 13 C 14 C 15 N、 18 F, 31 P, 32 P, 35 S, 36 Cl、 125 I. This invention includes various isotope-labeled compounds as defined herein, such as radioactive isotopes, such as... 3 H and 14 Compounds containing C, or non-radioactive isotopes, such as 2 H and 13 Compounds containing C. These isotope-labeled compounds can be used for metabolic studies (utilizing...) 14 C) Reaction kinetics studies (using, for example) 2 H or 3H) Detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), including drug or substrate tissue distribution assays, or in patients undergoing radiation therapy. Specifically, 18 F or labeled compounds are particularly desirable for PET or SPECT studies. Isotope-labeled compounds of formula (I) can generally be prepared using conventional techniques known to those skilled in the art or by methods similar to those described in the appended examples and preparations, using an appropriate isotope-labeled reagent instead of the previously used unlabeled reagent.
[0177] In addition, heavier isotopes, especially deuterium (i.e., 2 Substitution with H or D can provide certain therapeutic advantages due to increased metabolic stability, such as increased in vivo half-life or reduced dose requirement or improved therapeutic index. It should be understood that in this context, deuterium is considered a substituent for compounds of formula (I). The concentration of the heavier isotope, particularly deuterium, can be defined by an isotope enrichment factor. As used herein, the term "isotope enrichment factor" refers to the ratio between the isotopic abundance and the native abundance of the specified isotope. If the substituent in the compound of the present invention is indicated as deuterium, then the compound has an isotopic enrichment factor of at least 3500 (52.5% deuterium doping on each specified deuterium atom), at least 4000 (60% deuterium doping), at least 4500 (67.5% deuterium doping), at least 5000 (75% deuterium doping), at least 5500 (82.5% deuterium doping), at least 6000 (90% deuterium doping), at least 6333.3 (95% deuterium doping), at least 6466.7 (97% deuterium doping), at least 6600 (99% deuterium doping), or at least 6633.3 (99.5% deuterium doping) for each specified deuterium atom.
[0178] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delay agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, and combinations thereof, as known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th edition. Mack Printing Company, 1990, pp. 1289-1329). Consider the use of any conventional carrier in therapeutic or pharmaceutical compositions, except where any conventional carrier is incompatible with the active ingredient.
[0179] The term "therapeuticly effective amount" for compounds of the present invention refers to the amount of the compound of the present invention that will elicit a biological or medical response in a subject, such as a reduction or inhibition of enzyme or protein activity, or improvement of symptoms, relief of condition, slowing or delaying of disease progression, or prevention of disease. In a non-limiting embodiment, the term "therapeuticly effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, effectively at least partially relieves, inhibits, prevents and / or improves a condition or symptom or disease, or at least partially inhibits the activity of a target enzyme or receptor.
[0180] As used herein, the terms “inhibit,” “inhibition,” or “inhibiting” refer to the reduction or suppression of a given condition, symptom, ailment, or disease, or a significant reduction in the baseline activity of a biological activity or process.
[0181] As used herein, the term "treat," "treating," or "treatment" for any disease or condition, in one embodiment, means improving the disease or condition (i.e., slowing down or preventing or reducing the occurrence of the disease or at least one of its clinical symptoms). In another embodiment, "treat," "treatment," or "treatment" means alleviating or improving at least one physical parameter, including those that the patient may not be able to discern. In yet another embodiment, "treat," "treatment," or "treatment" means physically (e.g., stabilizing discernible symptoms), physiologically (e.g., stabilizing bodily parameters), or by both modulating the disease or condition. In yet another embodiment, "treat," "treatment," or "treatment" means preventing or delaying the onset or occurrence or progression of a disease or condition.
[0182] As used in this article, a subject “needs” treatment if the subject will benefit from the treatment biologically, medically, or in terms of quality of life.
[0183] As used herein, the terms “a,” “an,” “the,” and similar terms used in the context of this invention (especially in the context of the claims) will be understood to cover both singular and plural forms, unless otherwise stated herein or explicitly contradicted by the context.
[0184] As used herein, the term "thiol-maleimide" describes a group formed by the reaction of a thiol group with maleimide, which has this general formula.
[0185]
[0186] Wherein Y and Z are groups linked by a thiol-maleimide linker and can be linker units, and can be attached to an antibody or payload. In some cases, Y is the modified antibody of the present invention, and the sulfur atom shown in the formula comes from a cysteine residue at one of the substitution sites described herein; while Z represents a linker unit for attaching a payload.
[0187] As used herein, a “connector unit (LU)” refers to two parts, such as the covalent chemical link between an antibody and a payload. Each LU may contain one or more components as described herein, such as L1, L2, L3, L4, L5, and L6. Connector units can be selected to provide suitable spacing between the connected parts, provide certain physicochemical properties, or allow the connector unit to be cleaved under certain conditions.
[0188] As used in this paper, "cleavable" finger joints or joint units (LUs) connect two parts via covalent linkage, but are broken down under physiological conditions to separate the covalent linkage between the parts. Cleavage can be enzymatic or non-enzymatic, but generally releases the payload from the antibody without degrading it.
[0189] As used in this article, "uncuttable" refers to a linker or linker unit (LU) that is not sensitive to degradation under physiological conditions. Although the linker can be physiologically modified, it retains the payload to bind the antibody until the antibody is substantially degraded, i.e., antibody degradation in vivo before linker cleavage.
[0190] As used in this article, "cyclooctyne" refers to an 8-membered ring (acetylene) containing a carbon-carbon triple bond. This ring may optionally be fused with one or two benzene rings, and it can be 1-4 C-linked. 1-4 Alkyl, C 1-4 The cyclooctyne can be substituted with alkoxy, halogen, hydroxyl, COOH, COOL1, -C(O)NH-L1, O-L1, or similar groups, and may contain N, O, or S as ring members. In a preferred embodiment, the cyclooctyne can be a C8 hydrocarbon ring, particularly a saturated separated ring except for the triple bond, and it can be substituted with F or a hydroxyl group, and can be connected by a connector or LU via –O-, –C(O), C(O)NH, or C(O)O.
[0191] As used herein, "cyclooctyne" refers to an 8-membered ring containing at least one double bond, particularly a trans double bond. This ring may optionally incorporate one or two benzene rings, and can be 1-4 C-linked. 1-4 Alkyl, C 1-4The cyclooctene may be substituted with alkoxy, halogen, hydroxyl, COOH, COOL1, -C(O)NH-L1, O-L1, or similar groups, and may contain N, O, or S as ring members. In a preferred embodiment, the cyclooctene may be a saturated, isolated C8 hydrocarbon ring except for the trans double bond, and may optionally be substituted with F or hydroxyl groups, and may be connected via –O-, –C(O), C(O)NH, or C(O)O linkers or LU.
[0192] All methods described herein may be performed in any suitable order unless otherwise stated herein or explicitly contradicted by the context. Any and all instances or exemplary language (e.g., “as”) provided herein are intended only to better illustrate the invention and do not constitute a limitation on the scope of the invention as otherwise claimed. Brief description of the attached diagram
[0193] Figure 1. Surface accessibility of amino acid residues in the human IgG1 heavy chain (A) and κ light chain (B). Surface accessibility was calculated using SurfaceRacer 5.0 and expressed as square angstroms.
[0194] Figure 2 Location of the selected 92TAG mutation in the structure of human IgG1 with the κ light chain. The residues selected for the TAG mutation are shown in black on only one of the two heavy chains and the selected residues are shown on one of the two κ light chains (1HZH.pdb). The open-source molecular modeling software package PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0) was used. LLC) display structure.
[0195] Figure 3 Amino acid sequence alignment of the heavy chain constant region of trastuzumab and antibody 14090. Residues in trastuzumab and antibody 14090 that are mutated to Cys are underlined. Amino acid residues in the heavy chain are numbered using the Eu numbering system (Edelman et al., 1969).
[0196] Figure 4 Amino acid sequence alignment of the constant regions of trastuzumab, human IgG1, IgG2, IgG3 and IgG4.
[0197] Figure 5. Amino acid sequence alignment of the constant regions of the human κ and λ light chains. A. Residues mutated to Cys in the κ light chain of trastuzumab and the λ light chain of antibody 14090 are underlined. B. Residues selected for the Cys mutation in the PyMOL structural model of the human λ light chain (Protein Structure Databank entry 3G6D.pdb).
[0198] Figure 6 Trastuzumab Cys antibody was analyzed by non-reducing SDS-PAGE.
[0199] Figure 7 Size exclusion chromatography of trastuzumab LC-S156C mutant antibody (dashed line) and wild-type trastuzumab (solid line).
[0200] Figure 8. Analysis of wild-type trastuzumab (A) and trastuzumab LC-E158C mutant antibody (B) by reversed-phase high-performance liquid chromatography (RP-HPLC).
[0201] Figure 9 MS analysis of trastuzumab LC-R108C mutant antibody after protein A purification (complete MS).
[0202] Figure 10 The structure of MC-MMAF.
[0203] Figure 11. RP-HPLC analysis of conjugated mixtures of trastuzumab Cys antibody and MC-MMAF. RP-HPLC traces of the conjugated mixtures are shown as dashed lines. RP-HPLC traces of the unmodified antibody are shown as solid lines. A. LC-R108C-MMAF, B. HC-360C-MMAF, C. LC-S156C-MMAF, and D. HC-S275C-MMAF ADC.
[0204] Figure 12. RP-HPLC analysis of the conjugated mixture of trastuzumab Cys antibody and MC-MMAF. The RP-HPLC trace of the conjugated mixture is shown as a dashed line. The RP-HPLC trace of the unmodified antibody is shown as a solid line. A. HC-S134C-MMAF, and B. HC-S136C-MMAF ADC.
[0205] Figure 13 Trastuzumab Cys-MMAF ADCs were analyzed by analytical size exclusion chromatography (AnSEC). Trastuzumab HC-K290C-MMAF ADC (short dashed line), trastuzumab LC-R142C-MMAF ADC (dashed line), and trastuzumab LC-L154C-MMAF ADC (dotted dashed line) were compared with unmodified wild-type trastuzumab (solid line).
[0206] Figure 14 Thermolysis curves of unmodified wild-type trastuzumab and trastuzumab HC-T335C-MMAF, trastuzumab HC-S337C-MMAF and trastuzumab HC-K360C-MMAF ADCs.
[0207] Figure 15. Cell proliferation assay of trastuzumab LC-S159C-MMAF cells with A.HCC1954, B.MDA-MB231 clone 16 and C.MDA-MB231 clone 40 cells.
[0208] Figure 16 IC50 of trastuzumab Cys-MMAF ADCs in MDA-MB231 clone 16 cell proliferation assay 50 .
[0209] Figure 17. Cell proliferation assay of antibody 14090HC-S375C-MMAF ADC with A.CMK11-5 and B.Jurkat cells.
[0210] Figure 18. Pharmacokinetic studies of trastuzumab LC-Cys-MMAF ADCs without significant drug loss. A. Wild-type unconjugated trastuzumab, B. LC-K107C-MMAF, C. LC-R108C-MMAF, D. LC-L154C-MMAF, and E. LC-S159C-MMAF ADC.
[0211] Figure 19. Pharmacokinetic studies of trastuzumab HC-Cys-MMAF ADCs without significant drug loss. A. HC-K121C-MMAF, B. HC-L174C-MMAF, C. HC-E258C-MMAF, and D. HC-R292C-MMAF ADC.
[0212] Figure 20. Pharmacokinetic studies of trastuzumab Cys-MMAF ADCs with significant drug loss. A. LC-T129C-MMAF, B. LC-E143C-MMAF, C. HC-K246C-MMAF, and D. HC-R344C-MMAF ADC.
[0213] Figure 21. Pharmacokinetic studies of two trastuzumab Cys-MMAF ADCs demonstrating rapid clearance in vivo. A. HC-T335C-MMAF and B. HC-S337C-MMAF ADC.
[0214] Figure 22 In vivo efficacy study of trastuzumab Cys-MMAF ADCs in a clonal 16 xenograft mouse model of MDA-MB231.
[0215] Figure 23: Retention time of trastuzumab Pcl MMAF DAR 2 ADCs as measured by hydrophobic interaction chromatography. ABA-MMAF is attached to the Pcl residue that replaces the indicated HC or LC residue. A) HC-conjugated ADCs. B) LC-conjugated ADCs. Retention time (WT) of unconjugated wild-type antibody.
[0216] Figure 24. Localization of selected payload sites in the structure of human IgG1 with the κ light chain. Selected residues are shown in black on only one of the two heavy chains, and selected residues are shown for one of the two κ light chains (1HZH.pdb). The open-source molecular modeling software package (The PyMOL Molecular Graphics System, Version 1.5.0) was used. LLC) shows three rotations of the structure.
[0217] Figure 25. Pharmacokinetic studies of trastuzumab with DAR 4, 6 and 8 and antibody 14090 Cys-MMAF ADCs prepared using antibodies with 2, 3 or 4 Cys mutations. DAR 4 trastuzumab ADCs: HC-E258C-LC-S159C-MMAF (A), HC-S375C-LC-S159C-MMAF (B), HC-E258C-LC-E165C-MMAF (C), HC-S375C-LC-E165C-MMAF (D), HC-E152C-LC-R142C-MMAF (E), HC-P171C-LC-R142C-MMAF and HC-E152C-LC-S159C-MMAF (G); DAR 4 antibody 14090 ADCs: HC-S375C-LC-A143C-MMAF (H), HC-K360C-LC-V159C-MMAF (I), and HC-S375C-LC-V159C-MMAF (J); K.DAR 6 Trastuzumab ADCs: HC-K334C-S375C-LC-E165C-MMAF and HC-K334C-K392C-LC-E165C-MMAF; L. DAR 8 Trastuzumab ADCs: HC-K334C-K360C-S375C-LC-E165C-MMAF, HC-K334C-K360C-K392C-LC-E165C-MMAF and HC-K334C-S375C-K392C-LC-E165C-MMAF. Antibody 14090 is cross-reactive in mice and is therefore cleared more rapidly than trastuzumab ADCs that do not bind any mouse antigens. Invention Details
[0218] This invention provides a method for specifically labeling an antibody or antibody fragment by replacing one or more amino acid sites of a parent antibody or antibody fragment with a cysteine amino acid (“Cys”) at a specific position, thereby enabling the modified antibody or antibody fragment to conjugate a variety of reagents (e.g., cytotoxic agents). This invention also provides immunoconjugates generated using the methods described herein.
[0219] When cysteine is modified into a parent antibody or antibody fragment, the modified antibody or antibody fragment, having cysteine or glutathione (GSH) attached to the modified cysteine site via disulfide bonds, is first recovered from the expression medium (Chen et al., (2009) mAbs 16, 353-571). The attached cysteine or GSH is then removed in a reduction step, which also reduces all native interchain disulfide bonds of the parent antibody or antibody fragment. In a second step, these disulfide bonds are re-oxidized before conjugation occurs. This disclosure shows that the re-oxidation step does not proceed smoothly when cysteine is modified at certain sites, possibly due to incorrect disulfide bond formation. Therefore, this invention provides distinct sets of sites, respectively, on the antibody heavy chain constant region and the antibody light chain constant region, wherein Cys substitution as described herein produces modified antibodies or antibody fragments that perform well during re-oxidation and also produce stable and well-performing immunoconjugates.
[0220] The site-specific antibody labeling of the present invention can be achieved using a variety of chemically readily available labeling reagents, such as anticancer agents, fluorophores, peptides, sugars, detergents, polyethylene glycol, immunostimulants, radiographic probes, drug precursors, and other molecules.
[0221] Therefore, the present invention provides a method for preparing homogeneous immunoconjugates having a defined drug-to-antibody ratio for use in cancer treatment and other indications, as well as imaging reagents. The present invention also provides immunoconjugates thus prepared, and pharmaceutical compositions comprising these immunoconjugates. The method of the present invention can be used in combination with other conjugation methods known in the art.
[0222] The following embodiments represent certain aspects and variations of the present invention:
[0223]
[0224] Where Ab represents an antibody or antibody fragment that contains at least one cysteine residue at one of the preferred cysteine substitution sites described herein.
[0225] LU is the connector unit as described herein;
[0226] X represents the payload or drug component;
[0227] And n is an integer from 1 to 16. In these embodiments, n is preferably about 2, about 4, about 6, or about 8. LU is typically a set of formulas –L1-L2-L3-L4-L5-L6-, where L1, L2, L3, L4, L5, and L6 are independently selected from A1-, -A1X. 2 -and-X 2 -;in:
[0228] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(C(R 4 )2) n -、-(O(CH2) n ) m -、(O(C(R 4 )2) n ) m -、
[0229] -((CH2) n O) m -、-((C(R 4 )2) n O) m -、-((CH2) n O) m (CH2) n -、((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NH-、(CH2) n NHC(=O)-、-(C(R 4 )2) n NHC(=O)-, -NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2) n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-, -S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n-、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n NHC(=O)(CH2) n -、(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -, or (O(C(R) 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0230] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0231] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0232] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0233] Each R 6 Independently selected from H, fluorine, C(=O)OH substituted benzyloxy, –C(=O)OH substituted benzyl, C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0234] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0235] R 8 Selected independently
[0236] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0237] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0238] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0239] In some of these embodiments, the immune conjugate comprises a set of formulas
[0240]
[0241] The sulfur atom is the sulfur of a cysteine residue in the modified antibody or antibody fragment and is located at one of the substitution sites identified in this paper.
[0242] In any of the above embodiments, the cysteine substitution site can be a position corresponding to one of the sites identified by position numbering, even if the position of the site in the sequence has been altered by modification or truncation of the full-length antibody. The corresponding site can be easily identified by comparing the antibody or fragment with the full-length antibody.
[0243] 1. Site-specific cysteine-modified antibodies
[0244] Site-specific markers
[0245] The antibodies of this invention (e.g., parental antibodies, optionally containing one or more atypical amino acids) are numbered according to the EU numbering system described in Edelman et al., (1969) Proc. Natl. Acad. USA 63:78-85, except for the λ light chain, which is numbered according to the Kabat numbering system described in Kabat et al., (1991) 5th ed. NIH Publication No. 91-3242. The human IgG1 constant region is used as representative of this application. However, the invention is not limited to human IgG1; the corresponding amino acid positions can be readily deduced by sequence alignment. For example, Figure 4 The sequence alignment of the constant regions of the heavy chains of human IgG1, IgG2, IgG3, and IgG4 is shown, which can provide information for... Figure 4 The IgG2, IgG3, and IgG4 shown in the diagram readily identify the Cys modification sites identified in the IgG1 constant region. For the light chain constant region, IgG1, IgG2, IgG3, and IgG4 are identical. Table 1 below lists the amino acid positions in the constant region of the antibody heavy chain that can be substituted with cysteine. Table 2 lists the amino acid positions in the constant region of the antibody κ light chain that can be substituted with cysteine. Table 3 lists the amino acid positions in the constant region of the antibody λ light chain that can be substituted with cysteine.
[0246] Table 1. Cysteine substitution sites identified in the heavy chain constant region of human IgG1 (sites numbered according to the EU numbering system).
[0247]
[0248]
[0249]
[0250] Table 2. Cysteine substitution sites identified in the constant region of the κ light chain of human IgG1 (sites numbered according to the EU numbering system).
[0251]
[0252]
[0253] Table 3. Cysteine substitution sites identified on the λ light chain of human IgG1.
[0254]
[0255] Due to the high sequence homology of the constant regions of IgG1, IgG2, IgG3 and IgG4 antibodies, the discovery of this invention is not limited to any particular antibody or antibody fragment.
[0256] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof and a pharmaceutical moiety, wherein the modified antibody or antibody fragment thereof comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions in its heavy chain constant region selected from positions identified in Table 1. In a particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof and a pharmaceutical moiety, wherein the modified antibody or antibody fragment comprises cysteine substitutions for one or more amino acids in its constant region selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375, and 392 of the heavy chain. For example, the immunoconjugate of the present invention comprises a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof is located at positions selected from the heavy chain: 121 and 124, 121 and 152, 121 and 171, 121 and 174, 121 and 258, 121 and 292, 121 and 333, 121 and 334, 121 and 360, 121 and 375, 121 and 392, 124 and... 152, 124 and 171, 124 and 174, 124 and 258, 124 and 292, 124 and 333, 124 and 334, 124 and 360, 124 and 375, 124 and 3 92,152 and 171, 152 and 174, 152 and 258, 152 and 292, 152 and 333, 152 and 334, 152 and 360, 152 and 375, 152 and 392 ,171 and 174, 171 and 258, 171 and 292, 171 and 333, 171 and 360, 171 and 375, 174 and 258, 174 and 292, 174 and 333, 174 and 334, 174 and 360, 174 and 375, 174 and 392, 258 and 292, 258 and 333, 258 and 334, 258 and 360, 258 and 375, 25 The constant regions of 8 and 392, 292 and 333, 292 and 334, 292 and 360, 292 and 375, 292 and 392, 333 and 334, 333 and 360, 333 and 375, 333 and 392; 334 and 360, 334 and 375, 334 and 392, 360 and 375, 360 and 392 or 375 and 392 contain substitutions of two amino acids for cysteine.
[0257] In another embodiment, the immunoconjugate of the present invention comprises a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof is located at positions selected from the heavy chain: 121, 124, and 152; 121, 124, and 171; 121, 124, and 174; 121, 124, and 258; 121, 124, and 292; 121, 124, and 333; 121, 124, and 334; 121, 124, and 360; 121, 124, and 375; 121, 124, and 392; 121, 152, and 171; 121, 152, and 174; 121, 152, and 258; 121, 152, and 292; 121, 152, and 333; 121, 152, and 3... 34; 121, 152 and 360; 121, 152 and 375; 121, 152 and 392; 121, 171 and 174; 121, 171 and 258 ;121, 171 and 292; 121, 171 and 333; 121, 171 and 334; 121, 171 and 360; 121, 171 and 375; 1 21, 171 and 392; 121, 174 and 258, 121, 174 and 292; 121, 174 and 333; 121, 174 and 334; 121 , 174 and 360; 121, 174 and 375; 121, 174 and 392; 121, 258 and 292; 121, 258 and 333; 121, 25 8 and 334; 121, 258 and 360; 121, 258 and 375; 121, 258 and 392; 121, 292 and 333; 121, 292 and 334; 121, 292 and 360; 121, 292 and 375; 121, 292 and 392; 121, 333 and 334; 121, 333 and 36 0; 121, 333 and 375; 121, 333 and 392; 121, 334 and 360; 121, 334 and 375; 121, 334 and 392; 121, 360 and 375; 121, 360 and 392; 121, 375 and 392; 124, 152 and 171; 124, 152 and 174; 124 , 152 and 258; 124, 152 and 292; 124, 152 and 333; 124, 152 and 334; 124, 152 and 360; 124, 1 52 and 375; 124, 152 and 392; 124, 171 and 174; 124, 171 and 258; 124, 171 and 292; 124, 171 and 333; 124, 171 and 334; 124, 171 and 360; 124, 171 and 375; 124, 171 and 392; 124, 174 and 2 58; 124, 174 and 292; 124, 174 and 333; 124, 174 and 334; 124, 174 and 360; 124, 174 and 375;124, 174 + 392; 124, 258 + 292; 124, 258 + 333; 124, 258 + 334; 124, 258 + 360; 124, 258 + 375; 124, 258 + 392; 124, 292 + 333; 124, 292 + 334; 124, 292 + 360; 124, 292 sum 375; 124, 292 sum 392; 124, 333 sum 360; 124, 333 sum 334; 124, 333 sum 375; 124, 333 sum 392; 124, 334 sum 360; 124, 334 sum 375; 124, 334 sum 392; 124, 360 sum 375; 124, 360 sum 3 92; 124, 375 and 392; 152, 171 and 174; 152, 171 and 258; 152, 171 and 292; 152, 171 and 333; 152, 171 and 334; 152, 171 and 360; 152, 171 and 375; 152, 171 and 392; 152, 174 and 258; 1 52, 174 + 292; 152, 174 + 333; 152, 174 + 334; 152, 174 + 360; 152, 174 + 375; 152, 174 + 392; 152, 258 + 292; 152, 258 + 333; 152, 258 + 334; 152, 258 + 360; 152, 25 8 sum 375; 152, 258 sum 392; 152, 292 sum 333; 152, 292 sum 334; 152, 292 sum 360; 152, 292 sum 375; 152, 292 sum 392; 152, 333 sum 334; 152, 333 sum 360; 152, 333 sum 375; 152, 333 sum 39 2; 152, 334 + 360; 152, 334 + 375; 152, 334 + 392; 152, 360 + 375; 152, 360 + 392; 152, 375 + 392; 171, 174 + 258; 171, 174 + 292; 171, 174 + 333; 171, 174 + 334; 171 , 174 sum 360; 171, 174 sum 375; 171, 174 sum 392; 171, 258 sum 292; 171, 258 sum 292; 171, 258 sum 333; 171, 258 sum 334; 171, 258 sum 360; 171, 258 sum 375; 171, 258 sum 392; 171, 292 W333; 171, 292 W334; 171, 292 W360; 171, 292 W375; 171, 292 W392; 171, 333 W334; 171, 333 W360; 171, 333 W375; 171, 333 W392; 171, 334 W360; 171, 334 W392;171, 360 and 375; 171, 360 and 392; 171, 375 and 392; 174, 258 and 292; 174, 258 and 333; 174, 258 and 334; 174, 258 and 360; 174, 258 and 375; 174, 258 and 392; 174, 292 and 333; 174, 292 and 334; 174, 292 and 360; 174, 292 and 375; 174, 292 and 392; 174, 333 and 334; 174, 333 and 360; 174, 333 and 375; 174, 333 and 392; 174, 334 and 360; 174, 334 and 375; 174, 334 and 392; 174, 360 and 375; 174, 360 and 392; 174, 375 and 392; 258, 292 and 333; 258, 292 and 334; 258, 292 and 360; 258, 292 and 375; 258, 292 and 392; 258, 3 33 and 360; 258, 333 and 375; 258, 333 and 392; 258, 334 and 360; 258, 334 and 375; 258, 334 and 392; 258, 360 and 375; 258, 360 and 3 92; 258, 375 and 392; 292, 333 and 334; 292, 333 and 360; 292, 333 and 375; 292, 333 and 392; 292, 334 and 360; 292, 334 and 375; 2 92, 334, and 392; 292, 360, and 375; 292, 360, and 392; 292, 375, and 392; 333, 334, and 360; 333, 334, and 375; 333, 334, and 392; 333, 360, and 375; 333, 360, and 392; 333, 375, and 392; 334, 360, and 375; 334, 360, and 392; or 360, 375, and 392, wherein the constant region contains cysteine substitutions for three amino acids.
[0258] In one embodiment, the immunoconjugate of the present invention comprises a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises a cysteine substitution for four amino acids at positions selected from heavy chain positions 152, 333, 375 and 392; or 152, 334, 375 and 392 in their constant regions.
[0259] In a particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 2, 3, 9, 11, 12, 13, 14, 16, 21, 25, 26, 28, 30, 31, 32, 33, 34, 36, 38, 39, 40, 43, 44, 45, 46, 47, 51, 53, 54, 56, 57, or 60. In another particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 6, 7, 8, 15, 19, 20, 22, 23, 24, 27, 36, 37, 41, 49, 52, 55, 58, or 59.
[0260] In another embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises substitution of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) in its constant region at a position selected from those identified in Table 2. In a particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises substitution of one or more amino acids with cysteine in its constant region at positions selected from 107, 108, 142, 145, 159, 161, and 165 of the light chain, wherein the light chain is a human κ light chain. For example, the immunoconjugates of the present invention comprise an immunoconjugate of a modified antibody or an antibody fragment thereof and a pharmaceutical moiety, wherein the modified antibody or antibody fragment comprises, in its constant region selected from positions 107 and 108; 107 and 142; 107 and 145; 107 and 159; 107 and 161; 107 and 165; 108 and 142; 108 and 145; 108 and 159; 108 and 161; 108 and 165; 142 and 145; 142 and 159; 142 and 161; 142 and 165; 145 and 159; 145 and 161; 145 and 165; 159 and 161; 159 and 165; 161 and 165 of the light chain, wherein the light chain is a human κ light chain.In another embodiment, the immunoconjugate of the present invention comprises a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment is located at positions selected from light chains: 107, 108, and 142; 107, 108, and 145; 107, 108, and 159; 107, 108, and 161; 107, 108, and 165; 107, 142, and 145; 107, 142, and 159; 107, 142, and 161; 107, 142, and 165; 107, 145, and 159; 107, 142, and 161; 107, 142, and 165; 107, 145, and 159; 107, 145, and 161; 107, 145, and 165; 107, 159, and 161; 107, 159, and 165; 107, 161, and 165; 108, 142, and 145; 108, 1 42 and 159; 108, 142 and 161; 108, 142 and 165; 108, 145 and 159; 108, 145 and 161; 108, 145 and 1 65; 108, 159 and 161; 108, 159 and 165; 108, 161 and 165; 142, 145 and 159; 142, 145 and 161; 1 42, 145 and 165; 142, 159 and 161; 142, 159 and 165; 142, 161 and 165; 145, 159 and 161; 145, 159 and 165; 145, 161 and 165; or 159, 161 and 165, wherein the constant region of these compounds contains a substitution of three amino acids with cysteine, and wherein the light chain is the human κ light chain.
[0261] In a particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 63, 65, 68, 70, 72, 73, 74, 78, 79, 80, 81, 82, 83, 86, 87, or 88. In another embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 64, 66, 67, 84, 85, or 89.
[0262] In another embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises a substitution of one or more amino acids in a constant region of its light chain selected from positions identified in Table 3. In a particular embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises a substitution of one or more amino acids for cysteine in a constant region of its light chain selected from positions 143, 147, 159, 163, and 168, wherein the light chain positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain. For example, the immunoconjugates of the present invention comprise an immunoconjugate of a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment contains a cysteine substitution for two amino acids in its constant region selected from positions 143 and 147; 143 and 159; 143 and 163; 143 and 168; 147 and 159; 147 and 163; 147 and 168; 159 and 163; 159 and 168; or 163 and 168 of the light chain, wherein the light chain positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain. In another embodiment, the immunoconjugate of the present invention comprises an immunoconjugate of a modified antibody or an antibody fragment thereof and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises a cysteine substitution for three amino acids in its constant region selected from positions 143, 147 and 159; 143, 147 and 163; 143, 147 and 168; 143, 159 and 163; 143, 159 and 168; 143, 163 and 168; 147, 159 and 163; 147, 159 and 168; 147, 163 and 168; or 159, 163 and 168, wherein the light chain positions are numbered according to the Kabat system, and wherein the light chain is a human λ light chain.
[0263] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 92, 94, 96, 97, or 98. In another specific embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment thereof comprises SEQ ID NO: 93 or 95.
[0264] In one embodiment, the immunoconjugate may have about 2 or about 4 DARs. In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, wherein the modified antibody or antibody fragment comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid Cys substitutions on its heavy chain constant region at a position selected from those identified in Table 1, and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid Cys substitutions on its light chain constant region at a position selected from those identified in Table 2 or Table 3. In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises a Cys substitution of one or more amino acids in its heavy chain constant region selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375, and 392; and comprises a Cys substitution of one or more amino acids in its light chain constant region selected from positions 107, 108, 142, 145, 159, 161, and 165, wherein the light chain is a human κ light chain. In one embodiment, the modified antibody or antibody fragment of the present invention may comprise a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 107 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 108 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 142 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 145 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 159 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 161 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 165 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 165 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 165 of the human κ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 107 of the human κ light chain. Cys substitution at position 124 and Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and Cys substitution at position 107 of the human κ light chain.Cys substitution at position 152 of the heavy chain and at position 108 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and at position 142 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and at position 145 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and at position 159 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and at position 161 of the human κ light chain; or Cys substitution at position 152 of the heavy chain and at position 165 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and at position 108 of the human κ light chain. Cys substitution at position 7; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and... Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 258 of the heavy chain. Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 258 of the heavy chain; or Cys substitution at position 165 of the human κ light chain.Cys substitution at position 292 of the heavy chain and at position 107 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 108 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 142 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 145 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 159 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 161 of the human κ light chain; or Cys substitution at position 292 of the heavy chain and at position 161 of the human κ light chain. Cys substitution at position 5; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 333 of the heavy chain and... Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 334 of the heavy chain. Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 360 of the heavy chain, and Cys substitution at position 161 of the human κ light chain.Cys substitution at position 360 of the heavy chain and at position 165 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 107 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 108 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 142 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 145 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 159 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and at position 161 of the human κ light chain; or Cys substitution at position 375 of the heavy chain and... Cys substitution at position 165 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 107 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 108 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 142 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 145 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 159 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 161 of the human κ light chain; or Cys substitution at position 392 of the heavy chain and Cys substitution at position 165 of the human κ light chain. In one embodiment, the modified antibody or antibody fragment of the present invention comprises Cys substitution at positions 375 and 392 of the heavy chain and Cys substitution at position 165 of the human κ light chain. In one embodiment, the modified antibody or antibody fragment of the present invention may comprise Cys substitution at positions 334 and 375 of the heavy chain and Cys substitution at position 165 of the human κ light chain. In another embodiment, the modified antibody or antibody fragment of the present invention may comprise Cys substitution at positions 334 and 392 of the heavy chain and Cys substitution at position 165 of the human κ light chain. In one embodiment, those combined immunoconjugates may have about 4 or about 6 DARs.
[0265] In one embodiment, the modified antibody or antibody fragment of the present invention may comprise Cys substitutions at positions 334, 375, and 392 of the heavy chain, and a Cys substitution at position 165 of the human κ light chain. In one embodiment, the modified antibody or antibody fragment of the present invention may comprise Cys substitutions at positions 333, 375, and 392 of the heavy chain, and a Cys substitution at position 165 of the human κ light chain. In one embodiment, those combinations may have about 4, 6, or 8 DARs.
[0266] In one embodiment, the present invention provides an immunoconjugate comprising a modified antibody or an antibody fragment thereof, and a pharmaceutical portion, wherein the modified antibody or antibody fragment comprises a Cys substitution of one or more amino acids in its heavy chain constant region selected from positions 121, 124, 152, 171, 174, 258, 292, 333, 334, 360, 375, and 392; and comprises a Cys substitution of one or more amino acids in its light chain constant region selected from positions 143, 147, 159, 163, and 168, wherein the light chain is a human λ light chain. For example, the modified antibody or antibody fragment of the present invention may include a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 143 of the human λ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 147 of the human λ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 159 of the human λ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 163 of the human λ light chain; or a Cys substitution at position 121 of the heavy chain and a Cys substitution at position 168 of the human λ light chain. Cys substitution; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 143 of the light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 147 of the light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 159 of the light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 163 of the light chain; or Cys substitution at position 124 of the heavy chain and Cys substitution at position 168 of the light chain; or Cys substitution at position 159 of the heavy chain. Cys substitution at position 2, and Cys substitution at position 143 of the human λ light chain; or Cys substitution at position 152 of the heavy chain, and Cys substitution at position 147 of the human λ light chain; or Cys substitution at position 152 of the heavy chain, and Cys substitution at position 159 of the human λ light chain; or Cys substitution at position 152 of the heavy chain, and Cys substitution at position 163 of the human λ light chain; or Cys substitution at position 152 of the heavy chain, and Cys substitution at position 168 of the human λ light chain; or Cys substitution at position 171 of the heavy chain, and Cys substitution at position 171 of the human λ light chain. Cys substitution at position 143; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 147 of the light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 159 of the light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 163 of the light chain; or Cys substitution at position 171 of the heavy chain and Cys substitution at position 168 of the light chain; or Cys substitution at position 174 of the heavy chain and Cys substitution at position 143 of the light chain.Cys at position 174 of the heavy chain is replaced by Cys at position 147 of the light chain; or Cys at position 174 of the heavy chain is replaced by Cys at position 159 of the light chain; or Cys at position 174 of the heavy chain is replaced by Cys at position 163 of the light chain; or Cys at position 174 of the heavy chain is replaced by Cys at position 168 of the light chain; or Cys at position 258 of the heavy chain is replaced by Cys at position 143 of the light chain; or Cys at position 258 of the heavy chain is replaced by Cys at position 147 of the light chain; or Cys at position 258 of the heavy chain is replaced by Cys at position 159 of the light chain. Cys substitution at position 9; or Cys substitution at position 258 of the heavy chain, and Cys substitution at position 163 of the light chain; or Cys substitution at position 258 of the heavy chain, and Cys substitution at position 168 of the light chain; or Cys substitution at position 292 of the heavy chain, and Cys substitution at position 143 of the light chain; or Cys substitution at position 292 of the heavy chain, and Cys substitution at position 147 of the light chain; or Cys substitution at position 292 of the heavy chain, and Cys substitution at position 159 of the light chain; or Cys substitution at position 292 of the heavy chain, and Cys substitution at position 163 of the light chain; or Cys substitution at position 292 of the heavy chain, and Cys substitution at position 168 of the human λ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 143 of the human λ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 147 of the human λ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 159 of the human λ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 163 of the human λ light chain; or Cys substitution at position 333 of the heavy chain and Cys substitution at position 168 of the human λ light chain; or Cys substitution at position 334 of the heavy chain and Cys substitution at position 143 of the human λ light chain; or Cys substitution at position 334 of the heavy chain. Cys substitution on the light chain at position 147; or Cys substitution on the heavy chain at position 334; or Cys substitution on the light chain at position 159; or Cys substitution on the heavy chain at position 334; or Cys substitution on the light chain at position 163; or Cys substitution on the heavy chain at position 334; or Cys substitution on the light chain at position 168; or Cys substitution on the heavy chain at position 360; or Cys substitution on the light chain at position 143; or Cys substitution on the heavy chain at position 360; or Cys substitution on the light chain at position 147; or Cys substitution on the heavy chain at position 360; or Cys substitution on the light chain at position 159.Cys at position 360 of the heavy chain is replaced by Cys at position 163 of the light chain; or Cys at position 360 of the heavy chain is replaced by Cys at position 168 of the light chain; or Cys at position 375 of the heavy chain is replaced by Cys at position 143 of the light chain; or Cys at position 375 of the heavy chain is replaced by Cys at position 147 of the light chain; or Cys at position 375 of the heavy chain is replaced by Cys at position 159 of the light chain; or Cys at position 375 of the heavy chain is replaced by Cys at position 163 of the light chain. Cys at position 375 of the heavy chain is replaced by Cys at position 168 of the light chain; or Cys at position 392 of the heavy chain is replaced by Cys at position 143 of the light chain; or Cys at position 392 of the heavy chain is replaced by Cys at position 147 of the light chain; or Cys at position 392 of the heavy chain is replaced by Cys at position 159 of the light chain; or Cys at position 392 of the heavy chain is replaced by Cys at position 163 of the light chain; or Cys at position 392 of the heavy chain is replaced by Cys at position 168 of the light chain.
[0267] In embodiments of the invention, the amino acid substitution described herein is cysteine containing a thiol group. In some aspects of the invention, the thiol group is used for chemical conjugation and attachment to the linker unit (LU) and / or pharmaceutical moiety. In some embodiments, the immunoconjugates of the invention comprise a pharmaceutical moiety selected from V-ATPase inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule stabilizers, microtubule destabilizers, aristatin, dolalastatin, metansan derivatives, MetAP (methionine aminopeptidase), inhibitors of protein CRM1 nuclear export, DPPIV inhibitors, proteasome inhibitors, inhibitors of mitochondrial phosphoryl transfer reactions, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, kinin inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalating agents, DNA minor groove binding agents, and DHFR inhibitors. In some embodiments, the immunoconjugates of the invention comprise a pharmaceutical moiety that is an anticancer agent. The modified antibodies or antibody fragments of the present invention can be any form known in the art, such as monoclonal, chimeric, humanized, fully human, bispecific, or multispecific antibodies or antibody fragments thereof.
[0268] According to the present invention, the modified antibody heavy chain and / or light chain (or antibody fragment thereof) may contain 1, 2, 3, 4, 5, 6, 7, 8 or more cysteine substitutions in its constant region. In one embodiment, the modified antibody or antibody fragment contains 2, 4, 6, 8 or more cysteine substitutions in its constant region. In some embodiments, the modified antibody, its antibody fragment or immunoconjugate contains 2 or 4 Cys substitutions.
[0269] In one embodiment, the parent antibody (an antibody without cysteine substitution) is an IgG, IgM, IgE, or IgA antibody. In a particular embodiment, the parent antibody is an IgG1 antibody. In another particular embodiment, the parent antibody is an IgG2, IgG3, or IgG4 antibody.
[0270] The present invention also provides modified antibodies or antibody fragments thereof, which contain substitutions of one or more amino acids in their heavy chain constant regions at positions selected from those identified in Table 1. In some embodiments, the present invention provides modified antibodies or antibody fragments thereof, which contain substitutions of one or more amino acids in their light chain constant regions at positions selected from those identified in Table 2 or Table 3.
[0271] In some embodiments, the methods of the present invention are used in combination with other conjugation methods known in the art (including, but not limited to, chemically selective conjugation via lysine, histidine, tyrosine, formyl-lysine, pyrrolyl-lysine, pyrrololine-carboxy-lysine, non-natural amino acids, and protein tags (e.g., S6 tags) for enzyme-mediated conjugation) to label the modified antibodies or antibody fragments provided herein.
[0272] 2. Conjugation chemical action
[0273] The conjugated antibodies or antibody fragments thereof provided herein are generated through post-translational modification of at least one cysteine residue, which is incorporated into the antibody or antibody fragment by a site-specific labeling method. The conjugated antibodies or antibody fragments can be prepared using methods known in the art for conjugating a target payload to a naturally occurring cysteine residue in a protein, and using methods described for conjugating to a protein modified to contain an additional cysteine residue replacing another amino acid in the natural protein sequence.
[0274] In some embodiments, the modified antibodies or antibody fragments thereof provided herein are conjugated using known methods, wherein the incorporated cysteine (Cys) is conjugated to a maleimide derivative, as in scheme Ia below. The modified antibodies of the present invention undergoing this type of conjugation contain a thiol-maleimide linker.
[0275] Scheme Ia. Conjugation via thiol-maleimide adduct
[0276]
[0277] in:
[0278] LU stands for Connector Unit (LU), and
[0279] X represents the payload or drug portion.
[0280] In other embodiments, Cys incorporated into the modified antibody or antibody fragment can be conjugated by reacting with an α-halogen carbonyl compound, such as a chloro, brominated, or iodoacetamide as shown in Scheme Ib below. It should be understood that other leaving groups besides halogens, such as toluenesulfonate, trifluoromethanesulfonate, and other alkyl or aryl sulfonates, can be used as leaving group Y. Although Scheme Ib describes the reaction of the Cys thiol group with an α-halogen acetamide, the method involves alkylation of the sulfur of the incorporated Cys with a group of the formula Y-CHR-C(=O)-, where R is H or C. 1-4 Alkyl group, Y is a leaving group (usually C1, Br or I, and optionally alkyl sulfonate or aryl sulfonate); it is not limited to amides.
[0281] Scheme Ib. Conjugation by reaction with α-halogen carbonyl compounds.
[0282]
[0283] Y is a leaving group (Cl, Br, I, Otf, etc.).
[0284] LU is the connector unit.
[0285] X represents the payload or drug component.
[0286] Alternatively, Cys incorporated into modified antibodies or antibody fragments can be conjugated by reacting with an external thiol group under conditions that induce the formation of a disulfide bond between the external thiol group and the sulfur atom of the incorporated cysteine residue as shown in Scheme Ic below. In these examples, R can be H; however, it has been found that compounds that increase the stability of the disulfide, in which one or both R groups represent alkyl groups, such as methyl groups.
[0287] Scheme Ic. Conjugation formed by disulfides.
[0288]
[0289] Each R is independently H or C. 1-4 alkyl
[0290] LU is the connector unit.
[0291] X represents the payload or drug component.
[0292] Such post-translational modifications are illustrated by way of example in schemes (Ia)-(Ic) above, where the starting structure represents a cysteine residue incorporated into the light or heavy chain of the antibody at one of the specific sites identified herein. Methods for performing each of these conjugation methods are well known in the art. Antibodies can be modified in their light chain, or their heavy chain, or both, by these methods. Antibodies in which each light chain or each heavy chain has been modified to contain a single incorporated cysteine residue will generally contain two conjugation sites, as antibodies typically contain two light chains and two heavy chains.
[0293] During conjugation, the modified antibodies of the present invention typically contain 1-12, often 2-8, and preferably 2, 4, or 6 6–LU-X (linker unit-payload) moieties. In some embodiments, the antibody light or heavy chain is modified to incorporate two new Cys residues at two of the specific sites identified herein as Cys substitutions (or, one Cys residue is incorporated into the light chain and one into the heavy chain), so that the tetrameric antibody ultimately contains four conjugation sites. Similarly, the antibody can be modified by replacing 3 or 4 of its native amino acids with Cys residues at specific sites identified herein as identified in the light or heavy chain or a combination thereof, resulting in 6 or 8 conjugation sites in the tetrameric antibody.
[0294] In these conjugates, X represents the payload, which can be any chemical portion used to attach the antibody. In some embodiments, X is a pharmaceutical portion selected from cytotoxins, anticancer agents, anti-inflammatory agents, antifungal agents, antibacterial agents, antiparasitic agents, antiviral agents, immunostimulants, and anesthetics or any other therapeutic agent, or a bioactive or pharmaceutical portion. In another embodiment, X is a marker, such as a biophysical probe, fluorophore, affinity probe, spectroscopic probe, radioactive probe, spin label, or quantum dot. In other embodiments, X is a chemical portion that modifies the physicochemical properties of the antibody, such as lipid molecules, polyethylene glycol, polymers, polysaccharides, liposomes, or chelating agents. In other embodiments, X is a functional or detectable biomolecule, such as nucleic acid, ribonucleic acid, protein, peptide (e.g., enzyme or receptor), sugar or polysaccharide, antibody, or antibody fragment. In other embodiments, X is an anchoring portion, such as nanoparticles, PLGA particles, or a surface, or any binding portion used for specifically binding the conjugate to another portion, such as a histidine tag, polyG, biotin, avidin, streptoavidin, etc. In other embodiments, X is a reactive functional group that can be used to attach the antibody conjugate to another chemical portion, such as a pharmaceutical portion, a label, another antibody, another chemical portion, or a surface.
[0295] The linker unit (LU) can be any suitable chemical moiety that covalently attaches a thiol reactive group (e.g., maleimide, α-halocarbonyl, vinyl carbonyl (e.g., acrylate or acrylamide), vinyl sulfone, vinyl pyridine, or thiol) to the payload. Many suitable LUs are known in the art. For example, an LU may contain one, two, three, four, five, six, or more linkers referred to herein as L1, L2, L3, L4, L5, and L6. In some embodiments, the LU contains linkers selected from non-enzymatically cleavable linkers, non-cleavable linkers, enzymatically cleavable linkers, photostable linkers, photocleavable linkers, or any combination thereof, and the LU optionally contains a self-immolative spacer group.
[0296] In some embodiments, LU is a group of the formula -L1-L2-L3-L4- or -L1-L-L3-L4-L5-L6-. The linking groups L1, L2, L3, L4, L5, and L6 used for LU include alkylene groups (CH2). n -(where n is 1-20, usually 1-10 or 1-6), ethylene glycol unit (-CH2CH2O-) n (where n is 1-20, usually 1-10 or 1-6), amides –C(=O)-NH- or –NH-C(=O)-, esters –C(=O)-O- or –OC(=O)-, rings with two usable attachment sites such as divalent phenyl, C 3-8 cycloalkyl or C 4-8 Heterocyclic groups, amino acids –NH-CHR*-C=O- or –C(=O)-CHR*-NH-, where R* is a side chain of a known amino acid (often one of the typical amino acids, but also including, for example, valine, leucine, homoserine, homocysteine, phenylglycine, citrulline, and other named α-amino acids), polypeptides of known amino acids (e.g., dipeptides, tripeptides, tetrapeptides, etc.), thiol-maleimide linkages (from the addition of SH to maleimide), -S-CR2- and other thiol ethers such as -S-CR2-C(=O)- or -C(=O)-CR2-S-, where R is as defined above for scheme Ic, -CH2-C(=O)-, and disulfides (-SS-), and any combination of these with other linkers described below, such as bonds, non-enzymatically cleavable linkers, non-cleavable linkers, enzymatically cleavable linkers, photostable linkers, photostraceable linkers, or linkers containing self-degrading spacers.
[0297] In some implementations, when LU is -L1-L-L3-L4-L5-L6-, L1, L2, L3, L4, L5, and L6 can be selected from:
[0298] -A1-,-A1X2 -and-X 2 -;in:
[0299] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(C(R 4 )2) n -、-(O(CH2) n ) m -、-(O(C(R 4 )2) n ) m -,-((CH2) n O) m -、-((C(R 4 )2) n O) m -、-((CH2) n O) m (CH2) n -、-((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NH-、-(CH2) n NHC(=O)-、-(C(R 4 )2) n NHC(=O)-, -NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2) n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-, -S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R4 )2) n -、-(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n NHC(=O)(CH2) n -、-(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -or-(O(C(R) 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0300] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-,-CHR 4 (CH2) nNHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0301] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0302] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0303] Each R 6 Independently selected from H, fluorine, C(=O)OH substituted benzyloxy, –C(=O)OH substituted benzyl, C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0304] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0305] R 8 Selected independently
[0306] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0307] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0308] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0309] In some embodiments, at least one of L1, L2, L3, L4, L5, and L6 is a stable or non-cleavable linker. In some embodiments, at least one of L1, L2, L3, L4, L5, and L6 is a cleavable linker that can be chemically cleaved (hydrazone, disulfide) or enzymatically cleaved. In some embodiments, the enzymatically cleavable linker is one that is readily cleaved by peptidase: the dipeptide Val-Cit linker (valine-citrulline) is such a linker. In another embodiment, the enzymatically cleavable linker is one that is triggered by glucuronidase activity.
[0310]
[0311] This is an example of such a connector, which also contains a self-degrading spacer group that spontaneously separates under physiological conditions once the glycosidic bond is cleaved by glucuronidase.
[0312] In some embodiments, the immunoconjugates of the present invention comprise modified cysteine residues of formula IIA or IIB:
[0313]
[0314] Where –CH2-S- represents a Cys side chain incorporated at one of the selected Cys substitution sites described herein, and L2–L6 and X represent the linking group and the payload, respectively, as further described herein. In some embodiments of IIA, L is a bond. In some embodiments of IIB, L2 is NH or O. In some embodiments of IIA and IIB, L3 is selected from (CH2). 1-10 and (CH2CH2O) 1-6 L4, L5, and L6 are additional optional linkers selected from those described herein. In some embodiments, L6 may be a carbonyl (C=O) linker or a linker containing a self-degrading spacer group.
[0315] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where:
[0316] L1 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0317] L2 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0318] L3 can be a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostably cleavable adapter.
[0319] L4 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, a photostability adapter, or an adapter containing a self-degrading spacer group.
[0320] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0321] L1 can be a non-enzymatically cleavable adapter, an uncleavable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0322] L2 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0323] L3 can be a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostably cleavable adapter.
[0324] L4 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, a photostability adapter, or an adapter containing a self-degrading spacer group.
[0325] In some embodiments of the LU, at least one of L1, L2, L3, L4, L5, and L6 is a cuttable joint, and the LU is considered cuttable. Similarly, in some embodiments of the LU, at least one of L1, L2, L3, L4, L5, and L6 is a non-cuttable joint. In some of these embodiments, each joint of the LU is non-cuttable, and the LU is considered non-cuttable.
[0326] In some of the above embodiments, LU is –L1–L2–L3–L4–, and at least one of L1, L2, L3, and L4 is selected from -A1-, -A1X. 2 -and-X 2 - the connector; where:
[0327] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(C(R 4 )2) n -、-(O(CH2) n ) m -、-(O(C(R 4 )2) n ) m -、-((CH2) n O) m -、-((C(R 4 )2) n O) m -、-((CH2) n O) m (CH2) n -、-(((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NH-、-(CH2) n NHC(=O)-、-(C(R 4 )2) nNHC(=O)-、-NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2) n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-、-S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、-(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n NHC(=O)(CH2) n -、-(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4)2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -or-(O(C(R) 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0328] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0329] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0330] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0331] Each R 6 Independently selected from H, fluorine, C(=O)OH substituted benzyloxy, –C(=O)OH substituted benzyl, C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0332] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0333] R 8 Selected independently
[0334] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0335] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0336] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0337] In these implementations, the other connectors of the LU are independently selected from the key, A 1 -、-A1X 2 -、-X 2 - Non-enzymatically cleavable adapters, non-cleavable adapters, enzyme-cleavable adapters, photostable adapters, photostably cleavable adapters, and adapters containing self-degrading spacer groups.
[0338] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0339] L1 is a key, -A1-, -A1X 2 -or-X 2 -;in:
[0340] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(C(R 4 )2) n -、-(O(CH2) n ) m -、-(O(C(R 4 )2) n ) m -、-((CH2) n O) m -、-((C(R 4 )2) n O) m -、-((CH2) n O) m (CH2) n -、-(((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NH-、-(CH2) n NHC(=O)-、-(C(R 4 )2) n NHC(=O)-, -NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2)n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-、-S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、-(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n NHC(=O)(CH2) n -、-(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -、-(O(CH2) n ) m NHC(=O)(CH2)n -or-(O(C(R) 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0341] Each X 2 Independently selected from key, R 8 ,
[0342] -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0343] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0344] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0345] Each R 6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0346] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0347] R 8 Selected from
[0348] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0349] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0350] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
[0351] L2 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0352] L3 can be a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostably cleavable adapter.
[0353] L4 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, a photostability adapter, or an adapter containing a self-degrading spacer group.
[0354] In some implementations, L1 is C(=O)-CH2CH2-NH-C(=O)-CH2CH2-S-, so LU is –C(=O)-CH2CH2-NH-C(=O)-CH2CH2-S-L2-L3-L4-.
[0355] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0356] L1 is a key, -A1-, -A1X 2 -or-X 2 -;in:
[0357] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-(O(CH2) n ) m -、-((CH2) n O) m -、-((CH2) n O) m (CH2) n -、-(CH2) n C(=O)NH-、-(CH2) n NHC(=O)-, -NHC(=O)(CH2) n -、-C(=O)NH(CH2) n S-, -S(CH2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)(CH2) n -、-(CH2) n C(=O)-、-(CH2) n (O(CH2) n )m NHC(=O)(CH2) n -、-(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -or-(O(CH2)) n ) m NHC(=O)(CH2) n -;
[0358] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0359] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0360] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0361] Each R 6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0362] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0363] R 8 Selected independently
[0364] R 9Independently selected from H and C 1-6 Halogenated alkyl groups;
[0365] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0366] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
[0367] L2 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0368] L3 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0369] L4 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, a photostability adapter, or an adapter containing a self-degrading spacer group.
[0370] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0371] L1 is a key, -A1-, -A1X 2 -or-X 2 -;in:
[0372] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(CH2) n S-、-(O(CH2) n ) m -、-((CH2) n O) m (CH2) n -、-NHC(=O)(CH2) n -、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -or-(O(CH2)) n ) m NHC(=O)(CH2) n -;
[0373] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0374] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0375] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0376] Each R 6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0377] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0378] R 8 Selected independently
[0379] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0380] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0381] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
[0382] L2 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostable adapter.
[0383] L3 can be a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, or a photostably cleavable adapter.
[0384] L4 is a bond, a non-enzymatically cleavable adapter, an inoperable adapter, an enzyme-cleavable adapter, a photostable adapter, a photostability adapter, or an adapter containing a self-degrading spacer group.
[0385] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0386] L1 is a key, -A1-, -A1X 2 -or-X 2 -;in:
[0387] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(CH2) n S-、-(O(CH2) n ) m -、-((CH2) n O) m (CH2) n -、-NHC(=O)(CH2) n -、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -or-(O(CH2)) n ) m NHC(=O)(CH2) n -;
[0388] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0389] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0390] Each R 5 Independently selected from H and C 1-4C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0391] Each R 6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0392] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0393] R 8 Selected from
[0394] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0395] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0396] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9;
[0397] L2 is a bond, a non-enzymatically cleavable linker or an incleavable linker;
[0398] L3 is a bond, a non-enzymatically cleavable linker or an inoperable linker;
[0399] L4 is a linker that is bonded, enzymatically cleavable, or contains a self-degrading spacer.
[0400] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0401] L1 is a key, -A1-, -A1X 2 -or-X 2 -;
[0402] L2 is a key, -A2- or -A2X 2 -;
[0403] L3 is a key, -A3- or -A3X 2 -;
[0404] L4 is a key, -A4-, -A4X 2 -、
[0405] A1 is -C(=O)NH-, -NHC(=O)-, -C(=O)NH(CH2) n -, -C(=O)NH(C(R 4 )2) n -, -(O(CH2) n ) m -, -(O(C(R 4 )2) n ) m -, -((CH2) n O) m -, -((C(R 4 )2) n O) m -, -((CH2) n O) m (CH2) n -, -(((C(R 4 )2) n O) m C(R 4 )2) n -, -(CH2) n C(=O)NH-, -(C(R 4 )2) n C(=O)NH-, -(CH2) n NHC(=O)-, -(C(R 4 )2) n NHC(=O)-, -NHC(=O)(CH2) n -, -NHC(=O)(C(R 4 )2) n -, -C(=O)NH(CH2) n S-, -C(=O)NH(C(R 4 )2) n S-, -S(CH2) n C(=O)NH-, -S(C(R 4 )2) n C(=O)NH-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -, -C(=O)(CH2) n -, -C(=O)(C(R 4 )2) n -, -(CH2) nC(=O)-, -(C(R 4 )2) n C(=O)-, -(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -, -(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -, -(CH2) n NHC(=O)(CH2) n -, -(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -, -(CH2) n NH((CH2) n O) m (CH2) n -, -(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -, -(O(CH2) n ) m NHC(=O)(CH2) n - or -(O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0406] A2 is -C(=O)NH-, -C(=O)NH(CH2) n -, -C(=O)NH(C(R 4 )2) n -, -(O(CH2) n ) m -, -(O(C(R 4 )2) n ) m -, -((CH2) n O) m -, -((C(R 4 )2) n O)m -、-((CH2) n O) m (CH2) n -、-((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NR 4 -、-(CH2) n NHC(=O)-、-(C(R 4 )2) n NHC(=O)-、-NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2) n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-、-S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-(CH2) n S-、-(C(R 4 )2) n S-、-S(CH2) n -、-S(C(R 4 )2) n -、-(CH2) n NH-、-(C(R 4 )2) n NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、-(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2)n ) m NHC(=O)(CH2) n -, -(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -, -(CH2) n (O(CH2) n ) m OC(=O)NH(CH2) n -, -(C(R 4 )2) n (O(C(R 4 )2) n ) m OC(=O)NH(C(R 4 )2) n -, -(CH2) n NHC(=O)(CH2) n -, -(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -, -(CH2) n NH((CH2) n O) m (CH2) n -, -(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -, -(O(CH2) n ) m NHC(=O)(CH2) n -, -(O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -,
[0407] A3 is -C(=O)NH-, -C(=O)NH(CH2) n -, -C(=O)NH(C(R 4 )2) n -, -(O(CH2)n ) m -、-(O(C(R 4 )2) n ) m -、-((CH2) n O) m -、-((C(R 4 )2) n O) m -、-((CH2) n O) m (CH2) n -、-(((C(R 4 )2) n O) m C(R 4 )2) n -、-(CH2) n C(=O)NH-、-(C(R 4 )2) n C(=O)NH-、-(CH2) n NHC(=O)-、-(C(R 4 )2) n NHC(=O)-、-NHC(=O)(CH2) n -、-NHC(=O)(C(R 4 )2) n -、-C(=O)NH(CH2) n S-、-C(=O)NH(C(R 4 )2) n S-、-S(CH2) n C(=O)NH-、-S(C(R 4 )2) n C(=O)NH-、-(CH2) n S-、-(C(R 4 )2) n S-、-S(CH2) n -、-S(C(R 4 )2) n -、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、-(CH2)n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n (O(CH2) n ) m OC(=O)NH(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m OC(=O)NH(C(R 4 )2) n -、-(CH2) n (O(CH2) n ) m OC(=O)-、-(C(R 4 )2) n (O(C(R 4 )2) n ) m OC(=O)-、-(CH2) n (O(CH2) n ) m C(=O)-、-(C(R 4 )2) n (O(C(R 4 )2) n ) m C(=O)-、-(CH2) n NHC(=O)(CH2) n -、-(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -、-(O(C(R 4 )2) n )m NHC(=O)(C(R 4 )2) n -,
[0408] A4 is -C(=O)NH-, -C(=O)NH(CH2) n -, -C(=O)NH(C(R 4 )2) n -, -(O(CH2) n ) m -, -(O(C(R 4 )2) n ) m -, -((CH2) n O) m -, -((C(R 4 )2) n O) m -, -((CH2) n O) m (CH2) n -, -(((C(R 4 )2) n O) m C(R 4 )2) n -, -(CH2) n C(=O)NH-, -(C(R 4 )2) n C(=O)NH-, -(CH2) n NHC(=O)-, -(C(R 4 )2) n NHC(=O)-, -NHC(=O)(CH2) n -, -NHC(=O)(C(R 4 )2) n -, -C(=O)NH(CH2) n S-, -C(=O)NH(C(R 4 )2) n S-, -S(CH2) n C(=O)NH-, -S(C(R 4 )2) n C(=O)NH-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -C(=O)NH(C(R 4 )2) n NHC(=O)(C(R 4 )2) n-、-C(=O)(CH2) n -、-C(=O)(C(R 4 )2) n -、-(CH2) n C(=O)-、-(C(R 4 )2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(C(R 4 )2) n (O(C(R 4 )2) n ) m NHC(=O)(C(R 4 )2) n -、-(CH2) n NHC(=O)(CH2) n -、-(C(R 4 )2) n NHC(=O)(C(R 4 )2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(C(R 4 )2) n NH((C(R 4 )2) n O) m (C(R 4 )2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -or-(O(C(R) 4 )2) n ) m NHC(=O)(C(R 4 )2) n -;
[0409] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) nC(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0410] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0411] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0412] Each R 6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0413] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0414] R 8 Selected from
[0415] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0416] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0417] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0418] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0419] L1 is a key, -A1-, -A1X 2 -or-X 2 -;
[0420] L2 is a key, -A2- or -A2X 2 -;
[0421] L3 is a key, -A3- or -A3X 2 -;
[0422] L4 is a key, -A4-, -A4X2 -,
[0423] A1 is -C(=O)NH-, -C(=O)NH(CH2) n -, -(O(CH2) n ) m -, -((CH2) n O) m -, -((CH2) n O) m (CH2) n -, -(CH2) n C(=O)NH-, -NHC(=O)(CH2) n -, -(CH2) n NHC(=O)-, -C(=O)NH(CH2) n S-, -S(CH2) n C(=O)NH-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -C(=O)(CH2) n -, -(CH2) n C(=O)-, -(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -, -(CH2) n NHC(=O)(CH2) n -, -(CH2) n NH((CH2) n O) m (CH2) n - or -(O(CH2) n ) m NHC(=O)(CH2) n -;
[0424] A2 is -C(=O)NH-, -C(=O)NH(CH2) n -, -(O(CH2) n ) m -, -((CH2) n O) m -, -((CH2) n O) m (CH2) n -, -(CH2) n C(=O)NH-, -NHC(=O)(CH2)n -, -(CH2) n NHC(=O)-, -C(=O)NH(CH2) n S-, -S(CH2) n C(=O)NH-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -C(=O)(CH2) n -, -(CH2) n C(=O)-, -(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -, -(CH2) n NHC(=O)(CH2) n -, -(CH2) n NH((CH2) n O) m (CH2) n -, -(O(CH2) n ) m NHC(=O)(CH2) n - or
[0425] A3 is -C(=O)NH-, -C(=O)NH(CH2) n -, -(O(CH2) n ) m -, -((CH2) n O) m -, -((CH2) n O) m (CH2) n -, -(CH2) n C(=O)NH-, -NHC(=O)(CH2) n -, -(CH2) n NHC(=O)-, -C(=O)NH(CH2) n S-, -S(CH2) n C(=O)NH-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -C(=O)(CH2) n -, -(CH2) n C(=O)-, -(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n-、-(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -or
[0426] A4-C(=O)NH-, -C(=O)NH(CH2) n -、-(O(CH2) n ) m -、-((CH2) n O) m -、-((CH2) n O) m (CH2) n -、-(CH2) n C(=O)NH-、-NHC(=O)(CH2) n -、-(CH2) n NHC(=O)-、-C(=O)NH(CH2) n S-, -S(CH2) n C(=O)NH-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-C(=O)(CH2) n -、-(CH2) n C(=O)-、-(CH2) n (O(CH2) n ) m NHC(=O)(CH2) n -、-(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -or-(O(CH2)) n ) m NHC(=O)(CH2) n -;
[0427] Each X 2 Independently selected from keys, -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0428] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0429] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0430] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0431] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0432] In some implementations, the connector unit (LU) is –L1–L2–L3–L4–, where
[0433] L1 is a key, -A1-, -A1X 2 -or-X 2 -;
[0434] L2 is a key, -A2- or -A2X 2 -;
[0435] L3 is a key, -A3- or -A3X 2 -;
[0436] L4 is a key, -A4-, -A4X 2 -、
[0437] A1 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(CH2) n S-、-(O(CH2) n ) m -、-((CH2) n O) m (CH2) n -、-NHC(=O)(CH2) n -、-(CH2) nNHC(=O)-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -(CH2) n NH((CH2) n O) m (CH2) n - or -(O(CH2) n ) m NHC(=O)(CH2) n -;
[0438] A2 is -C(=O)NH-, -C(=O)NH(CH2) n -, -C(=O)NH(CH2) n S-, -(O(CH2) n ) m -, -((CH2) n O) m (CH2) n -, -NHC(=O)(CH2) n -, -(CH2) n NHC(=O)-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -(CH2) n NH((CH2) n O) m (CH2) n -, -(O(CH2) n ) m NHC(=O)(CH2) n - or
[0439] A3 is -C(=O)NH-, -C(=O)NH(CH2) n -, -C(=O)NH(CH2) n S-, -(O(CH2) n ) m -, -((CH2) n O) m (CH2) n -, -NHC(=O)(CH2) n -, -(CH2) n NHC(=O)-, -C(=O)NH(CH2) n NHC(=O)(CH2) n -, -(CH2) n NH((CH2) n O) m(CH2) n -、-(O(CH2) n ) m NHC(=O)(CH2) n -or
[0440] A4 is -C(=O)NH- or -C(=O)NH(CH2) n -、-C(=O)NH(CH2) n S-、-(O(CH2) n ) m -、-((CH2) n O) m (CH2) n -、-NHC(=O)(CH2) n -、-(CH2) n NHC(=O)-、-C(=O)NH(CH2) n NHC(=O)(CH2) n -、-(CH2) n NH((CH2) n O) m (CH2) n -or-(O(CH2)) n ) m NHC(=O)(CH2) n -;
[0441] Each X 2 Independently selected from key, R 8 , -S-、-Si(OH)2O-、 -CHR 4 (CH2) n C(=O)NH-、-CHR 4 (CH2) n NHC(=O)-, -C(=O)NH- and -NHC(=O)-;
[0442] Each R 4 Independently selected from H and C 1-4 Alkyl groups, side chains of known amino acids, -C(=O)OH and -OH,
[0443] Each R 5 Independently selected from H and C 1-4 C substituted with alkyl, phenyl or 1-3 –OH groups 1-4 alkyl;
[0444] Each R6 Independently selected from H, fluorine, -C(=O)OH substituted benzyloxy, -C(=O)OH substituted benzyl, -C(=O)OH substituted C 1-4 alkoxy and –C(=O)OH substituted C 1-4 alkyl;
[0445] R 7 Independently selected from H and C 1-4 Alkyl, phenyl, pyrimidine, and pyridine;
[0446] R 8 Selected independently
[0447] R 9 Independently selected from H and C 1-6 Halogenated alkyl groups;
[0448] Each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
[0449] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, and 9.
[0450] In one implementation, L1 is –(CH2). 1-10 -C(=O)-, for example –(CH2)5-C(=O)-; and L2, L3 and L4 each represent a bond.
[0451] In some implementations, the LU includes a val-cit connector of the formula, where X represents the payload, typically a drug portion, such as one with anticancer activity.
[0452]
[0453] When L4-L5-L6 are val-cit connectors as shown above, L3 is preferably –(CH2). 2-6 -C(=O)-.
[0454] In some embodiments, the X group is a metanzanoid compound, such as DM1 or DM4, or a dolasstatin analog or derivative, such as dolasstatin 10 or 15 and alistatin MMAF or MMAE, or galicariin such as N-acetyl-γ-galicariin, or a label or dye, such as rhodamine or tetramethylrhodamine.
[0455] As used herein, a "linker" is any chemical part capable of attaching an antibody or fragment thereof to an X group (payload) to form an immunoconjugate. Linkers can be sensitive to cleavage, such as acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage, provided the compound or antibody remains active. Alternatively, linkers can be substantially resistant to cleavage. Linkers may or may not include self-degrading spacers.
[0456] As used in this article, X 1 Non-limiting examples of non-enzymatically cleavable linkers conjugated to the modified antibodies or antibody fragments thereof provided herein include acid-instable linkers, linkers containing disulfide moieties, linkers containing triazole moieties, linkers containing hydrazone moieties, linkers containing thioether moieties, linkers containing diazonium moieties, linkers containing oxime moieties, linkers containing amide moieties, and linkers containing acetamide moieties.
[0457] Non-limiting examples of enzymatically cleavable adapters, such as those used herein, that conjugate an X group to a modified antibody or antibody fragment thereof provided herein include, but are not limited to, adapters cleaved by proteases, adapters cleaved by amidases, and adapters cleaved by β-glucuronidase or another glycosidase.
[0458] In some embodiments, such enzymatically cleavable linkers are linkers cleaved by cathepsins, including cathepsin Z, cathepsin B, cathepsin H, and cathepsin C. In some embodiments, the enzymatically cleavable linker is a dipeptide cleaved by cathepsins, including a dipeptide cleaved by cathepsin Z, cathepsin B, cathepsin H, or cathepsin C. In some embodiments, the enzymatically cleavable linker is a cathepsin B-cleavable peptide linker. In some embodiments, the enzymatically cleavable linker is a cathepsin B-cleavable dipeptide linker. In some embodiments, the enzymatically cleavable dipeptide linker is valine-citrulline or phenylalanine-lysine. Other non-limiting examples of enzymatically cleavable linkers that conjugate an X group to a modified antibody or antibody fragment thereof provided herein, as used herein, include, but are not limited to, examples that...
[0459] Linkages cleaved by β-glucuronidase, for example,
[0460] See Ducry et al, Bioconjugate Chem, (2010) vol. 21(1), 5-13.
[0461] A “self-degrading spacer” is a bifunctional chemical moiety covalently attached to a first chemical moiety at one end and a second chemical moiety at the other end, thereby forming a stable three-part molecule. The linker may contain a self-degrading spacer bonded to a third chemical moiety, which can be chemically or enzymatically cleaved from the spacer. After the bond between the self-degrading spacer and the first or third chemical moiety is cleaved, the self-degrading spacer undergoes a rapid and spontaneous intramolecular reaction and is thereby separated from the second chemical moiety. These intramolecular reactions generally involve electronic rearrangements, such as 1,4 or 1,6 or 1,8 elimination reactions, or cyclization to form a highly favorable five- or six-membered ring. In some embodiments of the invention, the first or third moiety is an enzyme-cleavable group, and the cleavage is induced by an enzymatic reaction; in other embodiments, the first or third moiety is an acid-labile group, and the cleavage occurs due to a change in pH. As applied to this invention, the second moiety is a “payload” group as defined herein. In some embodiments, the first or third portion originates from the cleavage of the self-degrading spacer due to cleavage by a proteolytic enzyme, while in other embodiments, it originates from the cleavage of a hydrolytic enzyme. In some embodiments, the first or third portion originates from the cleavage of the self-degrading spacer due to cleavage by a cathepsin or glucosidase.
[0462] In some embodiments, the enzyme-cleavable linker is a peptide linker with a self-degrading spacer covalently attached to the peptide linker at one end and the drug moiety at the other end. This tripartite molecule is stable and pharmacologically inactive in the absence of an enzyme, but it can be enzymatically cleaved at the bond between the covalently linked spacer and the peptide moiety. The cleavage of the peptide moiety from the tripartite molecule initiates the self-degradation of the spacer, leading to spontaneous cleavage of the bond between the covalently linked spacer and the drug moiety, thereby releasing the pharmacologically active form of the drug.
[0463] In other embodiments, the linker comprises a self-degrading spacer group that directly or indirectly links a peptide at one end and a payload at the other end; and the spacer group is attached to a third portion, which can be enzymatically cleaved from the spacer group, for example, by a glucuronidase. Upon cleavage of the third portion, the spacer group degrades or rearranges in a manner that causes the payload to be released. An example of a linker having this type of self-degrading spacer group is a glucuronidase-cleavable linker, wherein the hydrolysis of an acetal catalyzed by glucuronidase releases a phenolic compound that spontaneously decomposes under physiological conditions.
[0464]
[0465] Optionally used to transfer X 1Non-limiting examples of self-degrading spacers conjugated to modified antibodies or antibody fragments thereof provided herein include, but are not limited to, portions comprising a benzyl carbonyl moiety, a xylene ether moiety, a 4-aminobutyrate moiety, a hemithioaminal moiety, or an N-acylhemithioaminal moiety.
[0466] Other examples of self-degrading spacers include, but are not limited to, p-aminobenzyloxycarbonyl groups, and aromatic compounds with electrons similar to p-aminobenzyloxycarbonyl groups, such as 2-aminoimidazolium-5-methanol derivatives and o- or p-aminobenzyl acetals. In some embodiments, the self-degrading spacers used herein (which undergo cyclization upon hydrolysis of the amide bond) include substituted and unsubstituted 4-aminobutyric acid amides and 2-aminophenylpropionic acid amides.
[0467] In some implementations, the self-degrading spacer group is
[0468] In other embodiments, the self-degrading spacer group is Where n is 1 or 2. In other embodiments, the self-degrading spacer group is Where n is 1 or 2. In other embodiments, the self-degrading spacer group is Where n is 1 or 2. In other embodiments, the self-degrading spacer group is Where n is 1 or 2. In other embodiments, the self-degrading spacer group is Where n is 1 or 2.
[0469] Schemes (2a-2c) elucidate the post-translational modifications of the modified antibodies or antibody fragments thereof provided herein, wherein the linker unit (LU) is –L1–L2–L3–L4–, and L1 is a group that reacts with the new Cys in each case.
[0470] Option 2a.
[0471]
[0472] Option 2b.
[0473]
[0474] Option 3c.
[0475]
[0476] In each of schemes 2a-2c, the starting material is an antibody or antibody fragment modified as described herein, with substituted Cys residues, where dashed bonds indicate adjacent residues linked to the antibody or antibody fragment; each R is H or C. 1-4Alkyl, typically H or methyl; L2, L3 and L4 are components of the linking unit LU, as described above; X is the payload; and the group connecting L2 to the sulfur of the substituent Cys of the present invention is L1.
[0477] In some embodiments of the invention, X is a reactive functional group that can link a conjugated antibody to another chemical moiety by interacting with a suitable complementary functional group. Table 4 describes some examples of reactive functional groups that X can represent and complementary functional groups that can be used to link a conjugate containing X to another compound. Methods for using X to link corresponding complementary functional groups are well known in the art. Linkages using azide compounds are typically accomplished using 'Click' or copper-free click chemistry; reactions involving hydrazine, alkoxyamine, or acylhydrazine are typically carried out by forming a Schiff base with one of the carbonyl functional groups.
[0478] Table 4
[0479]
[0480] Exemplary linker products prepared using these components are described in Table 5, wherein Y 1 The antibody representing this invention, A1 represents the linker between the antibody and the payload X. a The linking unit (LU), in formula II-a, -L2-L3-L4- represents the unit that can exist in the molecule through X. a Connect the adapter unit of the conjugated antibody, and X 1 Represents the payload. Payload X a It is a reactive functional group, and X on formula II-a b These are the corresponding complementary functional groups, and Formula II-a itself represents the molecule of the antibody to be conjugated. The third column in Table 5 describes the molecules derived from X. a With X b The products of the reaction.
[0481] Table 5
[0482]
[0483]
[0484]
[0485]
[0486]
[0487] In some embodiments, the modified antibodies or antibody fragments thereof provided herein are conjugated at an “X-group-to-antibody” (load-to-antibody) ratio of about 1-16, such as 1-12, or 1, 2, 3, 4, 5, 6, 7, or 8, wherein the modified antibodies or antibody fragments thereof contain 1, 2, 3, 4, 5, 6, 7, or 8 cysteine residues incorporated at specific sites disclosed herein. For example, an “X-group-to-antibody” ratio of 4 can be achieved by incorporating two Cys residues into the heavy chain of an antibody, which will contain 4 conjugation sites, two from each heavy chain. Immunoconjugates of such antibodies will contain up to 4 load groups, which may be the same or different and preferably all the same. In another example, an “X-group-to-antibody” ratio of 4 can be achieved by incorporating one Cys residue into the heavy chain of an antibody and a second Cys residue into the light chain, resulting in 4 conjugation sites, two in the two heavy chains and two in the two light chains. A ratio of 6, 8, or higher can be achieved through combinations of substitutions of 3, 4, or more cysteine residues in the heavy and light chains of the antibody. Substitution of multiple cysteine groups into the antibody can lead to inappropriate disulfide formation and other problems. Therefore, to load more than four payload groups onto a single antibody molecule, the method of the present invention can alternatively be combined with reactions independent of cysteine sulfides, such as acylation on lysine residues, or conjugation via S6 tagging or Pcl methods.
[0488] Although the payload-to-antibody ratio has precise values for a particular conjugated molecule, it should be understood that when used to describe samples containing many molecules, this value is often an average value due to some degree of heterogeneity during the conjugation step. The average load of an immunoconjugated sample is referred herein to as the drug-to-antibody ratio, or DAR. In some embodiments, the DAR is between about 1 and about 16, typically about 1, 2, 3, 4, 5, 6, 7, or 8. In some embodiments, at least 50% of the sample by weight is a compound having an average ratio plus or minus 2, and preferably, at least 50% of the sample contains conjugates having an average ratio plus or minus 1. Preferred embodiments include immunoconjugates where the DAR is about 2 or about 8, for example, about 2, about 4, about 6, or about 8. In some embodiments, a DAR of 'about n' indicates that the measurement used for the DAR is within 10% of n (in formula (I)).
[0489] 3. Other changes to the architecture of the Fc area
[0490] This invention provides site-specific labeled immunoconjugates. The immunoconjugates of this invention may comprise modified antibodies or antibody fragments thereof, further comprising antibodies against V... H and / or V LModifications to the structural residues within the antibody can be made, for example, to improve the properties of the antibody. Typically, such structural modifications are performed to reduce the immunogenicity of the antibody. One approach, for example, is to “reverse mutate” one or more structural residues to the corresponding germline sequence. More particularly, antibodies that have undergone somatic mutations may contain structural residues different from the germline sequence from which the antibody originated. Such residues can be identified by comparing the antibody structural sequence with the germline sequence from which the antibody originated. To restore the structural region sequence to its germline conformation, somatic mutations can be “reverse mutated” to germline sequences, for example, through site-directed mutagenesis. This invention also aims to include such “reverse mutated” antibodies.
[0491] Another type of framework modification involves mutating one or more residues within, or even one or more CDR regions, the framework to remove T-cell epitopes, thereby reducing the potential immunogenicity of the antibody. This method is also known as “deimmunization” and is further described in detail in U.S. Patent Publication No. 20030153043 by Carr et al.
[0492] In addition to modifications within the framework or CDR region, or as alternatives, the antibodies of the present invention can be modified to include modifications within the Fc region, typically to alter one or more functional properties of the antibody, such as serum half-life, complement binding, Fc receptor binding, and / or antigen-dependent cell cytotoxicity. Furthermore, the antibodies of the present invention can be chemically modified (e.g., one or more chemical motifs can be attached to the antibody) or modified to alter their glycosylation, again altering one or more functional properties of the antibody. Each of these embodiments is described in further detail below.
[0493] In one embodiment, the hinge region of CH1 is modified such that the number of cysteine residues in the hinge region is altered, for example, increased or decreased. This method is further described in U.S. Patent No. 5,677,425 to Bodmer et al. For example, altering the number of cysteine residues in the hinge region of CH1 can promote the assembly of light and heavy chains or increase or decrease antibody stability.
[0494] In another embodiment, the Fc hinge region of the antibody is mutated to reduce the antibody's biological half-life. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment, thereby impairing the antibody's binding to Staphylococcus aureus protein A (SpA) relative to the native Fc-hinge domain SpA. This method is further described in detail in U.S. Patent No. 6,165,745 to Ward et al.
[0495] In another embodiment, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to change the antibody's effector function. For example, one or more amino acids can be replaced with different amino acid residues, thereby giving the antibody an altered affinity for the effector ligand but retaining the antigen-binding ability of the parent antibody. The effector ligand whose affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This method is described, for example, in U.S. Patent Nos. 5,624,821 and 5,648,260 to Winter et al.
[0496] In another embodiment, one or more amino acids selected from amino acid residues may be replaced with different amino acid residues, thereby giving the antibody altered C1q binding and / or reduced or eliminated complement-dependent cytotoxicity (CDC). This method is described, for example, in U.S. Patent No. 6,194,551 to Idusogie et al.
[0497] In another embodiment, one or more amino acid residues are altered, thereby changing the antibody's ability to fix complement. This method is described, for example, in PCT disclosure WO 94 / 29351 by Bodmer et al. In a particular embodiment, one or more amino acids of the antibody of the present invention or an antibody fragment thereof are replaced by one or more variant amino acid residues, such as… Figure 4 The substitutions are those amino acid residues shown in the IgG1 subclass and κ isoform. Isoamino acid residues also include, but are not limited to, the constant regions of the heavy chain of the IgG1, IgG2 and IgG3 subclasses and the constant regions of the light chain of the κ isoform, as described by Jefferis et al., MAbs.1:332-338 (2009).
[0498] In yet another embodiment, the Fc region is modified to increase the ability of the antibody to induce antibody-dependent cell cytotoxicity (ADCC) and / or to increase the antibody affinity for the Fcγ receptor by modifying one or more amino acids. This method is described, for example, in Presta's PCT disclosure WO 00 / 42072. Furthermore, the binding sites of human IgG1 with FcγR1, FcγRII, FcγRIII, and FcRn have been mapped, and variants with improved binding have been described (see Shields et al., J. Biol. Chem. 276:6591-6604, 2001).
[0499] In another embodiment, the glycosylation of the antibody is modified. For example, glycosylated-free antibodies (i.e., antibodies lacking glycosylation) can be prepared. Glycosylation can be altered, for example, to increase the antibody's affinity for the "antigen." Such carbohydrate modification can be achieved, for example, by altering one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be performed, resulting in the elimination of one or more variable region framework glycosylation sites, thereby removing the glycosylation at that site. Such glycosylation can increase the antibody's affinity for the antigen. This method is described, for example, in U.S. Patent Nos. 5,714,350 and 6,350,861, by Co et al.
[0500] Alternatively or additionally, antibodies with altered types of glycosylation can be prepared, such as hypofucosylated antibodies with reduced amounts of fucose residues or antibodies with increased bipartite GlcNac structures. Such altered glycosylation patterns have been shown to increase the ADCC capacity of antibodies. This type of carbohydrate modification can be achieved, for example, by expressing antibodies in host cells with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells for expressing the recombinant antibodies of the present invention, thereby producing antibodies with altered glycosylation. For example, EP 1,176,195 by Hang et al. describes a cell line with a dysfunctional FUT8 gene encoding fucosyltransferase, in which antibodies expressed exhibit hypofucosylation. Presta's PCT publication WO 03 / 035835 describes a variant CHO cell line, Lecl3 cells, which has a reduced ability to attach fucose to Asn(297)-linked carbohydrates, resulting in hypofucosylation of antibodies expressed in host cells (see also Shields et al., (2002) J. Biol. Chem. 277:26733-26740). Umana et al.'s PCT publication WO 99 / 54342 describes a cell line modified to express glycoprotein-modifying glycosyltransferases (e.g., β(1,4)-N-acetylglucosamine transferase III (GnTIII)), resulting in antibodies expressed in the modified cell line exhibiting increased bipartite GlcNac structures, leading to increased ADCC activity of the antibodies (see also Umana et al., Nat. Biotech. 17:176-180, 1999).
[0501] In another embodiment, the antibody is modified to increase its biological half-life. Several methods are possible. For example, one or more of the following mutations can be introduced: T252L, T254S, or T256F, as described in Ward's U.S. Patent No. 6,277,375. Alternatively, to increase the biological half-life, mutations can be introduced at CH1 or C... LThe antibody is modified within the region to contain two loops obtained from the CH2 domain of the Fc region of IgG, as described in U.S. Patents 5,869,046 and 6,121,022, such as Presta et al.
[0502] 4. Antibody conjugates
[0503] This invention provides a site-specific labeling method, modified antibodies and antibody fragments thereof, and immunoconjugates prepared therefrom. Using the method of this invention, modified antibodies or antibody fragments thereof can be conjugated to labels, such as pharmaceutical portions, for example, anticancer agents, autoimmune therapeutic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, antiparasitic agents, antiviral agents, or anesthetics, or imaging reagents, such as chelating agents for PET imaging, or fluorescent labels, or MRI contrast agents. Several identical or different labeling portions can also be used, combining the method of this invention with other conjugation methods to conjugate antibodies or antibody fragments.
[0504] In some embodiments, the immunoconjugates of the present invention comprise a pharmaceutical portion selected from V-ATPase inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule stabilizers, microtubule destabilizers, aristatin, dolalastatin, metansan derivatives, MetAP (methionine aminopeptidase), inhibitors of protein CRM1 nuclear export, DPPIV inhibitors, proteasome inhibitors, inhibitors of phosphorylation in mitochondria, protein synthesis inhibitors, kinase inhibitors, CDK2 inhibitors, CDK9 inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalating agents, DNA minor groove binding agents, topoisomerase inhibitors, RNA synthesis inhibitors, kinase inhibitors, protein-protein interaction inhibitors, and DHFR inhibitors.
[0505] Furthermore, the modified antibodies or antibody fragments of the present invention can be conjugated to a pharmaceutical moiety that modifies a given biological response. The pharmaceutical moiety is not to be construed as limited to classical chemotherapeutic agents. For example, the pharmaceutical moiety can be an immunomodulator, such as an immune enhancer, a small molecule immune enhancer, a TLR agonist, a CpG oligomer, a TLR2 agonist, a TLR4 agonist, a TLR7 agonist, a TLR9 agonist, a TLR8 agonist, a T-cell epitope peptide, etc. The pharmaceutical moiety can also be an oligonucleotide, siRNA, shRNA, cDNA, etc. Alternatively, the pharmaceutical moiety can be a protein, peptide, or polypeptide with the desired biological activity. Such proteins can include, for example, toxins such as abrin, ricin A, Pseudomonas exotoxin, cholera toxin, or diphtheria toxin; proteins such as tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet-derived growth factor, tissue plasminogen activator, cytokines, apoptosis agents, anti-angiogenic agents, or biological response modifiers such as, for example, lymphokines.
[0506] In one embodiment, the modified antibody or antibody fragment of the present invention is conjugated to a pharmaceutical moiety, such as a cytotoxin, a drug (e.g., an immunosuppressant), or a radiotoxin. Examples of cytotoxins include, but are not limited to, taxanes (see, for example, International (PCT) Patent Publication No. WO). 01 / 38318 and PCT / US03 / 02675), DNA alkylating agents (e.g., CC-1065 analogs), anthracyclines, tubulysin analogs, docalmicin analogs, arithmeticine E, arithmeticine F, metansin derivatives, and cytotoxic agents containing reactive polyethylene glycol moieties (see, for example, Sasse et al., J. Antibiot. (Tokyo), 53, 879-85 (2000), Suzawa et al., Bioorg. Med. Chem., 8, 2175-84 (2000), Ichimura et al., J. Antibiot. (Tokyo), 44, 1045-53 (1991), Francisco et al., Blo od(2003) (electronic publication prior to print publication), U.S. Patent Nos. 5,475,092, 6,340,701, 6,372,738, and 6,436,931, U.S. Patent Application Publication No. 2001 / 0036923A1, pending U.S. Patent Application Serial Nos. 10 / 024,290 and 10 / 116,053, and International (PCT) Patent Application No. WO01 / 49698), paclitaxel, pinocembrin B, bacitracin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, colchicine, doxorubicin, daunorubicin, dihydroxyanthraxine dione, mitoxantrone, scintillans, actinomycin D, 1-dehydrotestosterone, glucocorticoids, and puromycin and their analogues or homologues. Therapeutic agents also include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, aminopyrimidine), ablatives (e.g., nitrogen mustard, thiotepa, chlorambucil, melphalan, carmustine (BSNU) and roximate (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozomycin, mitomycin C, and cis-dichlorodiamineplatin(II) (DDP), cisplatin, anthracyclines (e.g., daunorubicin, (formerly donomycin) and doxorubicin), antibiotics (e.g., dermatomycin (formerly actinomycin), bleomycin, scintillan and atrazomycin (AMC)), and antimitotics (e.g., vincristine and vinblastine) (see, for example, Seattle Genetics US20090304721).
[0507] Other examples of therapeutic cytotoxic agents that can be conjugated with the modified antibodies or antibody fragments of the present invention include docalimicin, galicariin, maytansine, and arithmeticine, and their derivatives. Examples of galicariin antibody conjugates are commercially available (Mylotarg). Tm Wyeth-Ayerst).
[0508] For further discussion of the types of cytotoxins, the linkers used to conjugate therapeutic agents to antibodies, and the methods, see also Saito et al., (2003) Adv. Drug Deliv. Rev. 55:199-215; Trail et al., (2003) Cancer Immunol. Immunother. 52:328-337; Payne, (2003) Cancer Cell 3:207-212; Allen, (2002) Nat. Rev. Cancer 2:750-763; Pastan and Kreitman, (2002) Curr. Opin. Investig. Drugs 3:1089-1091; Senter and Springer, (2001) Adv. Drug Deliv. Rev. 53:247-264.
[0509] According to the present invention, modified antibodies or antibody fragments thereof can also be conjugated to radioactive isotopes to produce cytotoxic radiopharmaceuticals, referred to as radioimmunoconjugates. Examples of radioactive isotopes that can be conjugated to antibodies for diagnostic or therapeutic use include, but are not limited to, iodine. l31 ,indium 111 ,yttrium 90 Helu 177 Methods for preparing radioimmunoconjugates have been established in this art. Examples of radioimmunoconjugates are commercially available, including Zevalin. TM (DEC Pharmaceuticals) and Bexxar TM(Corixa Pharmaceuticals), and similar methods can be used to prepare radioimmunoconjugates using the antibodies of the present invention. In some embodiments, the macrocyclic chelating agent is 1,4,7,10-tetraazacyclododecane-N,N',N”,N”'-tetraacetic acid (DOTA), which can attach antibodies via a linker molecule. Such linker molecules are generally known in the art and described in Denardo et al., (1998) Clin. Cancer Res. 4(10):2483-90; Peterson et al., (1999) Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., (1999) Nucl. Med. Biol. 26(8):943-50, each of which is incorporated herein by reference in its entirety.
[0510] The present invention also provides modified antibodies or fragments thereof that specifically bind to antigens. The modified antibodies or fragments may be conjugated to or fused with heterologous proteins or peptides (or fragments thereof, preferably peptides of at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acids) to produce fusion proteins. Specifically, the present invention provides antibody fragments comprising those described herein (e.g., Fab fragments, Fd fragments, Fv fragments, F(ab)2 fragments, V...). H Fragment, V H CDR, V L Domain or V L A fusion protein consisting of a CDR and a heterologous protein, polypeptide, or peptide.
[0511] In some embodiments, a modified antibody fragment without antigen-binding specificity, such as, but not limited to, a modified Fc domain having the modified cysteine residues of the present invention, is used to generate a fusion protein comprising the antibody fragment (e.g., the modified Fc) and a heterologous protein, polypeptide, or peptide.
[0512] Additional fusion proteins can be generated through techniques such as gene shuttle, motif shuttle, exon shuttle, and / or codon shuttle (collectively, "DNA shuttle"). DNA shuttle can be used to alter the activity of the antibodies or fragments thereof of the present invention (e.g., antibodies or fragments thereof with higher affinity and lower dissociation constants). See generally U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252 and 5,837,458; Patten et al., (1997) Curr. Opinion Biotechnol. 8:724-33; Harayama, (1998) Trends Biotechnol. 16(2):76-82; Hansson et al., (1999) J. Mol. Biol. 287:265-76; and Lorenzo and Blasco, (1998) Biotechniques 24(2):308-313 (each of these patents and disclosures is incorporated herein by reference in its entirety). Antibodies or fragments thereof, or encoded antibodies or fragments thereof, can be altered prior to recombination by random mutagenesis using error-prone PCR, random nucleotide insertion or other methods. Polynucleotides encoding antibodies or fragments thereof that specifically bind to antigens can combine with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.
[0513] Furthermore, the modified antibodies or antibody fragments thereof of the present invention can be conjugated with marker sequences, such as peptides, to facilitate purification. In a preferred embodiment, the marker amino acid sequence is a hexahistine peptide, such as the tag provided in the pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), many of which are commercially available. As described in Gentz et al., (1989) Proc. Natl. Acad. Sci. USA 86:821-824, for example, hexahistine provides convenient purification of fusion proteins. Other peptide tags for purification include, but are not limited to, the hemagglutinin (“HA”) tag, which corresponds to an epitope from the influenza hemagglutinin protein (Wilson et al., (1984) Cell 37:767), and the “FLAG” tag (A. Einhauer et al., J. Biochem. Biophys. Methods 49:455–465, 2001). According to the present invention, antibodies or antibody fragments may also be conjugated with tumor-penetrating peptides to enhance their potency.
[0514] In other embodiments, the modified antibodies or antibody fragments of the present invention are conjugated to diagnostic or detectable reagents. Such immunoconjugations can be used to monitor or predict the onset, development, progression, and / or severity of a disease or condition as part of a clinical testing procedure, such as determining the efficacy of a particular therapy. This diagnosis and detection can be performed using conjugated antibodies and detectable substances, including but not limited to various enzymes such as, but not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; prosthetic groups such as, but not limited to, streptavidin / biotin and avidin / biotin; and fluorescent substances such as, but not limited to, Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and Alexa Fluor 633. 750. Umbelliferone, luciferin, luciferin isothiocyanate, rhodamine, dichlorotriazineamine luciferin, dansyl chloride, or phycoerythrin; luminescent substances, such as, but not limited to, luminol; bioluminescent substances, such as, but not limited to, luciferase, luciferin, and jellyfish luminescent protein; radioactive substances, such as, but not limited to, iodine ( 131 I, 125 I, 123 I, and 121 I,), carbon ( 14 C), sulfur 35 S), tritium ( 3 H), Indium 115 In、 113 In、 112 In, and 111 In,), Technetium ( 99 Tc), thallium 201 Ti, gallium 68 Ga、 67 Ga), Palladium ( 103 Pd), molybdenum ( 99 Mo), xenon ( 133 Xe), fluorine ( 18 F) 153 Sm、 177 Lu、 159 Gd, 149 Pm,140 La、 175 Yb、 166 Ho、 90 Y, 47Sc, 186 Re、 188 Re、 142 Pr、 105 Rh、 97 Ru、 68 Ge 57 Co、 65 Zn, 85 Sr、 32 P, 153 Gd, 169 Yb、 51 Cr 54 Mn, 75 Se、 64 Cu、 113 Sn, and 117 Sn; and positron-generating metallic and non-radioactive paramagnetic metallic ions using various positron emission tomography methods.
[0515] The modified antibodies or antibody fragments of the present invention can also be attached to solid supports, which are particularly useful for the immunoassay or purification of target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene.
[0516] 5. Pharmaceutical Composition
[0517] To prepare a pharmaceutical or sterile composition comprising an immunoconjugate, the immunoconjugate of the present invention is mixed with a pharmaceutically acceptable carrier or excipient. The composition may additionally contain one or more other therapeutic agents suitable for the treatment or prevention of cancers (breast cancer, colorectal cancer, lung cancer, multiple myeloma, ovarian cancer, liver cancer, gastric cancer, pancreatic cancer, acute myeloid leukemia, chronic myeloid leukemia, osteosarcoma, squamous cell carcinoma, peripheral nerve sheath tumors (e.g., schwannomas), head and neck cancer, bladder cancer, esophageal cancer, Barrett's esophagus, glioblastoma, soft tissue microcytic sarcoma, malignant mesothelioma, neurofibromatosis, renal cancer, melanoma, prostate cancer, benign prostatic hyperplasia (BPH), gynacomastica, and endometriosis).
[0518] Formulations of therapeutic and diagnostic agents can be prepared by mixing with physiologically acceptable carriers, excipients, or stabilizers, such as lyophilized powders, slurries, aqueous solutions, emulsions, or suspensions (see, for example, Hardman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY, 2001; Gennaro, Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY, 2000; Avis et al. (eds.), Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY, 1993; Lieberman et al. (eds.), Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY, 1990; Lieberman et al. (eds.), Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY, 1990; Weiner). and Kotkoskie, Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY, 2000).
[0519] The selection of an administration regimen for a therapeutic agent depends on several factors, including the serum or tissue turnover rate of the entity, symptom levels, the immunogenicity of the entity, and the accessibility of target cells in the biological matrix. In some embodiments, the administration regimen maximizes the therapeutic dose delivered to the patient, consistent with acceptable levels of side effects. Therefore, the amount of biological agent delivered depends in part on the specific entity and the severity of the condition being treated. Guidance can be obtained in selecting appropriate dosages of antibodies, cytokines, and small molecules (see, for example, Wawrzynczak, Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK, 1996; Kresina (ed.), Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY, 1991; Bach (ed.), Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, NY, 1993; Baert et al., New Engl. J. Med. 348:601-608, 2003; Milgrom et al., New Engl. J. Med. 341:1966-1973, 1999; Slamon et al., New...). Engl.J.Med.344:783-792, 2001; Beniaminovitz et al., New Engl.J.Med.342:613-619, 2000; Ghosh et al., New Engl.J.Med.348:24-32, 2003; Lipsky et al., New Engl. J. Med. 343:1594-1602, 2000).
[0520] The appropriate dosage is determined by a clinician, for example, using parameters or factors known or suspected in the art to affect or predict their effect on treatment. Generally, the dosage begins at a level less than the optimal dose and is then increased in small increments until the desired or optimal effect is achieved relative to any adverse side effects. Important diagnostic measures include, for example, those measuring the symptoms of inflammation or the levels of inflammatory cytokines produced.
[0521] The actual dose level of the active ingredient in the pharmaceutical composition of the present invention may vary to obtain an effective amount of the active ingredient that is effective for achieving the desired therapeutic response for a specific patient, composition, and route of administration, without toxicity to the patient. The selected dose level will depend on a variety of pharmacokinetic factors, including the activity of the specific composition of the present invention or its esters, salts, or amides used, the route of administration, the time of administration, the excretion rate of the specific compound used, the duration of treatment, other drugs, compounds, and / or substances used in combination with the specific composition used, the age, sex, weight, condition, general health, and medical history of the patient being treated, and similar factors known in the medical field.
[0522] Compositions containing antibodies or fragments thereof of the present invention can be delivered by continuous infusion or by intervals of dose, such as once a day, once a week, or once to seven times a week. Dosage can be delivered intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscularly, intracerebrally, or by inhalation. A specific dosing regimen is one involving the maximum dose or frequency to avoid significant unwanted side effects.
[0523] For the immunoconjugate of the present invention, the dosage administered to the patient can be 0.0001 mg / kg to 100 mg / kg of patient body weight. The dosage can be between 0.0001 mg / kg to 20 mg / kg, 0.0001 mg / kg to 10 mg / kg, 0.0001 mg / kg to 5 mg / kg, 0.0001 to 2 mg / kg, 0.0001 to 1 mg / kg, 0.0001 mg / kg to 0.75 mg / kg, 0.0001 mg / kg to 0.5 mg / kg, 0.0001 mg / kg to 0.25 mg / kg, 0.0001 to 0.15 mg / kg, 0.0001 to 0.10 mg / kg, 0.001 to 0.5 mg / kg, 0.01 to 0.25 mg / kg, or 0.01 to 0.10 mg / kg of patient body weight. The dosage of the antibody or fragment thereof of the present invention can be calculated by multiplying the patient's weight in kilograms (kg) by the dosage to be administered in mg / kg.
[0524] The dosage of the immunoconjugate of the present invention can be repeated, and the administration intervals can be at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months. In a specific embodiment, the dosage of the immunoconjugate of the present invention is repeated every 3 weeks.
[0525] The effective dose for a particular patient can vary depending on factors such as the treatment status, the patient's overall health, the route of administration and dosage, and the severity of side effects (see, for example, Maynard et al., A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla., 1996; Dent, Good Laboratory and Good Clinical Practice, Urch Publ., London, UK, 2001).
[0526] The route of administration can be, for example, local or epidermal application, intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intracerebrospinal, intralesional, or via injection or infusion through a continuous-release system or implant (see, for example, Sidman et al., Biopolymers 22:547-556, 1983; Langer et al., J. Biomed. Mater. Res. 15:167-277, 1981; Langer, Chem. Tech. 12:98-105, 1982; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692, 1985; Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034, 1980; U.S. Patent Nos. 6,350,466 and 6,316,024). When necessary, the composition may also include a solubilizer and a local anesthetic such as lidocaine to relieve pain at the injection site. Additionally, it may be administered to the lungs, for example, by using an inhaler or nebulizer, and by using an aerosol formulation. See, for example, U.S. Patent Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publications WO 92 / 19244, WO 97 / 32572, WO 97 / 44013, WO 98 / 31346, and WO 99 / 66903, each incorporated herein by reference in its entirety.
[0527] The compositions of the present invention can also be administered via one or more routes of administration using one or more of a variety of methods known in the art. Those skilled in the art will understand that the route and / or manner of administration will vary depending on the desired outcome. Routes of administration selected for the immunoconjugates of the present invention include intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spinal, or other parenteral administration routes, such as by injection or infusion. Parenteral administration can represent administration methods other than intestinal and local administration, generally by injection, including but not limited to intravenous, intramuscular, intraarterial, intrasheath, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, spinal, epidural, and intrasternal injections and infusions. Alternatively, the compositions of the present invention can be administered via non-parenteral routes, such as local, epidermal, or mucosal administration routes, such as intranasal, oral, vaginal, rectal, sublingual, or local administration. In one embodiment, the immunoconjugates of the present invention are administered by infusion. In another embodiment, the immunoconjugates of the present invention are administered subcutaneously.
[0528] If the immunoconjugates of the present invention are administered in a controlled-release or sustained-release system, a pump can be used to achieve controlled or sustained release (see Langer, above; Sefton, CRC Crit. Ref Biomed. Eng. 14:20, 1987; Buchwald et al., Surgery 88:507, 1980; Saudek et al., N. Engl. J. Med. 321:574, 1989). Polymer materials can be used to achieve controlled or sustained release of the treatments of the present invention (see, for example, Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla., 1974; Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York, 1984; Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61, 1983; also see Levy et al., Science). 228:190, 1985; During et al., Ann. Neurol. 25:351, 1989; Howard et al., J. Neurosurg. 71:105, 1989; U.S. Patent No. 5,679,377; U.S. Patent No. 5,916,597; U.S. Patent No. 5,912,015; U.S. Patent No. 5,989,463; U.S. Patent No. 5,128,326; PCT Publication No. WO99 / 15154; and PCT Publication No. WO99 / 20253). Examples of polymers used in sustained-release formulations include, but are not limited to, poly(2-hydroxyethyl isobutylene acrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(isobutylene acid), polyglycolic acid (PLG), polyanhydride, poly(N-vinylpyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactide (PLA), poly(lactide-co-glycolic acid) (PLGA), and polyorthoesters. In one embodiment, the polymer used in the sustained-release formulation is inert, free of filterable impurities, storage-stable, sterile, and biodegradable. Controlled or sustained-release systems can be placed near prophylactic or therapeutic targets, thus requiring only a portion of the systemic dose (see, for example, Goodson, in Medical Applications of Controlled Release, above, Vol. 2, pp. 115-138, 1984).
[0529] Controlled release systems are discussed in the review in Langer, Science 249:1527-1533, 1990. Any technique known to those skilled in the art can be used to produce sustained and appropriate formulations comprising one or more immunoconjugates of the present invention. See, for example, U.S. Patent Nos. 4,526,938, PCT Publication WO 91 / 05548, PCT Publication WO 96 / 20698, Ning et al., Radiotherapy & Oncology 39:179-189, 1996; Song et al., PDA Journal of Pharmaceutical Science & Technology 50:372-397, 1995; Cleek et al., Pro. Int'l. Symp. Control. Rel. Bioact. Mater. 24:853-854, 1997; and Lam et al., Proc. Int'l. Symp. Control. Rel. Bioact. Mater. 24:759-760, 1997, each of which is incorporated herein by reference in its entirety.
[0530] If the immunoconjugates of the present invention are applied topically, they can be formulated in the form of ointments, creams, transdermal patches, lotions, gels, shampoos, sprays, aerosols, solutions, emulsions, or other forms well known to those skilled in the art. See, for example, Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms, 19th edition, Mack Pub. Co., Easton, Pa. (1995). For non-spray topical dosage forms, viscous to semi-solid or solid forms containing a carrier or one or more excipients compatible with the topical application are typically used and have a kinetic viscosity (in some cases higher than water). Suitable formulations include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, liniments, ointments, etc., which, when necessary, are sterile or mixed with excipients (e.g., preservatives, stabilizers, humectants, buffers, or salts) to affect a variety of properties, such as, for example, osmotic pressure. Other suitable local dosage forms include aerosol formulations, in some cases where the active ingredient is packaged in combination with a solid or liquid inert carrier in conjunction with a pressurized volatile (e.g., a gaseous propellant such as Freon). TM In a mixture or squeeze bottle. If necessary, a humectant or wetting agent may also be added to the pharmaceutical composition and dosage form. Examples of such additional ingredients are well known in the art.
[0531] If a composition containing an immunoconjugate is administered intranasally, it can be formulated as an aerosol, spray, liquid spray, or drops. Specifically, the preventative or therapeutic agent according to the invention can be conveniently delivered by a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas) from a pressurized package or nebulizer aerosol. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a measured amount. Capsules and cartridges (e.g., composed of gelatin) can be formulated for inhalers or blowpipes containing a mixture of the compound and a suitable powder base, such as lactose or starch.
[0532] Methods of co-administering or using a second therapeutic agent are known in the art, such as cytokines, steroids, chemotherapy agents, antibiotics, or radiation (see, for example, Hardman et al., (edited) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10 sup. th ed., McGraw-Hill, New York, NY; Poole and Peterson (edited) (2001) Pharmacotherapeutics for Advanced Practice: A Practical Approach, Lippincott, Williams & Wilkins, Phila., Pa.; Chabner and Longo (edited) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., Pa.). An effective dose of the therapeutic agent can reduce symptoms by at least 10%; at least 20%; at least about 30%; at least 40% or at least 50%.
[0533] Additional therapies (e.g., prophylactic or therapeutic agents) that can be administered in combination with the immunoconjugates of the present invention may be administered at intervals of less than 5 minutes, less than 30 minutes, 1 hour, about 1 hour, about 1 to about 2 hours, about 2 hours to about 3 hours, about 3 hours to about 4 hours, about 4 hours to about 5 hours, about 5 hours to about 6 hours, about 6 hours to about 7 hours, about 7 hours to about 8 hours, about 8 hours to about 9 hours, about 9 hours to about 10 hours, about 10 hours to about 11 hours, about 11 hours to about 12 hours, about 12 hours to 18 hours, 18 hours to 24 hours, 24 hours to 36 hours, 36 hours to 48 hours, 48 hours to 52 hours, 52 hours to 60 hours, 60 hours to 72 hours, 72 hours to 84 hours, 84 hours to 96 hours, or 96 hours to 120 hours. Two or more therapies may be administered in the same patient visit.
[0534] In some embodiments, the immunoconjugates of the present invention can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds of the present invention cross the BBB (if necessary), they can be formulated in liposomes, for example. For methods of manufacturing liposomes, see, for example, U.S. Patent Nos. 4,522,811; 5,374,548; and 5,399,331. Liposomes may contain one or more portions that are selectively transported to specific cells or organs, thus enhancing targeted drug delivery (see, for example, Ranade, (1989) J. Clin. Pharmacol. 29:685). Exemplary targeting components include folic acid or biotin (see, for example, U.S. Patent No. 5,416,016 to Low et al.); mannosides (Umezawa et al., (1988) Biochem. Biophys. Res. Commun. 153:1038); antibodies (Bloeman et al., (1995) FEBS Lett. 357:140; Owais et al., (1995) Antimicrob. Agents Chemother. 39:180); surfactant protein A receptors (Briscoe et al., (1995) Am. J. Physiol. 1233:134); p120 (Schreier etal, (1994) J. Biol. Chem. 269: 9090); see also K. Keinanen; ML Laukkanen (1994) FEBS Lett. 346: 123; JJ Killion; IJ Fidler (1994) Immunomethods 4: 273.
[0535] This invention provides a method for administering to a subject in need a pharmaceutical composition comprising the immunoconjugate of this invention alone or in combination with other treatments. Treatments of the combination therapy of this invention (e.g., prophylactic or therapeutic agents) can be administered to the subject simultaneously or sequentially. Treatments of the combination therapy of this invention (e.g., prophylactic or therapeutic agents) can also be administered cyclically. Cyclic treatment involves administering a first treatment (e.g., a first prophylactic or therapeutic agent) for a period of time, followed by administering a second treatment (e.g., a second prophylactic or therapeutic agent) for a period of time, and repeating this sequential administration, i.e., cyclical administration, to reduce the development of resistance to a treatment (e.g., agent), to avoid or reduce the side effects of a treatment (e.g., agent), and / or to improve the efficacy of the treatment.
[0536] The combination therapy of the present invention (e.g., preventive or therapeutic agents) can be administered to the subject simultaneously.
[0537] The term "simultaneously" is not limited to administering treatments (e.g., prophylactic or therapeutic agents) at precisely the same time, but it also means administering a pharmaceutical composition comprising the antibody or a fragment thereof of the present invention to a subject sequentially at time intervals, so that the antibody of the present invention can act in conjunction with one or more other treatments to provide an increased benefit than if they were administered in another manner. For example, each treatment may be administered to the subject simultaneously or sequentially at different time points in any order; however, if not simultaneously, then they should be administered at sufficiently close intervals to provide the desired therapeutic or preventative effect. Each treatment may be administered to the subject separately in any suitable form and via any suitable route. In several embodiments, treatments (e.g., prophylactic or therapeutic agents) are administered to the subject at intervals of less than 15 minutes, less than 30 minutes, less than 1 hour, about 1 hour, about 1 hour to about 2 hours, about 2 hours to about 3 hours, about 3 hours to about 4 hours, about 4 hours to about 5 hours, about 5 hours to about 6 hours, about 6 hours to about 7 hours, about 7 hours to about 8 hours, about 8 hours to about 9 hours, about 9 hours to about 10 hours, about 10 hours to about 11 hours, about 11 hours to about 12 hours, 24 hours, 48 hours, 72 hours, or 1 week. In other embodiments, two or more treatments (e.g., prophylactic or therapeutic agents) are administered during the same patient visit.
[0538] Prophylactic or therapeutic agents in combination therapy may be administered to the subject in the same pharmaceutical composition. Alternatively, prophylactic or therapeutic agents in combination therapy may be administered to the subject simultaneously in separate pharmaceutical compositions. Prophylactic or therapeutic agents may be administered to the subject via the same or different routes of administration.
[0539] The invention has been fully described and further illustrated by the following embodiments and claims, which are illustrative and not intended to be further limiting. Example
[0540] Example 1. Selection of surface-accessible sites in the human IgG1 heavy and κ light chains for Cys mutation.
[0541] Using the computer program Surface Racer 5.0 described by Tsodikov et al., “A novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature,” J. Comput. Chem., 23, 600-609 (2002), surface-exposed residues in constant regions of the human IgG1 heavy chain and human κ light chain were identified in hIgG1 / κ antibody (Protein Databank structure entry 1HZH.pdb, Table 6, Table 7, Figure 1). Based on the following criteria, 88 residues were selected for Cys substitution, 59 sites in the hIgG heavy chain, and 29 sites in the human κ light chain: 1) Residues in the CH1, CH2, and CH3 domains of the heavy chain constant region and the light chain constant region were selected; 2) Surface-exposed residues were selected, but fully exposed residues and C-terminal regions were avoided to prevent the formation of antibody dimers; 3) Polar or charged residues, such as Ser, Thr, Lys, Arg, Glu, and Asp, were focused on; and 4) Residues in the FcRn binding domain, the protein A binding domain, and the heavy chain hinge region were excluded.
[0542] Criterion 1) selects Cys substitution sites in the constant region of the antibody to ensure the transferability of the conjugate site to many different antibodies. Criterion 2) is based on observations of inter-antibody dimer formation on residues primarily exposed for Cys substitution (residues excluded based on this criterion are listed in Table 6). Based on the IgG crystal structure, the speculative orientation of the Cys side chain is considered: such residues (Cys side chains may be partially shielded from interaction with another antibody but may still react with small molecule payloads) are more advantageous than residues with greater surface accessibility but with orientations that allow interaction with large molecules such as dimers. Criterion 3) is implemented to promote conserved mutations to minimize the destabilizing effects of mutations on the antibody. Similarly, Criterion 4) is used to avoid functional alterations to the antibody, such as effects on FcRn and protein A binding, which may affect the pharmacokinetic properties of the antibody or may lead to loss during purification. Residues excluded based on Criterion 4 are listed in Table 6. The localization of the 88 selected mutation sites in the hIgG1 / κ structural model indicates that the selected sites are surface accessible ( Figure 2 ).
[0543] Table 6. Surface accessibility of amino acid residues in the human IgG1 heavy chain. Surface accessibility was calculated using Surface Racer 5.0 and expressed as square angstroms. "Excluded sites" refers to sites excluded from the selection for the reasons mentioned in Example 1. "Selected sites" are sites selected in this invention to replace Cys.
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556] Table 7. Surface accessibility of amino acid residues in the human κ light chain. Surface accessibility was calculated using Surface Racer 5.0 and expressed as square angstroms. "Selected site" refers to the site selected in this invention for replacement with Cys.
[0557]
[0558]
[0559] Example 2. Preparation of trastuzumab Cys mutant antibody
[0560] DNA encoding the variable regions of the heavy and light chains of trastuzumab was chemically synthesized and cloned into two mammalian expression vectors, pOG-HC and pOG-LC, containing constant regions of the human IgG1 and human κ light chains, to produce two wild-type constructs, pOG-trastuzumab HC and pOG-trastuzumab LC, respectively. In these vectors, expression of the antibody heavy and light chain constructs in mammalian cells is driven by a CMV promoter. Each vector contains a synthetic 24-amino acid signal sequence at the N-terminus of either the heavy or light chain: MKTFILLLWVLLLWVIFLLPGATA (SEQ ID NO: 99) to guide its secretion from mammalian cells. This signal sequence has been confirmed to guide the secretion of trastuzumab from mammalian cells. TM It is effective in the secretion of hundreds of mammalian proteins in cells. Cys mutant constructs were prepared in trastuzumab using oligonucleotide-guided mutagenesis. Eighty-eight pairs of mutant primers (Table 8) were chemically synthesized, corresponding to 88 selected Cys mutation sites in the constant regions of the human IgG1 heavy chain and κ light chain described in Example 1. The sense and antisense mutant primer pairs were mixed prior to PCR amplification. PCR was performed using pOG-trastuzumab HC and pOG-trastuzumab LC as templates with PfuUltra II FusionHS DNA polymerase (Stratagene). After PCR, the PCR products were validated on agarose gels and treated with DPN I, followed by transformation in DH5α cells (Klock et al., (2009) Methods Mol Biol. 498:91-103).
[0561] The sequences of 88 Cys mutant constructs were verified by DNA sequencing. The full-length amino acid sequence of the wild-type trastuzumab heavy chain is shown as SEQ ID NO:1, and the full-length amino acid sequence of the light chain is shown as SEQ ID NO:90. The protein sequences encoding the constant regions of 59 trastuzumab HC Cys mutant constructs (SEQ ID NO:2-SEQ ID NO:60) and 29 trastuzumab LC Cys mutant constructs (SEQ ID NO:61-SEQ ID NO:89) are shown in Tables 9 and 10, respectively. The amino acid residues in the human IgG1 heavy chain and human κ light chain were numbered using the Eu numbering system (Edelman et al., (1969) Proc Natl Acad Sci USA, 63:78-85).
[0562] Table 8. DNA sequences of 88 Cys mutant heavy and light chain mutant primers used to prepare human IgG1.
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576] Table 9. Amino acid sequences of the constant region of Cys mutant constructs in the human IgG1 heavy chain. SEQ ID NO:1 is the sequence of the full-length trastuzumab (human IgG1). SEQ ID NO:2-SEQ ID NO:60 indicate the sequence IDs of 59 Cys mutant constructs in the human IgG1 heavy chain, showing only the sequences of the constant region.
[0577]
[0578]
[0579]
[0580]
[0581]
[0582]
[0583]
[0584]
[0585]
[0586]
[0587]
[0588]
[0589]
[0590]
[0591] Table 10.29 lists the amino acid sequences of the constant region of the human κ light chain Cys mutant constructs. SEQ ID NO:61 is the sequence of the constant region of the wild-type human κ light chain. SEQ ID NO:62-SEQ ID NO:90 indicate the sequence IDs of 29 Cys mutant constructs in the constant region of the human κ light chain.
[0592]
[0593]
[0594]
[0595]
[0596] Example 3. Transfer of trastuzumab heavy and light chain Cys mutations into different antibodies
[0597] For trastuzumab, all Cys mutations selected for drug payload attachment were located in the constant regions of its human IgG1 heavy chain and human κ light chain. Because the constant regions of antibodies are highly conserved in primary sequence and structure, Cys mutant residues identified as good payload attachment sites in the trastuzumab context will also serve as preferred attachment residues in other antibodies. To demonstrate the transferability of these general conjugation sites to other antibodies, we cloned a set of Cys mutations into antibody 14090. Antibody 14090 is an antibody with a human IgG1 heavy chain and a human λ light chain that binds to a different target protein than trastuzumab. DNA encoding the variable region of antibody 14090 was cloned into seven selected pOG trastuzumab HC Cys mutant plasmid constructs (SEQ ID NOs listed in Table 11) to replace the variable region of the trastuzumab construct as described in Example 2. As a result, the amino acid sequences of the heavy chain constant regions in the corresponding seven Cys constructs of antibody 14090 and trastuzumab were identical (…). Figure 3 Subsequent experiments showed that these sites could be readily conjugated. Conversely, due to the high similarity in primary and tertiary sequences of different human IgG isotypes (…),… Figure 4 The Cys mutation on the κ light chain of trastuzumab can be readily transferred to the equivalent light chain on human antibodies containing different isotype heavy chains. Similarly, sites identified in the constant region of IgG1 can be transferred to IgG2, IgG3, and IgG4.
[0598] Example 4. Cysteine mutation in the human λ light chain
[0599] Human λ and κ light chains share very little amino acid sequence similarity. Figure 5A Based on the protein crystal structure model of Fab containing the human λ light chain (Protein Databank structure entry 3G6D.pdb), the positions of desired residues in the κ light chain of trastuzumab were selected based on the approximate similarity to the positions of the desired residues. Mutations in the λ light chain of antibody 14090 were then selected. Figure 5A(and B). Seven additional Cys mutant constructs were generated in the antibody 14090-λ light chain plasmid using a combination of oligonucleotide directed mutagenesis (Higuchi et al. 1988) and the PIPE cloning strategy (Klock and Lesley, 2009). The mutation primers used to generate Cys point mutations in the λ light chain are listed in Table 12. The secretion of antibody 14090 was also directed by a synthesized 24-amino acid signal sequence: MKTFILLLWVLLLWVIFLLPGATA (SEQ ID NO: 99). The sequence of the antibody 14090 Cys construct was verified by DNA sequencing. The sequence of the constant region of the human wild-type λ light chain is shown as SEQ ID NO: 91. The protein sequences encoding the seven Cys mutant constructs in the light chain (SEQ ID NO: 92-SEQ ID NO: 98) are shown in Table 13. Subsequent experiments will show that these Cys mutants are effectively conjugated to the ADC payload. Because all these mutants are located in the constant region of the human λ light chain, these conjugate sites can be easily transferred to other antibodies that have the λ light chain.
[0600] Table 11. Sequence IDs of the trastuzumab heavy chain Cys construct used to clone the variable region of antibody 14090.
[0601] The sequence ID NO of the trastuzumab HC Cys construct: SEQ ID NO:5 SEQ ID NO:8 SEQ ID NO:9 SEQ ID NO:10 SEQ ID NO:18 SEQ ID NO:48 SEQ ID NO:50
[0602] Table 12. Nucleotide sequences of primers used to induce seven Cys mutant constructs in the λ light chain of human IgG1.
[0603]
[0604]
[0605] Table 13. Amino acid sequences of the constant region of the Cys mutant construct in the λ light chain of antibody 14090. SEQ ID NO:91 is the sequence of the constant region of the wild-type human λ light chain. SEQ ID NO:91-SEQ ID NO:98 indicate the sequences of the seven Cys mutants in the constant region of the human λ light chain of antibody 14090.
[0606]
[0607] Example 5. In 293 Freestyle TM Expression and purification of Cys mutant antibodies in cells
[0608] Using the previously described method (Meissner, et al., Biotechnol Bioeng. 75:197-203 (2001)), heavy and light chain plasmids were co-transfected in 293 Freestyle TMCys mutants expressing trastuzumab antibody were used in cells. DNA plasmids for co-transfection were prepared using the Qiagen plasmid preparation kit according to the manufacturer's protocol. (Freestyle) TM Expression medium (Invitrogen) was incubated in suspension at 37°C and 5% CO2 for 293 days. TM Cells. The day before transfection, the cells were divided into 0.7 x 10⁻⁶ cells. 6 Add cells / ml to fresh culture medium. On the day of transfection, the cell density typically reaches 1.5 x 10⁻⁶ cells / ml. 6 Cells / ml. Cells were transfected using the PEI method with a 1:1 mixture of heavy and light chain plasmids (Meissner et al., 2001). The transfected cells were then cultured for 5 days. The culture medium was collected by centrifugation at 2000 x g for 20 min and filtered through a 0.2 μm filter. Protein A-Sepharose was used. TM (GE Healthcare LifeSciences) purified the expressed antibody from the filtered culture medium. The antibody was removed from protein A-Sepharose by elution buffer (pH 3.0). TM Antibody IgG was eluted on the column and immediately neutralized with 1M Tris-HCl (pH 8.0), and then the buffer was exchanged for PBS.
[0609] 293 Freestyle, instantly dyed TM The expression levels of 88 Cys trastuzumab mutant antibodies were similar to those of wild-type trastuzumab, with an average yield of 18.6 mg / L ± 9.5 mg / L (Table 14), suggesting that single-point mutations at the selected sites do not significantly alter the retention of the expressed antibody through the cellular secretory mechanism. Analysis of the purified Cys trastuzumab mutant antibody using non-reducing SDS-PAGE showed that the Cys mutant antibody does not form disulfide-linked oligomers via modified cysteine residues. Figure 6 Size exclusion chromatography (SCI) Figure 7 This further supports the conclusion that all Cys-mutated trastuzumab antibodies are monomeric. HPLC reverse-phase analysis of the mutant antibodies also indicated that most Cys-mutated antibodies were indistinguishable from wild-type trastuzumab in terms of retention time and homogeneity (Figure 8). Mass spectrometry (intact LC-MS) analysis of the non-reducing deglycosylated full-length trastuzumab LC-R108C revealed that most antibodies were modified with two cysteine residues. Figure 9 (and Table 15). These observations are consistent with previous publications, which indicate that when in 293 freestyle TMWhen expressed in cells, the thiohydroxyl group of the modified cysteine in the trastuzumab Cys mutant antibody is modified with cysteine, and the modification needs to be removed by a reducing agent before conjugation with any thiohydroxyl reaction reagent (Chen, et al., mAbs 1:6, 563-571, 2009).
[0610] Using the PEI method (Meissner et al., 2001), co-transfection of HC and LC plasmids can also be performed in 293 freestyle. TM Cys mutant of antibody 14090 is expressed in cells. The expression level of Cys mutant of antibody 14090 is similar to that of wild-type antibody 14090 (Table 16).
[0611] Table 14. In 293 freestyle TM Yield of transiently expressed trastuzumab Cys mutant antibody in cells. Yield was measured by UV absorbance at 280 nm after protein A purification.
[0612]
[0613]
[0614]
[0615] Table 15. From 293 freestyle TM The theoretical and observational quality of purified trastuzumab LC-R108C antibody in cells.
[0616]
[0617] Table 16: In 293 freestyle TM The yield of the antibody 14090 Cys mutant transiently expressed in cells.
[0618]
[0619]
[0620] Example 6. Reduction, re-oxidation, and conjugation of Cys mutant antibody with MC-MMAF
[0621] Because the modified Cys in antibodies expressed in mammalian cells are modified with adducts (disulfides) such as glutathione (GSH) and / or cysteine during their biosynthesis, the modified Cys in the initially expressed product does not react with thiol-reacting agents such as maleimide or brominated or iodoacetamide groups. To express the modified cysteine by post-conjugation, it is necessary to remove the glutathione or cysteine adducts by reducing these disulfides, which generally requires the reduction of all disulfides in the expressed protein. This can be accomplished by first exposing the antibody to a reducing agent, such as dithiothreitol (DTT), and then allowing all native disulfide bonds of the antibody to be re-oxidized to restore and / or stabilize the functional antibody structure. Therefore, to reduce all native disulfide bonds and disulfides bound between the cysteine or modified cysteine residues and the GSH adduct, freshly prepared DTT is added to a final concentration of 20 mM to the previously purified trastuzumab and the Cys mutant of antibody 14090. After incubating the antibody and DTT at 37°C for 1 hour, the mixture was dialyzed against PBS at 4°C for 3 days, with the buffer changed daily to remove DTT and re-oxidize native disulfide bonds. An alternative method was to remove the reducing agent using a Sephadex G-25 desalting column. Once the protein was completely reduced, 1 mM oxidized ascorbic acid (dehydroascorbic acid) was added to the desalted sample, followed by re-oxidation incubation for 20 hours. Both methods produced similar results. However, attempts to follow the re-oxidation protocol described in previous literature using CuSO4 resulted in protein precipitation. All examples in this paper used the dialysis protocol described above. Re-oxidation restores intrachain disulfide bonds, while dialysis allows cysteine and glutathione to attach to newly generated cysteine residues for dialyzing out.
[0622] After re-oxidation, the antibody is ready for conjugation. Maleimide-MMAF (MC-MMAF, 10 equivalents of the antibody) is added to the re-oxidized antibody in PBS buffer (pH 7.2). Figure 10 Incubation was performed for 1 to 24 hours. The conjugation process was monitored by reversed-phase HPLC, which separates the conjugated antibody from the unconjugated antibody. The conjugated reaction mixture was analyzed on a PRLP-S 4000A column (50 mm x 2.1 mm, Agilent) heated to 80 °C, and eluted by the column at a flow rate of 1.5 mL / min using a linear gradient of 30–60% acetonitrile in water containing 0.1% TFA. Protein elution from the column was monitored at 280 nm, 254 nm, and 215 nm. The reversed-phase HPLC trace of a typical conjugated mixture is shown in Figure 11.
[0623] When the conjugated mixture is analyzed by reversed-phase HPLC, many Cys sites produce homogeneous conjugated products, as indicated by a uniform single-peak elution profile (Figure 11), while some Cys sites produce heterogeneous conjugated products (Figure 12). The method described above involves the reduction and reoxidation of native disulfide bonds and the reduction of bonds between cysteine and modified cysteine residues in their GSH adducts. During reoxidation, the modified cysteine residues may interfere with the reformation of the correct native disulfide bonds through a disulfide shuttle process. This can lead to the formation of mispaired disulfide bonds between the modified cysteine and native cysteine residues or between incorrectly paired native disulfide bonds. Such mispaired disulfide bonds can affect antibody retention on the reversed-phase HPLC column. The mispairing process can also produce unpaired cysteine residues other than the desired modified cysteine. Maleimide-MMAF attachment to different sites on the antibody can affect retention time differently (see the discussion of homogeneous conjugated ADCs below). In addition to the desired conjugation with the modified cysteine residues, incomplete reoxidation leaves antibodies with native cysteine residues, which will react with maleimide-MMAF. Any process that hinders the proper and complete formation of native disulfide bonds after conjugation with maleimide-MMAF will produce complex HPLC spectra (Figure 11). The yield of homogeneous ADCs, measured by UV absorbance of the unpurified reaction mixture, varies according to the Cys mutation (Table 17). Using the reduction / reoxidation scheme and conjugation method described above, 65 of the 88 Cys-mutant trastuzumab antibodies produced homogeneous conjugated products, and these sites are favorable sites for Cys substitution to be prepared when preparing cysteine-modified antibodies for conjugation.
[0624] These 65 Cys-MMAF ADCs were analyzed in detail using a variety of assays: differential scanning fluorescence (DSF) was used to measure thermal stability; analytical size exclusion chromatography (AnSEC) was used to measure aggregation; in vitro antigen-dependent cytotoxic efficacy was measured by cell viability assays; and pharmacokinetic behavior was measured in mice. These assays and their respective results are described in more detail below.
[0625] To assess the aggregation state of trastuzumab Cys-MMAF ADCs, the ADCs were analyzed on a size exclusion chromatography column (GE, Superdex 200, 3.2 / 30) at a flow rate of 0.1 ml / min in PBS. All 65 Cys-MMAF ADCs were monomers. Most ADCs contained less than 10% oligomers. Figure 13 Table 18 shows that the conjugation of MC-MMAF to the trastuzumab Cys mutant construct at the selected site does not cause antibody aggregation.
[0626] Table 17. Yields of MMAF ADCs generated using trastuzumab Cys mutant constructs. “Hetero” indicates a heterogeneous mixture of species with different residence times in reversed-phase HPLC.
[0627]
[0628]
[0629] Table 18. Percentage of oligomers in trastuzumab Cys-MMAF ADC formulation as determined by analytical size exclusion chromatography.
[0630]
[0631]
[0632] bd: below the detection limit.
[0633] Example 7. In vitro thermal stability determination of trastuzumab Cys-MMAF ADCs
[0634] MMAF payload conjugation to trastuzumab can stabilize or destabilize the antibody, leading to an alteration in the antibody's melting temperature, which can be determined by differential scanning fluoroscopy (DSF), based on temperature-induced denaturation monitored by an environmentally sensitive dye such as Sypro Orange. Triple aliquots of the ADC sample were placed in PBS (6.7 mM sodium phosphate, pH 7.2; 150 mM NaCl) in 384-well plates. In each well, 8 μl of 0.25 mg / mL antibody was mixed with 2 μl of 25x Sypro Orange dye (Invitrogen). The plates were sealed and analyzed using a Roche LightCycler 480, recording 20 fluorescence scans per degree Celsius, gradually increasing the temperature from 30°C to 85°C. The melting temperature was determined from the first derivative of the fluorescence intensity versus time curve.
[0635] Typical heat transfer assays for wild-type trastuzumab revealed two melting transitions (Tm), Tm1 at 69.7 °C and Tm2 at 81.2 °C (Table 19). When trastuzumab Cys-MMAF ADCs were subjected to protein thermostability assays, it was evident that conjugation of MC-MMAF to the antibody induced different Tm changes depending on the conjugation site (Table 19). When MC-MMAF conjugated to most Cys sites in the CH1 or CH3 domains, the resulting ADCs, such as HC-K356C-MMAF, showed a similar pattern to wild-type anti-Her, with minimal changes in Tm1 and Tm2. However, when MC-MMAF conjugated to Cys sites located in the CH2 domain, a decrease in Tm1 was observed for most sites, while Tm2 remained largely unchanged. The decrease in Tm1 observed for Cys-MMAF conjugates with most CH2 domains varied between 5 °C and 26 °C. The two ADCs with the largest decrease in Tm1 are HC-T335C-MMAF and HC-S337C-MMAF, with Tm1 at 42℃ and 45℃, respectively. Figure 14 The results show that the position of the MC-MMAF conjugate can significantly affect the stability of ADCs.
[0636] Table 19. Demosis temperatures Tm1 and Tm2 of trastuzumab Cys-MMAF ADCs as observed by differential scanning fluorescence (DSF).
[0637]
[0638]
[0639]
[0640] nd was not determined because the broad transition of Tm2 prevented accurate Tm determination, and na was not applicable.
[0641] Example 8. Cell proliferation assay to measure the in vitro cytotoxic efficacy of Cys ADCs
[0642] Cells naturally expressing target antigens or cell lines engineered to express target antigens are frequently used to assess the activity and potency of ADCs. To evaluate the cytotoxic potency of trastuzumab ADCs in vitro, two engineered cell lines, MDA-MB231 clones 16 and 40, and HCC1954 cells were used (Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B, Vitetta ES. Breast Cancer Res Treat. (2000) 61:217-228). MDA-MB231 clone 16 cells stably expressed high copy numbers (~5 x 10⁻⁶). 5 Recombinant human Her2 (copies / cell) was expressed in clone 40, while clone 40 expressed low copy numbers (~5 x 10^6). 5 Human Her2 (copy / cell) HCC1954 cells endogenously express high levels (~5 x 10^6) on the surface. 5 Human Her2 cells (copy / cell). To determine the cytotoxic efficacy of antibody 14090 ADCs, CMK11-5 and Jurkat cells were used. Although CMK11-5 cells expressed high levels of antigen against antibody 14090 on their cell surface, no detectable antigen expression was observed in Jurkat cells. Antigen-dependent cytotoxic effects should kill only cells expressing sufficient antigen on their cell surface, not those lacking antigen. Cells were incubated with multiple concentrations of ADCs for 5 days, and the cytotoxic efficacy was determined using Cell-Titer-Globe. TM (Promega) was used for cell proliferation assays (Riss et al., (2004) Assay Drug Dev Technol. 2:51-62). In some studies, cell-based assays are high-throughput and performed in automated systems (Melnick et al., (2006) ProcNatl Acad Sci US A. 103:3153-3158).
[0643] Trastuzumab Cys-MMAF ADCs specifically killed MDA-MB231 clone 16 and HCC1954 cells, but not MDA-MB231 clone 40 cells (Figure 15). The IC50 of trastuzumab Cys-MMAF ADCs in MDA-MB231 clone 16 cells was [not specified in the original text]. 50 It varies between 30 pM and 200 pM (Table 20). Figure 16Similarly, antibody 14090 Cys-MMAF ADCs exhibited antigen-dependent cell killing in cell proliferation assays. Antibody 14090 Cys-MMAF ADCs killed antigen-expressing CMK11-5 cells but not antigen-negative Jurkat cells (Fig. 17). The IC50 of antibody 14090-MMAF ADCs in CMK11-5 cell proliferation assays... 50 It varies between 400 pM and 1 nM (Table 21).
[0644] Table 20. MDA-MB231 clone 16Her2 + IC50 of trastuzumab Cys-MMAF ADCs in cell proliferation assay 50 .
[0645]
[0646]
[0647]
[0648] Table 21. IC50 of antibody 14090 Cys-MMAF ADCs in CMK11-5 cell proliferation assay 50 .
[0649] Antibody 14090 Cys-MMAF ADC <![CDATA[IC 50 (M)]]> HC-S124C 9.26E-04 HC-T139C 1.22E-03 HC-E152C 4.60E-04 HC-L174C 6.02E-04 HC-K360C 8.56E-04 HC-S375C 4.38E-04 LC-A143C 7.09E-04 LC-A147C 1.14E-03 LC-V159C 5.41E-04 LC-T163C 6.38E-04 LC-S168C 1.06E-03
[0650] Example 9. Pharmacokinetic Study of Trastuzumab Cys-MMAF ADCs
[0651] Long serum half-lives have been demonstrated to be crucial for high in vivo potency of ADCs (Hamblett et al., “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate,” Clin Cancer Res., 10:7063-7070 (2004); Alley et al., Bioconjug Chem. 19:759-765 (2008)). Attaching generally hydrophobic drug payloads to antibodies can significantly affect antibody properties, and this may lead to rapid clearance of ADCs in vivo (Hamblett et al., 2004) and weak in vivo potency. To assess the effect of different conjugation sites on the clearance of MMAF ADCs in vivo, pharmacokinetic studies were conducted in non-tumor carrier mice using 65 trastuzumab Cys-MMAF ADCs. Anti-MMAF antibodies were generated to detect MMAF-containing ADCs in mouse plasma. An ELISA assay for detecting ADCs was developed using the extracellular domain of human HER2 to capture trastuzumab IgG molecules from plasma and to generate signals with anti-human IgG (anti-hIgG) and MMAF antibodies in two separate assays. The two ELISA assays measure serum concentrations of trastuzumab antibody and “intact” ADCs, as discussed in more detail below.
[0652] Three mice per group were administered a single dose of trastuzumab Cys-MMAF ADC at 1 mg / kg. Ten plasma samples were then collected over two weeks, and all trastuzumab IgG molecules, including trastuzumab Cys-MMAF ADCs and MMAF-deficient trastuzumab, were captured by ELISA using the extracellular domain of human HER2. Anti-MMAF and anti-hIgG antibodies were then used in two separate assays. The anti-MMAF antibody ELISA measured only the concentration of the trastuzumab MMAF conjugate, while the anti-hIgG ELISA quantified both the trastuzumab Cys-MMAF conjugate and the MMAF-deficient trastuzumab antibody. Standard curves were generated for each ADC using the same substances injected into the mice. If no change in drug loading of the trastuzumab Cys-MMAF ADC occurred after injection into the mice, the assays using anti-MMAF and anti-hIgG should therefore produce the same concentration readings. For trastuzumab Cys-MMAF ADCs that have lost some MMAF payload, an ELISA assay using anti-MMAF antibody will measure concentrations lower than those obtained with an anti-hIgG ELISA. Comparison of the two concentration readings thus allows for the measurement of drug release from trastuzumab Cys-MMAF ADCs during incubation in mice.
[0653] As measured by anti-hIgG ELISA, 63 of the 65 ADCs exhibited pharmacokinetic profiles similar to those of unconjugated wild-type trastuzumab antibodies (Figures 18, 19, 20), indicating that conjugation of the MC-MMAF payload to these sites did not significantly affect antibody clearance. Two exceptions were HC-T335C and HC-S337C. Conjugation of MC-MMAF to these two sites resulted in rapid clearance of the ADCs, as measured by anti-MMAF and anti-hIgG ELISA (Figure 21). Protein thermal transfer assays revealed that the Tm1 of trastuzumab HC-T335C-MMAF and trastuzumab HC-S337C-MMAF decreased from 69°C to 42°C and 45°C, respectively, in wild-type trastuzumab antibodies. Figure 14 MC-MMAF conjugation to both sites significantly reduced the thermal stability of the ADC (by 27 °C and 24 °C, respectively). For 63 ADCs exhibiting pharmacokinetic profiles similar to those of the unconjugated antibody, the Tm1 change was less than 8 °C, suggesting that rapid clearance may be associated with the low thermal stability of the ADC.
[0654] To determine the chemical stability of the link between the MMAF payload and the antibody at multiple Cys sites, the concentration of trastuzumab Cys-MMAF ADC, measured by anti-MMAF ELISA, was compared with the concentration of all trastuzumab molecules, measured by anti-hIgG ELISA, for each sample. Within the measurement error, many trastuzumab Cys-MMAF ADCs showed good overlap between the two concentrations over a two-week period, suggesting that the bond between MC-MMAF and cysteine introduced at these sites is stable during circulation in mice during this period (Figs. 18, 19). Conversely, some trastuzumab Cys-MMAF ADCs showed significant drug loss, as indicated by higher anti-hIgG readings than anti-MMAF readings (Fig. 20). For some trastuzumab Cys-MMAF ADCs, the ADC concentration was approximately 50% of the hIgG concentration. These results suggest significant differences in the stability of the thiol-maleimide bond of the drug payload conjugated to different sites, as previously indicated (Shen et al. Nat. Biotechnol. 2012, 30(2):184-9). Sites with good stability are preferred for the preparation of ADCs as described herein.
[0655] In pharmacokinetic studies, the area under the plasma concentration-time curve (AUC) is an important parameter for assessing the total clearance and bioavailability of the administered drug. In our pharmacokinetic studies, for each trastuzumab Cys-MMAF ADC, two AUC values, AUC-MMAF and AUC-hIgG, were calculated from measurements using anti-MMAF and anti-hIgG ELISA, respectively. For all trastuzumab Cys-MMAF ADCs, the AUC-MMAF / AUC-hIgG ratio varied between 0.4 and 1.2 (Table 20). Figures 18, 19, and 20 include PK curves for the ADCs across the observed AUC-MMAF / AUC-hIgG ratio range and illustrate the variability and uncertainty of the measurements. A ratio >1 (Table 20) suggests an uncertainty >25%, as the ratio should remain close to 1 if no drug loss occurs. As shown in Table 20, among the 63 trastuzumab Cys-MMAF ADCs with measurable AUCs from the two ELISAs, 40 ADCs showed an AUC-MMAF / AUC-hIgG ratio > 0.7, indicating that, within the limits of measurement accuracy, minimal MMAF drug loss was observed at these sites after administration in mice. However, 23 ADCs showed an AUC-MMAF / AUC-hIgG ratio < 0.7, suggesting that the amount of MMAF payload conjugates at these 23 sites was significantly reduced during in vivo incubation in mice.
[0656] Differences in the stability of maleimide linkages at different conjugation sites have been previously reported for Cys-modified ADCs (see discussion and reference in Shen et al., (2012) Nat Biotechnol. 22; 30(2): 184-9). For preferred sites exhibiting enhanced serum stability, the antibody environment is likely to catalyze the hydrolysis of the succinimide ring formed by the reaction of maleimide with cysteine. The hydrolyzed form is irreversible and does not release the maleimide drug. In this way, the ability of the antibody environment to catalyze ring hydrolysis cannot be predicted and is an unexpected property of some modified Cys sites. Based on this criterion, sites in Table 22 with an AUC(MMAF) / AUC(hIgG) ratio greater than 0.7 are therefore particularly suitable sites for cysteine substitution, and sites with a ratio of about 0.9 or greater are particularly preferred cysteine substitution sites for the purposes of this invention. These include heavy chain sites 322, 334, 121, 288, 171, 139, 360, 117, 392, 375, 292, 333, 174, 258, 337, 422, 320, 390, and 335; and light chain sites 107, 203, 108, and 114.
[0657] Table 22. AUC-MMAF and AUC-hIgG of trastuzumab Cys-MMAF ADCs in mice
[0658]
[0659]
[0660]
[0661]
[0662] na: Not applicable.
[0663] Example 10: Combining Cys sites to generate antibody-drug conjugates with a drug-antibody ratio greater than 2.
[0664] Antibody conjugates generated by conjugation with lysine residues or partially with reduced native disulfide bonds are often characterized by a drug-antibody ratio (DAR) between 3 and 4. For certain indications, it may be desirable to generate ADCs with higher DARs, which in principle can be achieved by introducing multiple Cys mutations into the antibody. As the number of Cys mutations increases, the likelihood that the mutation will interfere with the required re-oxidation process during ADC preparation increases, thus leading to an increase in heterogeneous products. In this study, a large number of single-site heavy and light chain Cys mutants with good re-oxidation behavior were identified.
[0665] To demonstrate that several conjugation sites can be combined to generate ADCs with a DAR greater than 2, the 293 Freestyle described in Example 5... TM Several preferred unit sites of Cys constructs on the light and heavy chains of trastuzumab and antibody 14090 (Table 23) were co-expressed in cells. The purified antibodies, containing one Cys mutation on both the heavy and light chains and re-oxidized, were conjugated with MC-MMAF as described in Example 6. Reversed-phase high-performance liquid chromatography (HPLC) confirmed a single, distinct elution peak, indicating effective re-oxidation of the native disulfide bonds. HPLC after MC-MMAF conjugation also showed a single elution peak primarily for the DAR 4 ADC species. Mass spectrometry confirmed that the DAR of all ADCs in Table 23 was 4. Production yields varied between 16–24 mg / L transient cell cultures. As determined by analytical size exclusion chromatography, the ADCs were predominantly monomeric; small aggregates were detectable only for two of the eight antibodies (Table 23). Trastuzumab and 14090ADCs demonstrated antigen-dependent cell killing in MDA-MB231 clone 16 and CMK1105 cell proliferation assays, respectively (Table 23).
[0666] Table 23. Properties of Cys-modified MMAF ADCs with DAR of 4
[0667]
[0668]
[0669] nd is undetectable.
[0670] Inactivation: No signs of cell killing were observed at the highest concentration assessed (66 nM).
[0671] SEQ ID NOs only specify the constant region of the antibody sequence.
[0672] Example 11. Selection of Cys sites based on ADC hydrophobicity
[0673] To further optimize the selection of Cys mutants and mutant combinations for the preparation of ADCs with DAR 2, 4, 6 and 8, the properties of MMAF ADCs prepared using single-site trastuzumab Cys and Pcl mutants were analyzed (the preparation of Pcl ADCs is described in patent application 55573), and accessibility of the conjugation sites and solvent exposure were examined in the crystal structure of IgG.
[0674] One of the most informative data points observed was the significant variation in hydrophobicity of trastuzumab Pcl-MMAF ADCs when the payload attached to different sites (Figure 23). Hydrophobic interaction chromatography (HIC) was performed using a TSKgel Phenyl-5PW column (Tosoh Bioscience, TSKgel Phenyl-5PW, 13 μm, 21 x 150 mm, stainless steel, Cat#07656; electrophoresis buffer A: 1.5 M ammonium sulfate in 20 mM NaPi (pH 7.4); buffer B: 20 mM NaPi (pH 7.4) in 20% isopropanol; flow rate 5 ml / min; linear gradient of 20%–80% buffer B over 90 min; monitored by UV absorbance at 280 nm). Surprisingly, despite the only difference being the ABA-MMAF attachment site (Figure 23), the retention time of DAR2 species varied considerably among the ADCs. HIC separated molecules on a hydrophobic basis. All DAR 2 ADCs exhibited longer retention times than unconjugated antibodies (WT = 45 min, Figure 23), which is expected when hydrophobic drug molecules such as ABA-MMAF attach to antibodies. However, attaching payloads at different sites increased the hydrophobicity of the ADCs to varying degrees.
[0675] The surprisingly large differences in retention time can be theoretically explained by observations of the location of attachment sites on the antibody structure (Figure 24): if the drug payload attaches to an exposure site outside the antibody, such as at HC-K288Pcl, HC-N286Pcl, HC-V422Pcl, HC-L398Pcl, and HC-S415Pcl, then the retention time is longer, with retention times between 87 and 94 minutes measured for each ADC (Figure 23). Conversely, if the payload attaches to internal sites, such as the cavity formed between the antibody's variable domain and CH1 domain (e.g., HC-P153Pcl, HC-E152Pcl, HC-L174Pcl, HC-P171Pcl, LC-R142Pcl, LC-E161Pcl, LC-E165Pcl, LC-S159Pcl) or a large opening between the CH2 and CH3 domains (e.g., HC-K246C, HC-S375Pcl, HC-T393Pcl, HC-K334Pcl), then the HIC retention time increases to only 47 to 57 minutes because the payload is partially isolated from interactions with the solvent and the HIC column. For other sites, such as the relatively exposed sites LC-K107Pcl and HC-K360Pcl, intermediate retention times of 70 and 83 minutes were measured.
[0676] Reducing the hydrophobicity of protein drugs is generally considered beneficial because it may decrease aggregation and clearance from circulation. We present the HIC data shown in Figure 23 to enable the selection of preferred payload attachment sites. Regardless of the conjugation chemistry and payload type, it should be beneficial to attach drug payloads at sites where the payload is isolated from the solvent and attachment minimally increases the hydrophobicity of the antibody. Careful selection of attachment sites that result in minimal alteration of hydrophobicity may be particularly beneficial when each antibody is attached to 4, 6, or 8 drugs, or when particularly hydrophobic payloads are applicable.
[0677] Cys sites selected for ADCs with low hydrophobicity:
[0678] To minimize the hydrophobicity of ADCs, sites are selected that point inside multiple protein domains of the antibody. Where applicable, the selection is based on analysis of the antibody structure and the behavior of existing ADCs with DAR=2 (behavior = retention time on HIC and / or delayed retention time on AnSEC with conjugates interacting with SEC resin). Of the Cys sites identified in Tables 1 and 2, the sites listed in Table 24 meet the above criteria.
[0679] All ADCs were analyzed by hydrophobic interaction chromatography (HIC). Trastuzumab MMAF ADCs conjugated at exposure sites HC-K360C, LC-K107C, HC-E258C, and HC-R292C were used for comparison. The results are shown in Table 25. Trastuzumab Cys-MMAF ADCs and unconjugated wild-type antibodies were analyzed on a TSKgel Butyl-NPR column as described above. For comparison, HIC data previously obtained for Pcl-MMAF ADCs on a TSKgel Phenyl-5PW are also listed (Figure 23). Despite different instrument operations and protocols, and despite some variability expected due to the different geometries and structures of the two linkers, the retention ratio between ADCs conjugated at the same site but by different conjugation methods remained almost constant. The HIC data suggest that retention time is indeed a measure of how well the payload is isolated inside the antibody, independent of attachment chemistry and linker structure. As expected, the relative gradation of different attachment sites remained largely the same for Pcl-MMAF and Cys-MMAFADCs.
[0680] Attachment to the sites selected in Table 24, HC-E333C, HC-K392C, and HC-K326C produced MMAF ADCs with similar HIC retention times to the exposed site ADCs LC-K107C-MMAF, HC-E258C-MMAF, HC-R292C-MMAF, and HC-K360C-MMAF (Table 28). Compared to unconjugated wild-type antibodies, attachment to the HC-E152C, LC-E165C, HC-P171C, LC-R142C, LC-E161C, HC-L174C, and HC-S124C sites increased the retention time of the resulting ADCs by less than 15%. These sites are all located in the CH1 domain or on the light chain (LC), and the HIC retention time data suggest that they are preferred attachment sites. In the CH3 domain sites, HC-K334C and HC-S375C exhibit minimal increase in hydrophobicity upon fusion, making them preferred attachment sites.
[0681] Table 24. Cys mutant sites
[0682]
[0683]
[0684] Table 25. Hydrophobic interaction chromatography (HIC) retention times of DAR 2 types of trastuzumab MMAF ADCs.
[0685] Comparing the Cys and Pcl conjugation chemistry, the two groups agree very well: sites that hide drugs conjugated via one chemistry also tend to hide drugs conjugated via the other. Some variability is expected due to the different geometries of the two connector systems.
[0686]
[0687]
[0688] a Analytical HIC: Tosoh Bioscience (King of Prussia, PA, USA) TSKgel Butyl-NPR column (100 mm × 4.6 mm, 2.5 μm), run buffer A: 50 mM sodium phosphate, 1.5 M ammonium sulfate, pH 7.0; buffer B: 50 mM sodium phosphate, pH 7.0; gradient consisted of a linear gradient of 20-100% B over 40 minutes, held at 100% A for 5 minutes; monitored by UV absorbance at 280 nm.
[0689] b Semi-preparative HIC: Tosoh Bioscience (King of Prussia, PA, USA), TSKgel Phenyl-5PW, 13μm, 21x150mm; Run buffer A: 1.5M ammonium sulfate in 20mM NaPi (pH 7.4); Buffer B: 20% isopropanol in 20mM NaPi (pH 7.4); Flow rate 5ml / min; linear gradient from 20% to 80% Buffer B over 90 minutes; monitored by UV absorbance at 280nm.
[0690] Detailed analytical HIC protocol:
[0691] Analytical HIC data for trastuzumab Cys-MMAF ADCs were collected using a Tosoh Bioscience (King of Prussia, PA, USA) TSKgel Butyl-NPR column (100 mm × 4.6 mm, 2.5 μm) mounted on a Dionex UltiMate 3000 HPLC (Sunnyvale, CA, USA). The method consisted of a binary gradient of buffer A (50 mM sodium phosphate, 1.5 M ammonium sulfate, pH 7.0) and buffer B (50 mM sodium phosphate, pH 7.0). Samples were prepared by diluting approximately 50 μg of antibody (PBS) with an equal volume of 3 M ammonium sulfate. The gradient consisted of a 5-minute hold at 100% A, followed by a linear gradient of 20-100% B over 40 minutes, and a final reequilibration at initial conditions for 10 minutes prior to the next injection. Separation was monitored by UV absorbance at 280 nm.
[0692] Preparation and characterization of DAR 4, 6 and 8 Cys ADCs
[0693] Cys mutations can be combined to prepare DAR 4, 6, and 8 ADCs. Generally, a preferred combination is a combination of two Cys mutations, resulting in ADCs with DAR 4. Examples of combining heavy chain (HC) Cys mutants with light chain (LC) Cys mutants for the preparation of DAR 4 ADCs are shown in Example 10 for trastuzumab and antibody 14090. Additional data are provided in Table 26. Additional Cys combinations were prepared using the protocols described in Examples 2, 5, and 6 based on HIC data and examination of attachment sites in the IgG crystal structure. Data for selected examples of MMAF ADCs are shown in Table 26. Furthermore, double Cys mutations of the heavy chain were cloned by combining selected heavy chain sites and following the protocols listed in Example 2. Antibodies characterized by two HC Cys mutations were prepared and conjugated following the protocols described in Examples 5 and 6.
[0694] To prepare DAR 4 ADCs, combinations include the single-site mutations listed in Table 24. Combinations of single sites produce ADCs with low hydrophobicity (Table 25). In some combinations, one Cys mutation is located in the CH1 domain or on the light chain (LC), and a second site is located in the CH3 domain. Examples of such combinations are combinations of HC-E152C and HC-S375C with characteristic Cys-mutated antibodies, combinations of HC-E165C and HC-S375C with HC-E152C and HC-K334C with LC-E165C and HC-K334C.
[0695] ADCs with DAR 6 and 8 can also be prepared by combining three or four Cys mutations in a single antibody. Combinations of selected heavy chains were used to prepare DAR 4, 6, and 8 ADCs. Double and triple Cys mutations in the heavy chains were cloned according to the protocols listed in Example 2. Antibodies characterized by two, three, and four Cys mutations were prepared and conjugated according to the protocols described in Examples 5 and 6. The characteristics of some examples of DAR 4, DAR 6, and DAR 8 ADCs are summarized in Table 26. Some of these ADCs exhibit surprisingly good PK properties as shown in Figure 25. Antibody 14090 is mouse cross-reactive, and thus, as expected, antibody 14090 ADCs are cleared more rapidly than trastuzumab ADCs that do not bind any mouse antigens.
[0696] Combinations include those having three and four point mutations listed in Table 24. Combinations include those sites that produce ADCs with low hydrophobicity (Table 25). Combinations include one Cys mutation located in the CH1 domain or on the light chain (LC), and optionally one to three additional sites located in the CH3 domain. Examples of such combinations include antibodies characterized by Cys mutations of HC-E152C or LC-E165C, combined with HC-S375C, combined with HC-K334C and / or HC-K392C. Preferred combinations for the preparation of DAR 6 and DAR 8 ADCs are shown in Tables 27 and 28, respectively.
[0697] There are some exceptions. Attaching MMAF to the Cys site in all studies yielded ADCs with high thermal stability (Example 7, Table 19), low aggregation tendency (Example 6, Table 18), and good pharmacokinetic properties of DAR 2 ADCs (Example 9, Table 22, Figure 18). When using relatively soluble payloads such as MMAF, differences in ADC hydrophobicity do not significantly translate into large differences in biophysical and pharmacokinetic properties. In fact, as shown above, even exposed, “hydrophobic” sites, such as HC-K360C, can be used in combination with preferred attachment sites to prepare DAR 4, DAR 6, and DAR 8 MMAF ADCs with acceptable pharmacokinetic properties. However, when this does not work well, using more hydrophobic payloads and carefully selecting attachment sites that result in minimal alteration of hydrophobicity may be crucial to allowing the preparation of non-aggregating ADCs with good pharmacokinetic properties. For such hydrophobic payloads, when each antibody is attached to 4, 6, or 8 drugs, using a combination of sites that reduces the increase in hydrophobicity may be beneficial.
[0698] Table 26. Characterization of selected DAR 4, 6 and 8 MMAF ADCs prepared using Cys mutant combinations.
[0699]
[0700] *AUC was calculated based on mouse PK measurements using anti-MMAF and anti-IgG ELISA assays.
[0701] nd; Not detected, below the quantitation limit.
[0702] Table 27. Preferred Cys site combinations for the preparation of DAR 6 ADCs.
[0703]
[0704]
[0705] Table 28. Preferred Cys site combinations for the preparation of DAR 8 ADCs.
[0706] ADC combination Site 1 Site 2 Site 3 Site 4 1 HC-E152C HC-S375C HC-K334C HC-K392C 2 HC-E152C HC-S375C HC-E333C HC-K392C 3 LC-E165C HC-S375C HC-K334C HC-K392C 4 LC-E165C HC-S375C HC-E333C HC-K392C
[0707] Example 12. In vivo efficacy study of trastuzumab Cys-MMAF ADCs.
[0708] In vivo xenograft tumor models were used to observe bioactivity by transplanting relevant and well-characterized human primary tumors or tumor cell lines into immunodeficient nude mice. Studies using anticancer agents to treat xenograft mice have provided valuable information on the in vivo potency of test reagents (Sausville and Burger, 2006). Because MDA-MB231 clone 16 cells are sensitive to trastuzumab Cys-MMAF ADCs in an antigen-dependent manner (Figure 15), this cell line was chosen as an in vivo model to evaluate trastuzumab Cys-MMAF ADCs. (Based on the Guide for the Care and Use of Laboratory Animals (NIH publication; National Academy Press, 8...)) th All animal studies were conducted using the MDA-MB231 clone 16 cells (Morton and Houghton, 2001 edition). MDA-MB231 clone 16 cells were subcutaneously implanted into nu / nu mice (Morton and Houghton, 2007). Tumor sizes reached ~200 mm. 3 Subsequently, trastuzumab Cys-MMAF ADCs were administered to mice via intravenous injection at a single dose of 3 mg / kg. Tumor growth was measured weekly after ADC injection. Each treatment group consisted of 9 mice. Figure 22The document specifies examples of in vivo efficacy studies using three trastuzumab Cys-MMAF ADCs. Treatment of mice with 3 mg / kg trastuzumab Cys-MMAF ADCs induced tumor regression in all three tested Cys-MMAF ADCs. Figure 22 No weight loss was observed associated with ADC treatment. The results confirmed that trastuzumab Cys-MMAF ADCs effectively induced regression of MDA-MB231 clone 16 tumors with a single dose of 3 mg / kg.
Claims
1. An immunoconjugate comprising a modified IgG1 antibody or an antigen-binding fragment thereof, said modified IgG1 antibody or antigen-binding fragment thereof containing a heavy chain constant region and a single cysteine substitution, wherein said cysteine substitution is at amino acid position 152 in the heavy chain constant region, wherein said amino acid position is numbered according to the EU system, wherein said cysteine is used to conjugate a drug portion to said antibody or antigen-binding fragment thereof.
2. The immunoconjugate according to claim 1, wherein the modified antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO:
10.
3. The immunoconjugate according to claim 1 or 2, comprising a pharmaceutical portion.
4. The immunoconjugate according to claim 3, wherein the ratio of the drug to the antibody is 2.
5. The immunoconjugate of claim 3, wherein the pharmaceutical portion is attached to the modified antibody or antigen-binding fragment via the sulfur of the cysteine residue at amino acid position 152 in the heavy chain constant region.
6. The immunoconjugate of claim 5, wherein the pharmaceutical portion is connected via a linker unit to the sulfur of the cysteine residue at amino acid position 152 in the heavy chain constant region.
7. The immunoconjugate according to claim 6, wherein the connecting unit is selected from non-enzymatically cleavable connectors, non-cleavable connectors, enzyme-cleavable connectors, photostable connectors, photo-cleavable connectors, connectors containing self-degradable spacers, or any combination thereof.
8. The immunoconjugate according to claim 5, wherein the pharmaceutical portion is connected to the cysteine residue at amino acid position 152 in the heavy chain constant region via a linker comprising a thiol-maleimide bond, an S-CH2-C(=O)- bond, or a disulfide bond.
9. The immunoconjugate according to claim 3, wherein the pharmaceutical portion is a cytotoxic agent.
10. The immunoconjugate according to claim 3, wherein the pharmaceutical portion is selected from taxanes, DNA alkylating agents, anthracyclines, tubulysin analogs, docalmicin analogs, alistatin E, alistatin F, and metansan compounds.
11. The immunoconjugate according to claim 3, wherein the pharmaceutical portion is a nucleic acid.
12. The immunoconjugate according to claim 1 or 2, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a fully humanized antibody, a bispecific antibody, or a multispecific antibody.
13. The immunoconjugate according to claim 1 or 2, wherein the antibody or antigen-binding fragment specifically binds to tumor-characteristic cell surface markers.
14. A pharmaceutical composition comprising the immunoconjugate according to any one of claims 1-13.
15. A modified IgG1 antibody or antigen-binding fragment thereof, said modified IgG1 antibody or antigen-binding fragment thereof containing a heavy chain constant region and a single cysteine substitution, wherein said cysteine substitution is at amino acid position 152 in the heavy chain constant region, wherein said amino acid position is according to EU system number.
16. The modified antibody or antigen-binding fragment according to claim 15, comprising the amino acid sequence of SEQ ID NO:
10.
17. The modified antibody or antigen-binding fragment according to claim 15 or 16, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a fully humanized antibody, a bispecific antibody, or a multispecific antibody.
18. The modified antibody or antigen-binding fragment according to claim 15 or 16, wherein the antibody or antigen-binding fragment specifically binds to tumor-characteristic cell surface markers.
19. A nucleic acid encoding a modified antibody or antigen-binding fragment as described in any one of claims 15-18.
20. A host cell comprising the nucleic acid of claim 19.
21. A method for producing a modified antibody or antigen-binding fragment according to any one of claims 15-18, wherein the method comprises incubating the host cell of claim 20 under suitable conditions for expressing the antibody or antigen-binding fragment, and isolating the antibody or antigen-binding fragment.
22. A method of producing an immunoconjugate according to any one of claims 1-13, comprising attaching a linker unit LU or a linker unit-payload combination-LU-X to a cysteine residue at amino acid position 152 in the heavy chain constant region.
23. The method according to claim 22, wherein the immunoconjugate is an immunoconjugate of formula (I): Formula (I) Where Ab represents an antibody or antigen-binding fragment; LU stands for connector unit; X represents the payload or drug component; And n is 2.
24. Immunoconjugate of formula (I): Formula (I) Wherein Ab represents the modified antibody or antigen-binding fragment as described in any one of claims 15-18; LU is a linker unit that is linked to the modified antibody or antigen-binding fragment via a cysteine residue at amino acid position 152 in the heavy chain constant region; X represents the payload or drug component; And n is 2.
Citation Information
Patent Citations
Method for controlling the activity of immunologically functional molecule
EP1176195A1
Harmonic party-line telephone-ringer.
US1051989A
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20010036923A1
Method for the production of non-immunogenic proteins
US20030153043A1
Toxin conjugated eph receptor antibodies
US20090304721A1
